LTKBID	compound_name	smiles	mol_formula	CASN	drugbankid	atc_code	verified_dili_concern	label_section	severity_class	dili_description	green_annotation	xu_annotation	obrien_annotation	suzuki_annotation	Guo_annotation	sakatis_annotation	ver_disp
LT00003	mercaptopurine	C1=NC2=C(N1)C(=S)N=CN2	C5 H4 N4 S		50-44-2	DB01033	L01BB02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hepatotoxicity: A small number of deaths have been reported that may have been attributed to hepatic necrosis	HH	Positive	Severely	2	3	Hepatotoxic	1
LT00004	acetaminophen	CC(=O)NC1=CC=C(C=C1)O	C8 H9 N O2		103-90-2	DB00316	N02BE01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	5	Severe liver damage may occur if you take ¦ more than 8 tablets in 24 hours	HH	Positive	Severely	2	3	Hepatotoxic	2
LT00006	azathioprine	CN1C=NC(=C1SC2=NC=NC3=C2NC=N3)[N+](=O)[O-]	C9 H7 N7 O2 S		446-86-6 55774-33-9	DB00993	L04AX01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	5	These symptoms may also be accompanied by diarrhea, rash, fever, malaise, myalgias, elevations in liver enzymes, and occasionally, hypotension.	HH	Positive	Moderately	1	3	Hepatotoxic	1
LT00009	chlorpheniramine	CN(C)CCC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2	C16 H19 Cl N2		132-22-9	DB01114	R06AB04	vNo-DILI-Concern	No-DILI-Concern	No match	0		HH	Positive					2
LT00011	clofibrate	CCOC(=O)C(C)(C)OC1=CC=C(C=C1)Cl	C12 H15 Cl O3		637-07-0	DB00636	C10AB01	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Liver-function tests abnormal	HH		Moderately			non-hepatotixic	1
LT00013	cyclophosphamide	C1CNP(=O)(OC1)N(CCCl)CCCl	C7 H15 Cl2 N2 O2 P		50-18-0	DB00531	L01AA01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Veno-occlusive liver disease (VOD) including fatal outcome has been reported in patients receiving cyclophosphamide-containing regimens.	HH	Positive	Moderately	2	2	Hepatotoxic	1
LT00015	dopamine	C1=CC(=C(C=C1CCN)O)O	C8 H11 N O2		51-61-6	DB00988	C01CA04	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative					2
LT00016	estradiol	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=C3C=CC(=C4)O	C18 H24 O2		50-28-2 35380-71-3	DB00783	G03CA03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	Cholestatic jaundice	WE	Negative	Moderately	1		Hepatotoxic	1
LT00018	fluoxetine	CNCCC(C1=CC=CC=C1)OC2=CC=C(C=C2)C(F)(F)F	C17 H18 F3 N O		54910-89-3	DB00472	N06AB03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Infrequent: abnormal liver function tests ; Rare: hepatitis, liver fatty deposit	WE	Negative		2		non-hepatotixic	1
LT00020	gemfibrozil	CC1=CC(=C(C=C1)C)OCCCC(C)(C)C(=O)O	C15 H22 O3		25812-30-0	DB01241	C10AB04	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	4	Abnormal liver function tests have been observed occasionally during gemfibrozil administration, including elevations of AST, ALT, LDH, bilirubin, and alkaline phosphatase.	HH	Positive		1			1
LT00022	indomethacin	CC1=C(C2=C(N1C(=O)C3=CC=C(C=C3)Cl)C=CC(=C2)OC)CC(=O)O	C19 H16 Cl N O4		53-86-1	DB00328	M01AB01 S01BC01 C01EB03 M02AA23	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	In addition, rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure, some of them with fatal outcomes have been reported.	HH	Positive	Severely	2	3	Hepatotoxic	1
LT00023	ketoprofen	CC(C1=CC=CC(=C1)C(=O)C2=CC=CC=C2)C(=O)O	C16 H14 O3		22071-15-4	DB01009	M01AE03 M02AA10	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3		NE		Moderately	1	2		2
LT00024	mannitol	C(C(C(C(C(CO)O)O)O)O)O	C6 H14 O6		69-65-8	DB00742	B05CX04 A06AD16 B05BC01	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00026	methotrexate	CN(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O	C20 H22 N8 O5		59-05-2	DB00563	L01BA01 L04AX03	vMost-DILI-Concern	Most-DILI-Concern	Box warning	3	Methotrexate causes hepatotoxicity, fibrosis and cirrhosis, but generally only after prolonged use. Acutely, liver enzyme elevations are frequently seen. These are usually transient and asymptomatic, and also do not appear predictive of subsequent hepatic	HH	Positive	Severely	1	3	Hepatotoxic	1
LT00030	phenobarbital	CCC1(C(=O)NC(=O)NC1=O)C2=CC=CC=C2	C12 H12 N2 O3		50-06-6	DB01174	N03AA02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Prolonged therapy with barbiturates should be accompanied by periodic laboratory evaluation of organ systems, including hematopoietic, renal, and hepatic systems				1		Hepatotoxic	1
LT00032	phenytoin	C1=CC=C(C=C1)C2(C(=O)NC(=O)N2)C3=CC=CC=C3	C15 H12 N2 O2		57-41-0	DB00252	N03AB02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Cases of acute hepatotoxicity, including infrequent cases of acute hepatic failure, have been reported with Phenytoin Infatabs. The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes.	HH	Positive		2	2	Hepatotoxic	1
LT00034	rifampin	C[C@H]1/C=C/C=C(\C(=O)NC\2=C(C3=C(C(=C4C(=C3C(=O)/C2=C/NN5CCN(CC5)C)C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C	C43 H58 N4 O12		13292-46-1	DB01045	J04AB02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Fatalities associated with jaundice have occurred in patients with liver disease and in patients taking rifampin with other hepatotoxic agents.	WE		Moderately	2	3	Hepatotoxic	1
LT00036	tetracycline	CC1(C2CC3C(C(=O)/C(=C(\N)/O)/C(=O)C3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)N(C)C)O	C22 H24 N2 O8		60-54-8 64-75-5	DB00759	S03AA02 S01AA09 A01AB13 J01AA07 S02AA08 D06AA04	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	2	If renal impairment exists, even usual oral or parenteral dose may lead to excessive systemic accumulation of the drug and possible liver toxicity	HH	Positive	Moderately	1	3	Hepatotoxic	1
LT00040	abacavir	C1CC1NC2=NC(=NC3=C2N=CN3C4C[C@H](C=C4)CO)N	C14 H18 N6 O		136470-78-5	DB01048	J05AF06	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Liver failure, renal failure, hypotension, adult respiratory distress syndrome, respiratory failure, and death have occurred in association with hypersensitivity reactions; Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, ha	HH			2			1
LT00041	acyclovir	C1=NC2=C(N1COCCO)NC(=NC2=O)N			59277-89-3	DB00787	S01AD03 D06BB03 J05AB01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Hepatobiliary Tract and Pancreas: elevated liver function tests, hepatitis, hyperbilirubinemia, jaundice							1
LT00043	allopurinol	C1=C2C(=NC=NC2=O)NN1	C5 H4 N4 O		315-30-0	DB00437	M04AA01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	more severe hypersensitivity reactions such as exfoliative, urticarial and purpuric lesions, as well as Stevens-Johnson syndrome (erythema multiforme exudativum), and/or generalized vasculitis, irreversible hepatotoxicity, and, on rare occasions, death.	HH	Positive		2	2	Hepatotoxic	1
LT00045	amineptine	C1CC2=CC=CC=C2C(C3=CC=CC=C31)NCCCCCCC(=O)O	C22 H28 N O2 . Cl		57574-09-1	DB04836	N06AA19	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH			2			1
LT00046	amiodarone	CCCCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)OCCN(CC)CC)I	C25 H29 I2 N O3		1951-25-3	DB01118	C01BD01	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Liver injury is common with Cordarone, but is usually mild and evidenced only by abnormal liver enzymes. Overt liver disease can occur, however, and has been fatal in a few cases.	HH	Positive	Severely	2		Hepatotoxic	1
LT00047	amitriptyline	CN(C)CCC=C1C2=CC=CC=C2CCC3=CC=CC=C31	C20 H23 N		50-48-6 549-18-8	DB00321	N06AA09	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Rarely hepatitis (including altered liver function and jaundice);	WE	Negative	Severely	1		Hepatotoxic	2
LT00048	amphotericin b	C[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@@H](C[C@H]2[C@@H]([C@H](C[C@](O2)(C[C@H](C[C@H]([C@@H](CC[C@H](C[C@H](CC(=O)O[C@H]([C@@H]([C@@H]1O)C)C)O)O)O)O)O)O)O)C(=O)O)O[C@H]3[C@H]([C@H]([C@@H]([C@H](O3)C)O)N)O	C47 H73 N O17		1397-89-3	DB00681	J02AA01 A01AB04 A07AA07 G01AA03	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	monitor on a regular basis liver function,	WE					Hepatotoxic	2
LT00049	ampicillin	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)C(=O)O)C	C16 H19 N3 O4 S		69-53-4	DB00415	S01AA19 J01CA01	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Transient elevation of serum transaminase has been observed following administration of ampicillin							2
LT00052	donepezil	COC1=C(C=C2C(=C1)CC(C2=O)CC3CCN(CC3)CC4=CC=CC=C4)OC	C24 H29 N O3		120014-06-4	DB00843	N06DA02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	gamma glutamyl transpeptidase increase;hepatitis	WE	Negative		1	0	non-hepatotixic	2
LT00053	aspirin	CC(=O)OC1=CC=CC=C1C(=O)O	C9 H8 O4		50-78-2	DB00945	N02BA01 B01AC06 A01AD05	vLess-DILI-Concern	No-DILI-Concern	No match	0			Negative	Moderately	2		non-hepatotixic	2
LT00054	aminohippurate	C1=CC(=CC=C1C(=O)NCC(=O)O)N	C9 H10 N2 O3				V04CH30	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00056	bicalutamide	CC(CS(=O)(=O)C1=CC=C(C=C1)F)(C(=O)NC2=CC(=C(C=C2)C#N)C(F)(F)F)O	C18 H14 F4 N2 O4 S		90357-06-5	DB01128	L02BB03	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Rare cases of death or hospitalization due to severe liver injury have been reported post-marketing in association with the use of bicalutamide. Hepatotoxicity in these reports generally occurred within the first three to four months of treatment. Hepatit	HH	Positive		1	3		1
LT00058	bupropion	CC(C(=O)C1=CC(=CC=C1)Cl)NC(C)(C)C	C13 H18 Cl N O		34841-39-9	DB01156	N06AX12	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Hepatitis, jaundice,liver damage	WE	Negative	Moderately	2	2		1
LT00059	captopril	C[C@H](CS)C(=O)N1CCC[C@H]1C(=O)O	C9 H15 N O3 S		62571-86-2	DB01197	C09AA01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	6	Jaundice, hepatitis, including rare cases of necrosis, cholestasis	HH	Positive	Moderately	2	3		1
LT00060	carbamazepine	C1=CC=C2C(=C1)C=CC3=CC=CC=C3N2C(=O)N	C15 H12 N2 O		298-46-4	DB00564	N03AF01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	Hepatic effects, ranging from slight elevations in liver enzymes to rare cases of hepatic failure have been reported	HH			2	2	Hepatotoxic	1
LT00061	carboplatin	C1CC(C1)(C(=O)O)C(=O)O.[Pt]	C6 H8 O4 . Pt . 2 H2 N		41575-94-4	DB00958	L01XA02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	High dosages of carboplatin (more than 4 times the recommended dose) have resulted in severe abnormalities of liver function tests.	HH				2		1
LT00062	ceftazidime	CC(C)(C(=O)O)O/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)C[N+]4=CC=CC=C4)C(=O)[O-]	C22 H22 N6 O7 S2		72558-82-8	DB00438	J01DD02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	slight elevations in one or more of the hepatic enzymes, aspartate aminotransferase (AST, SGOT) (1 in 16), alanine aminotransferase (ALT, SGPT) (1 in 15), LDH (1 in 18), GGT (1 in 19), and alkaline phosphatase (1 in 23).	WE		Moderately			Hepatotoxic	2
LT00065	chenodeoxycholic acid	C[C@H](CCC(=O)O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2[C@@H](C[C@H]4[C@@]3(CC[C@H](C4)O)C)O)C	C24 H40 O4		474-25-9	DB06777	A05AA01	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	8	One patient with sclerosing cholangitis, biliary cirrhosis and history of jaundice died during chenodiol treatment for hepatic duct stones. the patient was hospitalized with advanced hepatic failure and E. coli peritonitis; death ensued at the eight weeks	HH	Positive					2
LT00066	chlorcyclizine	CN1CCN(CC1)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl	C18 H21 Cl N2		82-93-9		R06AE04	vLess-DILI-Concern	No-DILI-Concern	No match	0								2
LT00067	chlorzoxazone	C1=CC2=C(C=C1Cl)NC(=O)O2	C7 H4 Cl N O2		95-25-0	DB00356	M03BB03	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Serious (including fatal) hepatocellular toxicity has been reported rarely in patients	HH	Positive		1	3		1
LT00068	chlorpromazine	CN(C)CCCN1C2=CC=CC=C2SC3=C1C=C(C=C3)Cl	C17 H19 Cl N2 S		50-53-3 69-09-0	DB00477	N05AA01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	Chronic jaundice has been reported	HH	Positive	Moderately	2	3	Hepatotoxic	1
LT00071	cisplatin	N.N.Cl[Pt+2]Cl	Cl2 Pt . 2 H3 N		15663-27-1	DB00515	L01XA01	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Liver function should be monitored periodically	HH				1		1
LT00074	dimercaprol	C(C(CS)S)O	C3 H8 O S2		59-52-9	DB06782	V03AB09	vNo-DILI-Concern	No-DILI-concern	No match	0		HH						2
LT00076	colchicine	CC(=O)N[C@H]1CCC2=CC(=C(C(=C2C3=CC=C(C(=O)C=C13)OC)OC)OC)OC	C22 H25 N O6		64-86-8	DB01394	M04AC01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	6	hepatic necrosis	WE	Negative	Moderately			non-hepatotixic	1
LT00077	corticotropin	CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C	C208 H343 N59 O64 S2				H01AA01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00079	dactinomycin	CC1C(C(=O)NC(C(=O)N2CCCC2C(=O)N(CC(=O)N(C(C(=O)O1)C(C)C)C)C)C(C)C)NC(=O)C3=C4C(=C(C=C3)C)OC5=C(C(=O)C(=C(C5=N4)C(=O)NC6C(OC(=O)C(N(C(=O)CN(C(=O)C7CCCN7C(=O)C(NC6=O)C(C)C)C)C)C(C)C)C)N)C	C62 H86 N12 O16		50-76-0	DB00970	L01DA01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Veno-occlusive disease (primarily hepatic) may result in fatality, particularly in children younger than 48 months.	HH				3	Hepatotoxic	2
LT00080	dantrolene	C1C(=O)NC(=O)N1N=CC2=CC=C(O2)C3=CC=C(C=C3)[N+](=O)[O-]	C14 H10 N4 O5		7261-97-4	DB01219	M03CA01	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Dantrium (dantrolene sodium) has a potential for hepatotoxicity, and should not be used in conditions other than those recommended. Symptomatic hepatitis (fatal and non-fatal) has been reported at various dose levels of the drug.	HH	Positive	Severely		3	Hepatotoxic	1
LT00081	demeclocycline	CN(C)[C@H]1[C@@H]2C[C@@H]3[C@@H](C4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=C(C1=O)C(=O)N)O)O)O)O)Cl)O			127-33-3 64-73-3	DB00618	J01AA01 D06AA01	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	possible liver toxicity	HH	Positive					2
LT00082	dexamethasone	C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CO)O)C)O)F)C	C22 H29 F O5		50-02-2	DB01234	D07XB05 S02BA06 S01BA01 R01AD03 D07AB19 A01AC02 H0	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Elevation in serum liver enzyme levels, hepatomegaly.		Negative	Non-toxic			non-hepatotixic	1
LT00083	propoxyphene	CCC(=O)OC(CC1=CC=CC=C1)(C2=CC=CC=C2)C(C)CN(C)C	C22 H29 N O2		469-62-5	DB00647	N02AC04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Hepatobiliary Disorder: hepatic steatosis, hepatomegaly, hepatocellular injury				2			2
LT00084	diclofenac	C1=CC=C(C(=C1)CC(=O)O)NC2=C(C=CC=C2Cl)Cl	C14 H11 Cl2 N O2		15307-86-5	DB00586	M01AB05 D11AX18 S01BC03 M02AA15	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Postmarketing surveillance has reported cases of severe hepatic reactions, including liver necrosis, jaundice, fulminant hepatitis with and without jaundice, and liver failure. Some of these reported cases resulted in fatalities or liver transplantation.	HH	Positive	Severely	2	3	Hepatotoxic	1
LT00085	diflunisal	C1=CC(=C(C=C1C2=C(C=C(C=C2)F)F)C(=O)O)O	C13 H8 F2 O3		22494-42-4	DB00861	N02BA11	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including diflunisal tablets. These laboratory abnormalities may progress, may remain unchanged, or may be transient with continuing therapy. Notable elevati	HH	Positive			2		2
LT00087	diphenhydramine	CN(C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	C17 H21 N O		58-73-1	DB01075	R06AA02 D04AA32	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative	Non-toxic			non-hepatotixic	1
LT00091	epirubicin	C[C@H]1[C@@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O	C27 H29 N O11		56420-45-2	DB00445	L01DB03	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Evaluate serum total bilirubin and AST levels before and during treatment with ELLENCE.	NE				2		2
LT00092	erythromycin	CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)O)(C)O	C37 H67 N O13		114-07-8	DB00199	D10AF02 S01AA17 J01FA01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	5	There have been reports of hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice	HH	Positive	Moderately	2	2	Hepatotoxic	1
LT00094	etoposide	C[C@@H]1OC[C@@H]2[C@@H](O1)[C@@H]([C@H]([C@@H](O2)O[C@H]3[C@H]4COC(=O)[C@@H]4[C@@H](C5=CC6=C(C=C35)OCO6)C7=CC(=C(C(=C7)OC)O)OC)O)O	C29 H32 O13		33419-42-0	DB00773	L01CB01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Hepatic toxicity, generally in patients receiving higher doses of the drug than those recommended, has been reported with etoposide.	HH	Positive	Severely		2	Hepatotoxic	2
LT00095	famotidine	C1=C(N=C(S1)N=C(N)N)CSCCC(=NS(=O)(=O)N)N	C8 H15 N7 O2 S3		76824-35-6	DB00927	A02BA03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Cholestatic jaundice, liver enzyme abnormalities	WE	Negative	Moderately	1	3		1
LT00097	felbamate	C1=CC=C(C=C1)C(COC(=O)N)COC(=O)N	C11 H14 N2 O4		25451-15-4	DB00949	N03AX10	vMost-DILI-Concern	Most-DILI-Concern	Box warning	7	EVALUATION OF POSTMARKETING EXPERIENCE SUGGESTS THAT ACUTE LIVER FAILURE IS ASSOCIATED WITH THE USE OF FELBAMATE	HH	Positive	Severely		3	Hepatotoxic	1
LT00098	fenofibrate	CC(C)OC(=O)C(C)(C)OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl	C20 H21 Cl O4		49562-28-9	DB01039	C10AB05	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Liver Function: Increases in serum transaminases [AST (SGOT) or ALT (SGPT); Hepatocellular, chronic active and cholestatic hepatitis associated with fenofibrate therapy have been reported after exposures of weeks to several years. In extremely rare cases,	HH	Positive	Moderately	1		Hepatotoxic	1
LT00099	fenoprofen	CC(C1=CC(=CC=C1)OC2=CC=CC=C2)C(=O)O	C15 H14 O3		29679-58-1	DB00573	M01AE04	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	A patient with symptoms and/or signs suggesting liver dysfunction, or in whom an abnormal liver test has occurred, should be evaluated for evidence of the development of a more severe hepatic reaction while on therapy with Nalfon.	HH	Positive			3		1
LT00101	flutamide	CC(C)C(=O)NC1=CC(=C(C=C1)[N+](=O)[O-])C(F)(F)F	C11 H11 F3 N2 O3		13311-84-7	DB00499	L02BB01	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	There have been postmarketing reports of hospitalization and rarely death due to liver failure in patients taking flutamide.	HH	Positive	Severely	2	3	Hepatotoxic	1
LT00106	hydroxyurea	C(=O)(N)NO	C H4 N2 O2		127-07-1	DB01005	L01XX05	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hepatotoxicity and hepatic failure resulting in death have been reported during post-marketing surveillance	HH	Positive		1	1		1
LT00107	imatinib	CC1=C(C=C(C=C1)NC(=O)C2=CC=C(C=C2)CN3CCN(CC3)C)NC4=NC=CC(=N4)C5=CN=CC=C5	C29 H31 N7 O		152459-95-5 220127-57-1	DB00619	L01XE01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Severe hepatotoxicity including fatalities may occur. Assess liver function before initiation of treatment and monthly thereafter or as clinically indicated.				1			2
LT00108	imipramine	CN(C)CCCN1C2=CC=CC=C2CCC3=CC=CC=C31	C19 H24 N2		50-49-7	DB00458	N06AA02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Jaundice (simulating obstructive); altered liver function	HH	Positive	Severely	1		Hepatotoxic	1
LT00109	iproniazid	CC(C)NNC(=O)C1=CC=NC=C1	C9 H13 N3 O		54-92-2	DB04818	N06AF05	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH			3		Hepatotoxic	1
LT00110	hydroxyprogesterone caproate	CC(=O)[C@]1(CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O	C21 H30 O3		630-56-8		G03DA03	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	2	Carefully monitor women who develop jaundice while receiving Makena							2
LT00111	ketoconazole	CC(=O)N1CCN(CC1)C2=CC=C(C=C2)OC[C@@H]3CO[C@@](O3)(CN4C=CN=C4)C5=C(C=C(C=C5)Cl)Cl	C26 H28 Cl2 N4 O4		65277-42-1	DB01026	D01AC08 G01AF11 J02AB02	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	When used orally, ketoconazole has been associated with hepatic toxicity, including some fatalities.	HH		Severely	2	3	Hepatotoxic	1
LT00112	labetalol	CC(CCC1=CC=CC=C1)NCC(C2=CC(=C(C=C2)O)C(=O)N)O	C19 H24 N2 O3		36894-69-6	DB00598	C07AG01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hepatic Injury: Severe hepatocellular injury, confirmed by rechallenge in at least one case, occurs rarely with therapy with labetalol therapy. The hepatic injury is usually reversible, but hepatic necrosis and death have been reported. Injury has occurre	HH	Positive	Severely	3		Hepatotoxic	1
LT00113	leflunomide	CC1=C(C=NO1)C(=O)NC2=CC=C(C=C2)C(F)(F)F	C12 H9 F3 N2 O2		75706-12-6	DB01097	L04AA13	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Severe liver injury, including fatal liver failure, has been reported in some patients treated with leflunomide.	HH	Positive	Moderately	1	3		1
LT00116	mefenamic acid	CC1=C(C(=CC=C1)NC2=CC=CC=C2C(=O)O)C	C15 H15 N O2		61-68-7	DB00784	M01AG01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including MEFENAMIC ACID. 	HH	Positive				Hepatotoxic	2
LT00117	meloxicam	CC1=CN=C(S1)NC(=O)C2=C(C3=CC=CC=C3S(=O)(=O)N2C)O			71125-38-7	DB00814	M01AC06	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	If clinical signs and symptoms consistent with liver or renal disease develop, systemic manifestations occur (e.g., eosinophilia, rash, etc.) or if abnormal liver tests persist or worsen, meloxicam should be discontinued. 				1			2
LT00119	metformin	CN(C)C(=N)N=C(N)N	C4 H11 N5		657-24-9	DB00331	A10BA02	vLess-DILI-Concern	No-DILI-Concern	No match	0		WE			1			2
LT00121	methyldopa	C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)N	C10 H13 N O4		555-30-6	DB00968	C02AB01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Liver disorders may occur with methyldopa therapy. Rarely, fatal hepatic necrosis has been reported after use of methyldopa	HH		Severely	2	3	Hepatotoxic	1
LT00124	nefazodone	CCC1=NN(C(=O)N1CCOC2=CC=CC=C2)CCCN3CCN(CC3)C4=CC(=CC=C4)Cl	C25 H32 Cl N5 O2		83366-66-9	DB01149	N06AX06	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Cases of life-threatening hepatic failure have been reported in patients treated with nefazodone hydrochloride tablets	HH	Positive		3	3	Hepatotoxic	1
LT00125	nitrofurantoin	C1C(=O)NC(=O)N1/N=C\C2=CC=C(O2)[N+](=O)[O-]	C8 H6 N4 O5		67-20-9	DB00698	J01XE01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hepatotoxicity: Hepatic reactions, including hepatitis, cholestatic jaundice, chronic active hepatitis, and hepatic necrosis, occur rarely. Fatalities have been reported.	HH		Severely	2	3	Hepatotoxic	1
LT00126	olsalazine	C1=CC(=C(C=C1N/N=C\2/C=CC(=O)C(=C2)C(=O)O)C(=O)O)O	C14 H10 N2 O6		15722-48-2	DB01250	A07EC03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	8	Reports of hepatotoxicity, including elevated liver function tests (SGOT/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin), jaundice, cholestatic jaundice, cirrhosis, and possible hepatocellular damage including liver necrosis and liver failure. S							2
LT00128	paroxetine	C1CNC[C@H]([C@@H]1C2=CC=C(C=C2)F)COC3=CC4=C(C=C3)OCO4	C19 H20 F N O3		61869-08-7	DB00715	N06AB05	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	8	elevated liver function tests, deaths due to liver necrosis, liver dysfunction	WE	Negative	Moderately	2		non-hepatotixic	1
LT00129	pentamidine	C1=CC(=CC=C1C(=N)N)OCCCCCOC2=CC=C(C=C2)C(=N)N	C19 H24 N4 O2		100-33-4	DB00738	P01CX01	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Liver function test, including serum bilirubin, alkaline phosphatase, AST (SGOT), and ALT (SGPT).							2
LT00130	pentobarbital	CCCC(C)C1(C(=O)NC(=O)NC1=O)CC	C11 H18 N2 O3		76-74-4	DB00312	N05CA01	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	periodic laboratory evaluation of organ systems, including hematopoietic, renal, and hepatic systems							2
LT00131	perhexiline	C1CCC(CC1)C(CC2CCCCN2)C3CCCCC3	C19 H35 N		6621-47-2	DB01074	C08EX02	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH	Positive		3		Hepatotoxic	1
LT00133	physostigmine	C[C@@]12CCN([C@@H]1N(C3=C2C=C(C=C3)OC(=O)NC)C)C	C15 H21 N3 O2		57-47-6	DB00981	V03AB19 S01EB05	vNo-DILI-Concern	No-DILI-concern	No match	0		NE	Negative	Non-toxic				2
LT00134	pioglitazone	CCC1=CN=C(C=C1)CCOC2=CC=C(C=C2)CC3C(=O)NC(=O)S3	C19 H20 N2 O3 S		111025-46-8	DB01132	A10BG03	vLess-DILI-Concern	Less-DILI-concern	Warnings and precautions	3	Hepatic effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded.	WE	Negative	Non-toxic	1		non-hepatotixic	1
LT00136	propylthiouracil	CCCC1=CC(=O)NC(=S)N1	C7 H10 N2 O S		51-52-5	DB00550	H03BA02	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Severe liver injury and acute liver failure, in some cases fatal, have been reported in patients treated with propylthiouracil.			Severely	2	3	Hepatotoxic	1
LT00137	pseudoephedrine	C[C@@H]([C@H](C1=CC=CC=C1)O)NC	C10 H15 N O		90-82-4	DB00852	R01BA02	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative					2
LT00138	ranitidine	CN/C(=C\[N+](=O)[O-])/NCCSCC1=CC=C(O1)CN(C)C	C13 H22 N4 O3 S		66357-35-5	DB00863	A02BA02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	There have been occasional reports of hepatocellular, cholestatic, or mixed hepatitis, with or without jaundice	WE	Negative		2	3	Hepatotoxic	1
LT00139	rifabutin	C[C@H]1/C=C/C=C(\C(=O)NC2=C3C(=NC4(N3)CCN(CC4)CC(C)C)C5=C6C(=C(C(=C5C2=O)O)C)O[C@@](C6=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)/C	C46 H62 N4 O11		72559-06-9	DB00615	J04AB04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	hepatitis (	HH			1			2
LT00140	rosiglitazone	CN(CCOC1=CC=C(C=C1)CC2C(=O)NC(=O)S2)C3=CC=CC=N3	C18 H19 N3 O3 S		122320-73-4	DB00412	A10BG02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Liver enzymes should be measured prior to the initiation of therapy with AVANDIA in all patients and periodically. If jaundice is observed, drug therapy should be discontinued.	WE	Negative	Non-toxic			non-hepatotixic	2
LT00141	indocyanine green	CC1(C(=[N+](C2=C1C3=CC=CC=C3C=C2)CCCCS(=O)(=O)[O-])C=CC=CC=CC=C4C(C5=C(N4CCCCS(=O)(=O)[O-])C=CC6=CC=CC=C65)(C)C)C.[Na+]	C43 H47 N2 O6 S2 . Na		3599-32-4			vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00142	simvastatin	CCC(C)(C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C	C25 H38 O5		79902-63-9	DB00641	C10AA01	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3			Negative	Moderately	2		non-hepatotixic	1
LT00143	spironolactone	CC(=O)S[C@@H]1CC2=CC(=O)CC[C@@]2([C@@H]3[C@@H]1[C@@H]4CC[C@]5([C@]4(CC3)C)CCC(=O)O5)C	C24 H32 O4 S		52-01-7	DB00421	C03DA01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	A very few cases of mixed cholestatic/hepatocellular toxicity, have been reported	HH	Positive			0		1
LT00144	stavudine	CC1=CN(C(=O)NC1=O)[C@H]2C=C[C@H](O2)CO	C10 H12 N2 O4		3056-17-5	DB00649	J05AF04	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases. Fatal lactic acidosis has been reported in pregnant women who received the combination of stavudine and didanosine	HH	Positive	Severely	2		Hepatotoxic	1
LT00145	streptomycin	C[C@H]1[C@@]([C@H]([C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H]([C@@H]([C@H]2O)O)N=C(N)N)O)N=C(N)N)O[C@H]3[C@H]([C@@H]([C@H]([C@@H](O3)CO)O)O)NC)(C=O)O	C21 H39 N7 O12		57-92-1	DB01082	J01GA01 A07AA04	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative					1
LT00146	sulfadiazine	C1=CN=C(N=C1)NS(=O)(=O)C2=CC=C(C=C2)N	C10 H10 N4 O2 S		68-35-9	DB00359	J01EC02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	hepatitis,				1			2
LT00147	sulfasalazine	C1=CC=NC(=C1)NS(=O)(=O)C2=CC=C(C=C2)N/N=C/3\C=CC(=O)C(=C3)C(=O)O	C18 H14 N4 O5 S		599-79-1	DB00795	A07EC01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	5	The presence of clinical signs such as sore throat, fever, pallor, purpura or jaundice may be indications of serious blood disorders or hepatotoxicity.	HH	Positive		2	3	Hepatotoxic	2
LT00148	sulindac	CC1=C(C2=C(C1=CC3=CC=C(C=C3)S(=O)C)C=CC(=C2)F)CC(=O)O	C20 H17 F O3 S		38194-50-2	DB00605	M01AB02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hepatic Effects: Cholestatic hepatitis; Rare cases of severe hepatic reactions, including jaundice and fatal fulminant hepatitis, liver necrosis and hepatic failure,	HH	Positive	Severely	1	3	Hepatotoxic	1
LT00152	tamoxifen	CC/C(=C(\C1=CC=CC=C1)/C2=CC=C(C=C2)OCCN(C)C)/C3=CC=CC=C3	C26 H29 N O		10540-29-1	DB00675	L02BA01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Tamoxifen has been associated with changes in liver enzyme levels, and on rare occasions, a spectrum of more severe liver abnormalities including fatty liver, cholestasis, hepatitis and hepatic necrosis. A few of these serious cases included fatalities. I	HH	Positive	Moderately	2	3	Hepatotoxic	1
LT00153	temozolomide	CN1C(=O)N2C=NC(=C2N=N1)C(=O)N	C6 H6 N6 O2		85622-93-1	DB00853	L01AX03	vLess-DILI-Concern	Less-DILI-concern	Adverse reactions	4	There have been reported cases of hepatotoxicity, including elevations of liver enzymes, hyperbilirubinemia, cholestasis, and hepatitis.		Negative			1		2
LT00154	theophylline	CN1C2=C(C(=O)N(C1=O)C)NC=N2	C7 H8 N4 O2		58-55-9	DB00277	R03DA04	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE					non-hepatotixic	2
LT00155	tizanidine	C1CN=C(N1)NC2=C(C=CC3=NSN=C32)Cl	C9 H8 Cl N5 S		51322-75-9	DB00697	M03BX02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	In occasional symptomatic cases, nausea, vomiting, anorexia and jaundice have been reported. Based upon postmarketing experience, death associated with liver failure has been a rare occurrence reported in patients treated with tizanidine.				1			2
LT00156	tolcapone	CC1=CC=C(C=C1)C(=O)C2=CC(=C(C(=C2)O)O)[N+](=O)[O-]	C14 H11 N O5		134308-13-7	DB00323	N04BX01	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Because of the risk of potentially fatal, acute fulminant liver failure, TASMAR (tolcapone) should ordinarily be used in patients with Parkinson's disease	HH			3	3		1
LT00158	toremifene	CN(C)CCOC1=CC=C(C=C1)/C(=C(/CCCl)\C2=CC=CC=C2)/C3=CC=CC=C3	C26 H28 Cl N O		89778-26-7	DB00539	L02BA02	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Periodic liver function tests should be obtained					2		1
LT00160	valproic acid	CCCC(CCC)C(=O)O	C8 H16 O2		99-66-1	DB00313	N03AG01	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Hepatotoxicity, including fatalities, usually during first 6 months of treatment. Children under the age of two years are at considerably higher risk of fatal hepatotoxicity.	HH		Severely	2	3	Hepatotoxic	1
LT00161	vancomycin	C[C@H]1[C@H]([C@@](C[C@@H](O1)O[C@@H]2[C@H]([C@@H]([C@H](O[C@H]2OC3=C4C=C5C=C3OC6=C(C=C(C=C6)[C@H](C(C(=O)N[C@H](C(=O)N[C@H]5C(=O)N[C@@H]7C8=CC(=C(C=C8)O)C9=C(C=C(C=C9[C@@H](NC(=O)[C@H]([C@@H](C1=CC(=C(O4)C=C1)Cl)O)NC7=O)C(=O)O)O)O)CC(=O)N)NC(=O)[C@@H](CC	C66 H75 Cl2 N9 O24		1404-90-6	DB00512	A07AA09 J01XA01	vLess-DILI-Concern	No-DILI-Concern	No match	0		HH	Positive					1
LT00162	vitamin a	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/CO)/C)/C			68-26-8	DB00162	D10AD02 S01XA02 R01AX02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	hepatomegaly, cholestasis in Pediatric Use		Positive					2
LT00163	zidovudine	CC1=CN(C(=O)NC1=O)[C@H]2C[C@@H]([C@H](O2)CO)N=[N+]=[N-]	C10 H13 N5 O4		30516-87-1	DB00495	J05AF01	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases, have been reported with the use of nucleoside analogues including zidovudine	HH	Positive	Moderately	1		Hepatotoxic	1
LT00164	zolpidem	CC1=CC=C(C=C1)C2=C(N3C=C(C=CC3=N2)C)CC(=O)N(C)C	C19 H21 N3 O		82626-48-0	DB00425	N05CF02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	7	Infrequent: abnormal hepatic function, increased SGPT. Rare: bilirubinemia, increased SGOT.	WE					non-hepatotixic	2
LT00165	zonisamide	C1=CC=C2C(=C1)C(=NO2)CS(=O)(=O)N	C8 H8 N2 O3 S		68291-97-4	DB00909	N03AX15	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	cholestatic jaundice							2
LT00166	pyrazinamide	C1=CN=C(C=N1)C(=O)N	C5 H5 N3 O		98-96-4	DB00339	J04AK01	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Patients started on pyrazinamide should have baseline serum uric acid and liver function determinations. Those patients with preexisting liver disease or those at increased risk for drug related hepatitis (e.g., alcohol abusers) should be followed closely	HH	Positive	Severely	2	3	Hepatotoxic	1
LT00167	finasteride	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2C(=O)NC(C)(C)C)CC[C@@H]4[C@@]3(C=CC(=O)N4)C	C23 H36 N2 O2		98319-26-7	DB01216	G04CB01 D11AX10	vLess-DILI-Concern	No-DILI-Concern	No match	0					1		non-hepatotixic	2
LT00168	troglitazone	CC1=C(C(=C2CCC(OC2=C1C)(C)COC3=CC=C(C=C3)CC4C(=O)NC(=O)S4)C)O	C24 H27 N O5 S		97322-87-7	DB00197	A10BG01	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH	Positive		3	3	Hepatotoxic	1
LT00172	fluvastatin	CC(C)N1C2=CC=CC=C2C(=C1/C=C/[C@@H](C[C@@H](CC(=O)O)O)O)C3=CC=C(C=C3)F	C24 H26 F N O4		93957-54-1	DB01095	C10AA04	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3			Negative		1			2
LT00173	glimepiride	CCC1=C(CN(C1=O)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCC(CC3)C)C	C24 H34 N4 O5 S		93479-97-1	DB00222	A10BB12	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	7	Impairment of liver function (e.g. with cholestasis and jaundice), as well as hepatitis, which may also lead to liver failure have been reported	WE	Negative	Non-toxic				1
LT00174	venlafaxine	CN(C)CC(C1=CC=C(C=C1)OC)C2(CCCCC2)O	C17 H27 N O2		93413-69-5	DB00285	N06AX16	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	7	Hepatitis, jaundice; abnormalities of unspecified liver function tests; liver damage, necrosis, or failure; and fatty liver				2		non-hepatotixic	1
LT00175	amlodipine	CCOC(=O)C1=C(NC(=C(C1C2=CC=CC=C2Cl)C(=O)OC)C)COCCN	C20 H25 Cl N2 O5		88150-42-9	DB00381	C08CA01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	postmarketing experience, jaundice and hepatic enzyme elevations (mostly consistent with cholestasis or hepatitis), in some cases severe enough to require hospitalization, have been reported in association with use of amlodipine.				1		non-hepatotixic	2
LT00177	vinblastine	CC[C@@]1(C[C@H]2C[C@@](C3=C(CCN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC)O	C46 H58 N4 O9		865-21-4	DB00570	L01CA01	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE						2
LT00178	ciprofloxacin	C1CC1N2C=C(C(=O)C3=CC(=C(C=C32)N4CCNCC4)F)C(=O)O	C17 H18 F N3 O3		85721-33-1	DB00537	S02AA15 S03AA07 J01MA02 S01AX13	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	hepatitis; jaundice; acute hepatic necrosis or failure	HH	Positive		2		Hepatotoxic	1
LT00179	fluconazole	C1=CC(=C(C=C1F)F)C(CN2C=NC=N2)(CN3C=NC=N3)O	C13 H12 F2 N6 O		86386-73-4	DB00196	J02AC01 D01AC15	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hepatic injury: associated with rare cases of serious hepatic toxicity, including fatalities	HH	Positive		1	3	Hepatotoxic	1
LT00180	prednisone	C[C@]12CC(=O)[C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C	C21 H26 O5		53-03-2	DB00635	H02AB07 A07EA03	vLess-DILI-Concern	Less-DILI-concern	Adverse reactions	3	Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT) and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome are reversible upo	WE	Negative				non-hepatotixic	2
LT00181	lorazepam	C1=CC=C(C(=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O)Cl	C15 H10 Cl2 N2 O2		846-49-1	DB00186	N05BA06	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	periodic blood counts and liver-function tests are recommended for patients on long-term therapy.							2
LT00182	itraconazole	CCC(C)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OC[C@H]5CO[C@](O5)(CN6C=NC=N6)C7=C(C=C(C=C7)Cl)Cl	C35 H38 Cl2 N8 O4		84625-61-6	DB01167	J02AC02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Itraconazole has been associated with rare cases of serious hepatotoxicity, including liver failure and death			Severely	2	3		2
LT00183	raloxifene	C1CCN(CC1)CCOC2=CC=C(C=C2)C(=O)C3=C(SC4=C3C=CC(=C4)O)C5=CC=C(C=C5)O	C28 H27 N O4 S		84449-90-1	DB00481	G03XC01	vNo-DILI-Concern	No-DILI-Concern	No match	0		WE	Negative				non-hepatotixic	2
LT00184	mifepristone	CC#C[C@@]1(CC[C@@H]2[C@@]1(C[C@@H](C3=C4CCC(=O)C=C4CC[C@@H]23)C5=CC=C(C=C5)N(C)C)C)O	C29 H35 N O2		84371-65-3	DB00834	G03XB01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00185	clomipramine	CN(C)CCCN1C2=CC=CC=C2CCC3=C1C=C(C=C3)Cl	C19 H23 Cl N2		303-49-1	DB01242	N06AA04	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Rare reports of more severe liver injury, some fatal, have been recorded in foreign postmarketing experience	HH	Positive		1			2
LT00186	pravastatin	CC[C@H](C)C(=O)O[C@H]1C[C@@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@H](C[C@H](CC(=O)O)O)O)O	C23 H36 O7		81093-37-0	DB00175	C10AA03	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3				Moderately	1		non-hepatotixic	1
LT00187	clarithromycin	CC[C@@H]1[C@@]([C@@H]([C@H](C(=O)[C@@H](C[C@@]([C@@H]([C@H]([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)OC)C)C)O)(C)O	C38 H69 N O13		81103-11-9	DB01211	J01FA09	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hepatic dysfunction, including increased liver enzymes, and hepatocellular and/or cholestatic hepatitis, with or without jaundice, has been reported with clarithromycin. This hepatic dysfunction may be severe and is usually reversible. In some instances,	HH			2	3	non-hepatotixic	2
LT00188	hydrocortisone	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2[C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O	C21 H30 O5		50-23-7	DB07886	H02AB09 S01CB03 A07EA02 C05AA01 A01AC03 S01BA02 D0	vNo-DILI-Concern	No-DILI-Concern	No match	0			Negative					2
LT00192	progesterone	CC(=O)[C@H]1CC[C@@H]2[C@@]1(CC[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C	C21 H30 O2		57-83-0	DB00396	G03DA04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	The following laboratory results may be altered by the use of estrogen-progestin combination drugs: increased sulfobromophthalein retention and other hepatic function tests	HH	Positive		1		non-hepatotixic	2
LT00194	ergocalciferol	C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](CCC3=C)O)C	C28 H44 O		50-14-6	DB00153	A11CC01	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative					1
LT00199	ibuprofen	CC(C)CC1=CC=C(C=C1)C(C)C(=O)O	C13 H18 O2		15687-27-1	DB01050	M01AE01 M02AA13 G02CC01 C01EB16	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including ibuprofen.	WE		Moderately	2	3	Hepatotoxic	1
LT00200	isoproterenol	CC(C)NCC(C1=CC(=C(C=C1)O)O)O	C11 H17 N O3		7683-59-2	DB01064	R03AB02 R03CB01 C01CA02	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative	Non-toxic				1
LT00204	ketorolac	C1CN2C(=CC=C2C(=O)C3=CC=CC=C3)C1C(=O)O	C15 H13 N O3		74103-06-3	DB00465	M01AB15 S01BC05	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3		HH	Positive	Severely	1	2		1
LT00205	promethazine	CC(CN1C2=CC=CC=C2SC3=CC=CC=C31)N(C)C	C17 H20 N2 S		60-87-7 58-33-3	DB01069	R06AD02 D04AA10	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	jaundice.	NE	Negative			3		2
LT00206	omeprazole	CC1=CN=C(C(=C1OC)C)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC	C17 H19 N3 O3 S		73590-58-6	DB00338	A02BC01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	Hepatobiliary: jaundice, abnormal liver function tests, hepatitis (some cases have been fatal)				2		non-hepatotixic	2
LT00207	carvedilol	COC1=CC=CC=C1OCCNCC(COC2=CC=CC3=C2C4=CC=CC=C4N3)O	C24 H26 N2 O4		72956-09-3	DB01136	C07AG02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Liver and Biliary System: SGPT increased, SGOT increased.				1			2
LT00209	cytarabine	C1=CN(C(=O)N=C1N)[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)O	C9 H13 N3 O5		147-94-4	DB00987	L01BC01	vMost-DILI-Concern	Most-DILI-Concern	Box warning	3	Less serious toxicity includes nausea, vomiting, diarrhea and abdominal pain, oral ulceration, and hepatic dysfunction					1	Hepatotoxic	1
LT00211	norethindrone	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC(=O)CC[C@H]34	C20 H26 O2		68-22-4	DB00717	G03DC02 G03AC01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Abnormalities of liver tests (i.e., AST, ALT, Bilirubin)	HH	Positive					2
LT00213	tromethamine	C(C(CO)(CO)N)O	C4 H11 N O3		77-86-1		B05BB03 B05XX02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	6	has been associated with hepatocellular necrosis	NE						2
LT00216	pergolide	CCCN1C[C@@H](C[C@H]2[C@H]1CC3=CNC4=CC=CC2=C34)CSC	C19 H26 N2 S		66104-22-1	DB01186	N04BC02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	hepatitis, stomach ulcer, melena, hepatomegaly, hematemesis,							2
LT00217	nisoldipine	CC1=C(C(C(=C(N1)C)C(=O)OCC(C)C)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC	C20 H24 N2 O6		63675-72-9	DB00401	C08CA07	Ambiguous DILI-concern	Less-DILI-concern	Adverse reactions	3	abnormal liver function tests;hepatomegaly	NE	Negative				non-hepatotixic	2
LT00219	citalopram	CN(C)CCC[C@@]1(C2=C(CO1)C=C(C=C2)C#N)C3=CC=C(C=C3)F			59729-33-8	DB00215	N06AB04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	7	Infrequent: increased hepatic enzymes,	WE	Negative		1			2
LT00220	megestrol	CC1=C[C@@H]2[C@H](CC[C@]3([C@H]2CC[C@@]3(C(=O)C)O)C)[C@@]4(C1=CC(=O)CC4)C	C22 H30 O3		3562-63-8	DB00351	G03DB02 G03AC05 L02AB01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	1	hepatomegaly					1		2
LT00222	methyltestosterone	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@H]2CC[C@]4([C@H]3CC[C@]4(C)O)C	C20 H30 O2		58-18-4	DB06710	G03EK01 G03BA02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	2	Cholestatic hepatitis and jaundice occur with 17-alpha-alkylandrogens at a relatively low dose.				1			2
LT00223	testosterone	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)CCC4=CC(=O)CC[C@]34C	C19 H28 O2		58-22-0 57-85-2	DB00624	G03BA03	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Prolonged use of high doses of androgens has been associated with the development of peliosis hepatis and hepatic neoplasms. Peliosis hepatis can be a life-threatening or fatal complicat. Testosterone is not known to produce these adverse effects.				1		non-hepatotixic	2
LT00225	praziquantel	C1CCC(CC1)C(=O)N2CC3C4=CC=CC=C4CCN3C(=O)C2	C19 H24 N2 O2		55268-74-1	DB01058	P02BA01	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Minimal increases in liver enzymes have been reported in some patients	NE	Negative	Non-toxic				2
LT00227	ticlopidine	C1CN(CC2=C1SC=C2)CC3=CC=CC=C3Cl	C14 H14 Cl N S		55142-85-3	DB00208	B01AC05	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	4	Associated with elevations of alkaline phosphatase, bilirubin, and transaminases	HH	Positive		2		Hepatotoxic	1
LT00230	diazepam	CN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3	C16 H13 Cl N2 O		439-14-5	DB00829	N05BA01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	elevated transaminases and alkaline phosphatase				1			2
LT00233	clomifene	CCN(CC)CCOC1=CC=C(C=C1)/C(=C(/C2=CC=CC=C2)\Cl)/C3=CC=CC=C3	C26 H28 Cl N O		911-45-5	DB00882	G03GB02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Transient liver function test abnormalities suggestive of hepatic dysfunction, which may be accompanied by morphologic changes on liver biopsy, have been reported in association with OHSS.	HH	Positive		1			2
LT00234	isotretinoin	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C	C20 H28 O2		4759-48-2	DB00982	D10AD04 D10BA01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	5	Hepatotoxicity: Clinical hepatitis considered to be possibly or probably related.Mild to moderate elevations of liver enzymes have been observed in approximately 15% of individuals treated during clinical trials. Serious skin reations was warned.	HH	Positive	Moderately	1	2		1
LT00235	oxymetholone	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(CC(=CO)C(=O)C4)C	C21 H32 O3		434-07-1		A14AA05	vMost-DILI-Concern	Most-DILI-Concern	Box warning	7	Peliosis hepatitis, a condition in which liver and sometimes splenic tissue is replaced with blood-filled cysts, has been reported in patients receiving androgenic anabolic steroid therapy. These cysts are sometimes present with minimal hepatic dysfunctio				1			1
LT00240	etodolac	CCC1=CC=CC2=C1NC3=C2CCOC3(CC)CC(=O)O	C17 H21 N O3		41340-25-4	DB00749	M01AB08	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hepatic Effects: Rare cases of liver necrosis and hepatic failure, some of them with fatal outcomes have been reported				2	2		1
LT00243	glipizide	CC1=NC=C(N=C1)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3	C21 H27 N5 O4 S		29094-61-9	DB01067	A10BB07	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Cholestatic and hepatocellular forms of liver injury accompanied by jaundice have been reported rarely in association with glipizide; GLUCOTROL XL should be discontinued if this occurs.s. Occasional mild to moderate elevations of SGOT				1			2
LT00246	pemoline	C1=CC=C(C=C1)C2C(=O)N=C(O2)N	C9 H8 N2 O2		2152-34-3	DB01230	N06BA05	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn		Hepatic effects, ranging from slight elevations in liver enzymes to rare cases of hepatic failure have been reported	HH			3	3		1
LT00248	clotrimazole	C1=CC=C(C=C1)C(C2=CC=CC=C2)(C3=CC=CC=C3Cl)N4C=CN=C4	C22 H17 Cl N2		23593-75-1	DB00257	D01AC01 A01AB18 G01AF02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Abnormal liver function tests have been reported in patients	WE	Negative				non-hepatotixic	1
LT00252	celecoxib	CC1=CC=C(C=C1)C2=CC(=NN2C3=CC=C(C=C3)S(=O)(=O)N)C(F)(F)F	C17 H14 F3 N3 O2 S		169590-42-5	DB00482	M01AH01 L01XX33	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	In controlled clinical trials of CELEBREX, the incidence of borderline elevations (greater than or equal to 1.2 times and less than 3 times the upper limit of normal) of liver associated enzymes was 6% for CELEBREX and 5% for placebo,				1			2
LT00256	amoxapine	C1CN(CCN1)C2=NC3=CC=CC=C3OC4=C2C=C(C=C4)Cl	C17 H16 Cl N3 O		14028-44-5	DB00543	N06AA17	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	allerge hepatitis; altered liver function (<1%)	WE	Negative					2
LT00257	iothalamate sodium	CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)C(=O)NC)I	C11 H9 I3 N2 O4				V08AA04	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00258	atorvastatin	CC(C)C1=C(C(=C(N1CC[C@H](C[C@H](CC(=O)O)O)O)C2=CC=C(C=C2)F)C3=CC=CC=C3)C(=O)NC4=CC=CC=C4	C33 H35 F N2 O5		134523-00-5		C10AA05	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	5	Liver Dysfunction; One patient in clinical trials developed jaundice				2		Hepatotoxic	2
LT00259	olanzapine	CC1=CC2=C(NC3=CC=CC=C3N=C2S1)N4CCN(CC4)C	C17 H20 N4 S		132539-06-1	DB00334	N05AH03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Livery enzymes increased				1	2	non-hepatotixic	2
LT00260	nevirapine	CC1=C2C(=NC=C1)N(C3=C(C=CC=N3)C(=O)N2)C4CC4	C15 H14 N4 O		129618-40-2	DB00238	J05AG01	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Fatal and non-fatal hepatotoxicity				1		Hepatotoxic	1
LT00261	primidone	CCC1(C(=O)NCNC1=O)C2=CC=CC=C2	C12 H14 N2 O2		125-33-7	DB00794	N03AA03	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative			2		1
LT00262	vinorelbine	CCC1=CC2C[C@@](C3=C(CN(C2)C1)C4=CC=CC=C4N3)(C5=C(C=C6C(=C5)[C@]78CCN9[C@H]7[C@@](C=CC9)([C@H]([C@@]([C@@H]8N6C)(C(=O)OC)O)OC(=O)C)CC)OC)C(=O)OC	C45 H54 N4 O8		71486-22-1	DB00361	L01CA04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Hepatic: Transient elevations of liver enzymes were reported without clinical symptoms.							2
LT00263	anastrozole	CC(C)(C#N)C1=CC(=CC(=C1)CN2C=NC=N2)C(C)(C)C#N	C17 H19 N5		120511-73-1	DB01217	L02BG03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Hepatic: Gamma GT increased; SGOT increased; SGPT increased				1	2		2
LT00264	rabeprazole	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCCCOC	C18 H21 N3 O3 S		117976-89-3	DB01129	A02BC04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	hepatic enzyme increase, hepatitis, hepatic encephalopathy,							2
LT00265	azithromycin	CC[C@@H]1[C@@]([C@@H]([C@H](N(C[C@@H](C[C@@]([C@@H](C([C@@H]([C@H](C(=O)O1)C)O[C@H]2C[C@@]([C@H]([C@@H](O2)C)O)(C)OC)C)O[C@H]3[C@@H]([C@H](C[C@H](O3)C)N(C)C)O)(C)O)C)C)C)O)(C)O	C38 H72 N2 O12		83905-01-5	DB00207	S01AA26 J01FA10	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	7	cholestatic jaundice;Liver/Biliary: Abnormal liver function including hepatitis and cholestatic jaundice, as well as rare cases of hepatic necrosis and hepatic failure, some of which have resulted in death.	WE	Negative		2	3	Hepatotoxic	2
LT00266	tolazamide	CC1=CC=C(C=C1)S(=O)(=O)NC(=O)NN2CCCCCC2	C14 H21 N3 O3 S		1156-19-0	DB00839	A10BB05	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	Cholestatic jaundice may occur rarely	HH		Moderately				2
LT00267	quetiapine	C1CN(CCN1CCOCCO)C2=NC3=CC=CC=C3SC4=CC=CC=C42	C21 H25 N3 O2 S		111974-69-7	DB01224	N05AH04	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Asymptomatic, transient and reversible elevations in serum transaminases (primarily ALT) have been reported				2			2
LT00270	famciclovir	CC(=O)OCC(CCN1C=NC2=CN=C(N=C21)N)COC(=O)C	C14 H19 N5 O4		104227-87-4	DB00426	S01AD07 J05AB09	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Abnormal liver function tests, cholestatic jaundice							2
LT00277	atenolol	CC(C)NCC(COC1=CC=C(C=C1)CC(=O)N)O	C14 H22 N2 O3		29122-68-7	DB00335	C07AB03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	elevated liver enzymes and/or bilirubin	NE	Negative		2			2
LT00278	benzbromarone	CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)Br)O)Br	C17 H12 Br2 O3		3562-84-3		M04AB03	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH	Positive		3		Hepatotoxic	1
LT00279	bromocriptine	CC(C)C[C@H]1C(=O)N2CCC[C@H]2[C@]3(N1C(=O)[C@](O3)(C(C)C)NC(=O)[C@H]4CN([C@@H]5CC6=C(NC7=CC=CC(=C67)C5=C4)Br)C)O	C32 H40 Br N5 O5		25614-03-3	DB01200	G02CB01 N04BC01	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	periodic evaluation of hepatic, hematopoietic, cardiovascular, and renal function is recommended							2
LT00280	busulfan	CS(=O)(=O)OCCCCOS(=O)(=O)C	C6 H14 O6 S2		55-98-1	DB01008	L01AB01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hepatic veno-occlusive disease, which may be life threatening, has been reported	HH	Positive			3	Hepatotoxic	1
LT00286	chlorambucil	C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl	C14 H19 Cl2 N O2		305-03-3	DB00291	L01AA02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Patients should be informed that the major toxicities of chlorambucil are related to hypersensitivity, drug fever, myelosuppression, hepatotoxicity					1		2
LT00287	clozapine	CN1CCN(CC1)C2=C3C=CC=CC3=NC4=C(N2)C=C(C=C4)Cl	C18 H19 Cl N4		5786-21-0	DB00363	N05AH02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	5	If the elevation of these values is clinically relevant or if symptoms of jaundice occur, treatment with clozapine should be discontinued	HH	Positive		1	2	Hepatotoxic	1
LT00288	dacarbazine	CN(C)N/N=C\1/C(=NC=N1)C(=O)N	C6 H10 N6 O		03/04/4342	DB00851	L01AX04	vMost-DILI-Concern	Most-DILI-Concern	Box warning	6	Hepatic necrosis has been reported	HH				3	Hepatotoxic	1
LT00289	dapsone	C1=CC(=CC=C1N)S(=O)(=O)C2=CC=C(C=C2)N	C12 H12 N2 O2 S		80-08-0	DB00250	J04BA02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Toxic hepatitis and cholestatic jaundice have been reported early in therapy	HH	Positive		2		Hepatotoxic	2
LT00292	digoxin	C[C@@H]1[C@H]([C@H](C[C@@H](O1)O[C@@H]2[C@H](O[C@H](C[C@@H]2O)O[C@@H]3[C@H](O[C@H](C[C@@H]3O)O[C@H]4CC[C@]5([C@@H](C4)CC[C@@H]6[C@@H]5C[C@H]([C@]7([C@@]6(CCC7C8=CC(=O)OC8)O)C)O)C)C)C)O)O	C41 H64 O14		20830-75-5	DB00390	C01AA05	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative				non-hepatotixic	1
LT00294	dipyridamole	C1CCN(CC1)C2=NC(=NC3=C2N=C(N=C3N4CCCCC4)N(CCO)CCO)N(CCO)CCO	C24 H40 N8 O4		58-32-2	DB00975	B01AC07	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Dipyridamole has been associated with elevated hepatic enzymes.	NE						2
LT00295	disulfiram	CCN(CC)C(=S)SSC(=S)N(CC)CC	C10 H20 N2 S4		97-77-8	DB00822	P03AA04 N07BB01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hepatic toxicity including hepatic failure resulting in transplantation or death have been reported.			Severely	2	3	Hepatotoxic	1
LT00296	enalapril	CCOC(=O)[C@@H](CCC1=CC=CC=C1)N[C@@H](C)C(=O)N2CCC[C@H]2C(=O)O	C20 H28 N2 O5		75847-73-3	DB00584	C09AA02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	Liver Function Tests: Elevations of liver enzymes and/or serum bilirubin have occurred			Moderately	2	3		1
LT00298	flurbiprofen	CC(C1=CC(=C(C=C1)C2=CC=CC=C2)F)C(=O)O	C15 H13 F O2		5104-49-4	DB00712	S01BC04 M01AE09 M02AA19	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3		HH	Positive					1
LT00299	furosemide	C1=COC(=C1)CNC2=CC(=C(C=C2C(=O)O)S(=O)(=O)N)Cl	C12 H11 Cl N2 O5 S		54-31-9	DB00695	C03CA01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	Jaundice (intrahepatic cholestatic jaundice)	HH	Positive	Moderately			Hepatotoxic	1
LT00300	gabapentin	C1CCC(CC1)(CC(=O)O)CN	C9 H17 N O2		60142-96-3	DB00996	N03AX12	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	DRESS typically, although not exclusively, presents with fever, rash, and/or lymphadenopathy, in association with other organ system involvement, such as hepatitis, nephritis, hematological abnormalities,	NE	Negative		1			2
LT00302	glibenclamide	COC1=C(C=C(C=C1)Cl)C(=O)NCCC2=CC=C(C=C2)S(=O)(=O)NC(=O)NC3CCCCC3	C23 H28 Cl N3 O5 S		10238-21-8	DB01016	A10BB01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Liver function abnormalities, including isolated transaminase elevations, have been reported.			Moderately	1			2
LT00306	isoniazid	C1=CN=CC=C1C(=O)NN	C6 H7 N3 O		54-85-3	DB00951	J04AC01	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Severe and sometimes fatal hepatitis associated with isoniazid therapy has been reported and may occur or may develop even after many months of treatment.	HH	Positive	Severely	2	3	Hepatotoxic	1
LT00307	lansoprazole	CC1=C(C=CN=C1CS(=O)C2=NC3=CC=CC=C3N2)OCC(F)(F)F	C16 H14 F3 N3 O2 S		103577-45-3	DB00448	A02BC03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Abnormal liver function tests, increased SGOT (AST), increased SGPT (ALT				1			2
LT00308	mebendazole	COC(=O)NC1=NC2=C(N1)C=C(C=C2)C(=O)C3=CC=CC=C3	C16 H13 N3 O3		31431-39-7	DB00643	P02CA01	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Periodic assessment of organ system functions, including hematopoietic and hepatic, is advisable	HH	Positive					1
LT00309	metoprolol	CC(C)NCC(COC1=CC=C(C=C1)CCOC)O	C15 H25 N O3		51384-51-1	DB00264	C07AB02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Postmarketing experience reveals very rare reports of hepatitis, jaundice and non-specific hepatic dysfunction.				1			1
LT00310	mycophenolic acid	CC1=C(C(=C(C2=C1COC2=O)O)C/C=C(\C)/CCC(=O)O)OC	C17 H20 O6		24280-93-1	DB01024	L04AA06	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	ncreased, liver function tests abnormal							2
LT00311	naltrexone	C1CC1CN2CC[C@]34[C@@H]5C(=O)CC[C@]3([C@H]2CC6=C4C(=C(C=C6)O)O5)O	C20 H23 N O4		16590-41-3	DB00704	N07BB04	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Cases of hepatitis and clinically significant liver dysfunction were observed in association with naltrexone hydrochloride exposure during the clinical development program and in the postmarketing period	HH	Positive			2		1
LT00312	niacin	C1=CC(=CN=C1)C(=O)O	C6 H5 N O2		59-67-6	DB00627	C10AD02 C04AC01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	Liver Dysfunction: Cases of severe hepatic toxicity, including fulminant hepatic necrosis	HH	Positive	Severely	1		Hepatotoxic	1
LT00313	nifedipine	CC1=C(C(C(=C(N1)C)C(=O)OC)C2=CC=CC=C2[N+](=O)[O-])C(=O)OC	C17 H18 N2 O6		21829-25-4	DB01115	C08CA05	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Rare, usually transient, but occasionally significant elevations of enzymes such as alkaline phosphatase, CPK, LDH, SGOT, and SGPT; and cholestasis with or without jaundice has been reported	HH	Positive				Hepatotoxic	1
LT00314	nimesulide	CS(=O)(=O)NC1=C(C=C(C=C1)[N+](=O)[O-])OC2=CC=CC=C2	C13 H12 N2 O5 S		51803-78-2	DB04743	M01AX17	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH	Positive	Severely	3		Hepatotoxic	1
LT00315	nizatidine	CN/C(=C\[N+](=O)[O-])/NCCSCC1=CSC(=N1)CN(C)C	C12 H21 N5 O2 S2		76963-41-2	DB00585	A02BA04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Hepatocellular and cholestatic injury, elevated liver enzyme tests; hepatitis and jaundice have been reported.			Moderately		3		1
LT00322	methenamine hippurate	C1N2CN3CN1CN(C2)C3	C6 H12 N4		100-97-0		J01XX05	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	the serum transaminase levels were slightly elevated during treatment but returned to normal while the patients were still takingÂ methenamine hippurate tablets,Â USP.							2
LT00327	dextrose	C([C@@H]1[C@H]([C@@H]([C@H](C(O1)O)O)O)O)O	C6 H12 O6		50-99-7		B05CX01 V06DC01 V04CA02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00328	cholestyramine	CC(C)(C(=O)NCCS(=O)(=O)[O-])OC1=CC=C(C=C1)C(=O)C2=CC=C(C=C2)Cl	C19 H19 Cl N O6 S		11041-12-6	DB01432	C10AC01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Liver function abnormalities							2
LT00330	sodium lactate	[13CH3]C(C(=O)[O-])O.[Na+]	C3 H5 O3 . Na		72-17-3			vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00332	verapamil	CC(C)C(CCCN(C)CCC1=CC(=C(C=C1)OC)OC)(C#N)C2=CC(=C(C=C2)OC)OC	C27 H38 N2 O4		52-53-9	DB00661	C08DA01	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Elevated liver enzymes: Elevations of transaminases with and without concomitant elevations in alkaline phosphatase and bilirubin have been reported.	WE			1			1
LT00335	doxorubicin	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)CO)O)N)O	C27 H29 N O11		23214-92-8	DB00997	L01DB01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Digestive: hepatitis.			Moderately	1	2	Hepatotoxic	2
LT00338	tretinoin	CC1=C(C(CCC1)(C)C)/C=C/C(=C/C=C/C(=C/C(=O)O)/C)/C	C20 H28 O2		302-79-4	DB00755	L01XX14 D10AD01	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Clinical hepatitis considered to be possibly or probably related to isotretinoin therapy has been reported. Additionally, mild to moderate elevations of liver enzymes have been observed in approximately 15% of individuals treated during clinical trials wi	HH					Hepatotoxic	2
LT00340	isosorbide mononitrate	C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O)O			16051-77-7	DB01020	C01DA14	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Liver and Biliary System Disorders: SGOT increase, SGPT increase.							1
LT00341	clorazepate	C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)C(=O)O	C16 H11 Cl N2 O3		23887-31-2 57109-90-7	DB00628	N05BA05	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Patients taking TRANXENE tablets for prolonged periods should have blood counts and liver function tests periodically				1			2
LT00349	protirelin	C1C[C@H](N(C1)C(=O)[C@H](CC2=CN=CN2)NC(=O)[C@@H]3CCC(=O)N3)C(=O)N	C16 H22 N6 O4		24305-27-9		V04CJ02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00350	sincalide	CSCC[C@@H](C(=O)NCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N)NC(=O)[C@H](CC4=CC=C(C=C4)OS(=O)(=O)O)NC(=O)[C@H](CC(=O)O)N	C49 H62 N10 O16 S3		25126-32-3		V04CC03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00355	secretin	CC(C)CC(C(=O)NC(C(C)C)C(=O)O)NC(=O)CNC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CCC(=O)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(C)NC(=O)C(CO)NC(=O)C(CC(=O)O)NC(=O)C(CCCNC(=N)N)NC(=O)C(CC(C)C)NC(=O)C(CCCNC(=N)N)NC(=O)C(CO)N	C130 H219 N43 O42		1393-25-5		V04CK01	vNo-DILI-Concern	No-DILI-concern	No match	0								2
LT00358	sucralfate	C([C@@H]1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@]2([C@H]([C@@H]([C@H](O2)OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])COS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-])OS(=O)(=O)[O-].O.O.O.[Al]	C11 H12 O35 S8 . Al . 3 H2 O		54182-58-0	DB00364	A02BX02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00361	cupric chloride	Cl[Cu]Cl	Cl2 Cu		7447-39-4			vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00375	trientine hydrochloride	C(CNCCNCCN)N.Cl.Cl	C6 H18 N4 . 2 Cl H		112-24-3			vNo-DILI-Concern	No-DILI-Concern	No match	1		HH						2
LT00379	chlorpropamide	CCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)Cl	C10 H13 Cl N2 O3 S		94-20-2	DB00672	A10BB02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	Cholestatic jaundice may occur rarely.	HH			1		Hepatotoxic	1
LT00380	cyclosporine	CCC1C(=O)N(CC(=O)N(C(C(=O)NC(C(=O)N(C(C(=O)NC(C(=O)NC(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N(C(C(=O)N1)[C@@H]([C@H](C)C/C=C/C)O)C)C(C)C)C)CC(C)C)C)CC(C)C)C)C)C)CC(C)C)C)C(C)C)CC(C)C)C)C	C62 H111 N11 O12		59865-13-3	DB00091	L04AD01 S01XA18	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	Cases of hepatotoxicity and liver injury including cholestasis, jaundice, hepatitis and liver failure have been reported in patients treated with cyclosporine.	HH	Positive	Severely		2	Hepatotoxic	1
LT00381	enalaprilat	C[C@@H](C(=O)N1CCC[C@H]1C(=O)O)N[C@@H](CCC2=CC=CC=C2)C(=O)O	C18 H24 N2 O5		76420-72-9			Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	7	ACE inhibitors have been associated with a syndrome that starts with cholestatic jaundice and progresses to fulminant hepatic necrosis, and (sometimes) death.							2
LT00385	decitabine	C1[C@@H]([C@H](O[C@H]1N2C=NC(=NC2=O)N)CO)O	C8 H12 N4 O4		2353-33-5	DB01262	L01BC08	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	increased blood bilirubin, intracranial hemorrhage, abnormal liver function tests.							2
LT00386	deferoxamine	CC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCNC(=O)CCC(=O)N(CCCCCN)O)O)O	C25 H48 N6 O8		70-51-9	DB00746	V03AC01	vLess-DILI-Concern	No-DILI-Concern	No match	0		HH	Positive					1
LT00393	doxycycline	C[C@@H]1[C@H]2[C@@H]([C@H]3[C@@H](C(=O)/C(=C(\N)/O)/C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)N(C)C)O	C22 H24 N2 O8		564-25-0	DB00254	J01AA02 A01AB22	vLess-DILI-Concern	Less-DILI-Concern	Aderse reactions	3	In long-term therapy, periodic laboratory evaluation of organ systems, including hematopoietic, renal and hepatic studies should be performed.	HH	Positive		2			1
LT00394	exemestane	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CC(=C)C4=CC(=O)C=C[C@]34C	C20 H24 O2		107868-30-4	DB00990	L02BG06	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	4	Elevations of serum levels of AST, ALT, alkaline phosphatase, and gamma glutamyl transferase > 5 times the upper value of the normal range (i.e., â‰¥ CTC grade 3) have been rarely reported in patients treated for advanced breast cancerIn patients with ear					1		2
LT00397	felodipine	CCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C	C18 H19 Cl2 N O4		72509-76-3	DB01023	C08CA02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	ALT (SGPT) increased; ;Liver Enzymes— 1 of 2 episodes of elevated serum transaminases decreased once drug was discontinued in clinical studies; no follow-up was available for the other patient.				2			2
LT00399	fludrocortisone	C[C@]12CCC(=O)C=C1CC[C@@H]3[C@@]2([C@H](C[C@]4([C@H]3CC[C@@]4(C(=O)CO)O)C)O)F	C21 H29 F O5		127-31-1	DB00687	H02AA02	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative					2
LT00400	fluphenazine	C1CN(CCN1CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F)CCO	C22 H26 F3 N3 O S		69-23-8	DB00623	N05AB02	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Facilities should be available for periodic checking of hepatic function, renal function and the blood picture.					3		2
LT00401	fulvestrant	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@@H]2O)[C@@H](CC4=C3C=CC(=C4)O)CCCCCCCCCS(=O)CCCC(C(F)(F)F)(F)F	C32 H47 F5 O3 S		129453-61-8	DB00947	L02BA03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	7	post-baseline increases of CTC grade in either AST, ALT, or alkaline phosphatase were observed in > 15% of patients receiving FASLODEX. Elevation of bilirubin, elevation of gamma GT, hepatitis, and liver failure have been reported infrequently (<1%)							2
LT00402	gefitinib	COC1=C(C=C2C(=C1)N=CN=C2NC3=CC(=C(C=C3)F)Cl)OCCCN4CCOCC4	C22 H24 Cl F N4 O3		184475-35-2	DB00317	L01XE02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	4	Asymptomatic increases in liver transaminases have been observed in IRESSA treated patients; therefore, periodic liver function (transaminases, bilirubin, and alkaline phosphatase) testing should be considered. Discontinuation of IRESSA should be consider							2
LT00405	haloperidol	C1CN(CCC1(C2=CC=C(C=C2)Cl)O)CCCC(=O)C3=CC=C(C=C3)F	C21 H23 Cl F N O2		52-86-8	DB00502	N05AD01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Impaired liver function and/or jaundice have been reported				1			1
LT00414	mesalazine	C1=CC(=C(C=C1N)C(=O)O)O	C7 H7 N O3		89-57-6	DB00244	A07EC02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	7	There have been rare reports of hepatotoxicity including, jaundice, cholestatic jaundice, hepatitis, and possible hepatocellular damage including liver necrosis and liver failure. Some of these cases were fatal. Asymptomatic elevations of liver enzymes wh			Moderately	1			2
LT00416	minocycline	CN(C)[C@H]1[C@@H]2C[C@@H]3CC4=C(C=CC(=C4C(=C3C(=O)[C@@]2(C(=O)/C(=C(/N)\O)/C1=O)O)O)O)N(C)C	C23 H27 N3 O7		10118-90-8	DB01017	J01AA08 A01AB23	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Postmarketing cases of serious liver injury, including irreversible drug-induced hepatitis and fulminant hepatic failure (sometimes fatal) have been reported with minocycline use in the treatment of acne.	HH		Severely	1	3	Hepatotoxic	1
LT00419	ioversol	C(CO)N(C1=C(C(=C(C(=C1I)C(=O)NCC(CO)O)I)C(=O)NCC(CO)O)I)C(=O)CO	C18 H24 I3 N3 O9				V08AB07	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00426	histrelin acetate	CCNC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CN(C=N2)CC3=CC=CC=C3)NC(=O)[C@H](CC4=CC=C(C=C4)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC5=CNC6=CC=CC=C65)NC(=O)[C@H](CC7=CN=CN7)NC(=O)[C@@H]8CCC(=O)N8.CC(=O)O	C66 H86 N18 O12 . C2 H4 O2		76712-82-8		H01CA03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Hepatic disorder							2
LT00429	oxaprozin	C1=CC=C(C=C1)C2=C(OC(=N2)CCC(=O)O)C3=CC=CC=C3	C18 H15 N O3		21256-18-8	DB00991	M01AE12	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including DAYPRO	HH			1	2		2
LT00430	paclitaxel	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)C6=CC=CC=C6)O)O)OC(=O)C7=CC=CC=C7)(CO4)OC(=O)C)O)C)OC(=O)C	C47 H51 N O14		33069-62-4	DB01229	L01CD01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	AST, billitubin	HH		Moderately	1	3		2
LT00433	phentolamine	CC1=CC=C(C=C1)N(CC2=NCCN2)C3=CC(=CC=C3)O	C17 H19 N3 O		50-60-2	DB00692	G04BE05 C04AB01	vNo-DILI-Concern	No-DILI-Concern	No match	0		HH	Positive					1
LT00435	prazosin	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4=CC=CO4)N)OC	C19 H21 N5 O4		19216-56-9	DB00457	C02CA01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	liver function abnormalities							2
LT00437	prochlorperazine	CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl	C20 H24 Cl N3 S		58-38-8	DB00433	N05AB04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	There have been a few observations of fatty changes in the livers	HH				3	Hepatotoxic	2
LT00438	corticorelin ovine triflutate	CC[C@H](C)[C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC1=CC=CC=C1)C(=O)N[C@@H](CC2=CN=CN2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(=N)N)C(=O)N[C@@H](CCC(=O)O)C	C205 H339 N59 O63 S		79804-71-0		V04CD04	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00439	sodium thiosulfate	[O-]S(=O)(=S)[O-].[Na+].[Na+]	2 Na . O3 S2		7772-98-7			vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00443	sirolimus	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)CC4CC[C@H]([C@@H](C4)OC)O)C)/C)O)OC)C)C)/C)OC	C51 H79 N O13		53123-88-9	DB00877	L04AA10	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	8	epatobiliary Disorders â€“ Hepatotoxicity, including fatal hepatic necrosis, with elevated sirolimus trough concentrations.							2
LT00448	tacrolimus	C[C@@H]1C[C@@H]([C@@H]2[C@H](C[C@H]([C@@](O2)(C(=O)C(=O)N3CCCC[C@H]3C(=O)O[C@@H]([C@@H]([C@H](CC(=O)[C@@H](C=C(C1)C)CC=C)O)C)C(=C[C@@H]4CC[C@H]([C@@H](C4)OC)O)C)O)C)OC)OC	C44 H69 N O12		104987-11-3	DB00864	D11AH01 L04AD02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Cholangitis, cholestatic jaundice, hepatitis, jaundice, liver damage, abnormal liver function test					2		1
LT00450	thalidomide	C1CC(=O)NC(=O)C1N2C(=O)C3=CC=CC=C3C2=O	C13 H10 N2 O4		50-35-1	DB01041	L04AX02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	SGOT (increased); Bilirubin (increased)							2
LT00451	thioridazine	CN1CCCCC1CCN2C3=CC=CC=C3SC4=C2C=C(C=C4)SC	C21 H26 N2 S2		50-52-2	DB00679	N05AC02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Hepatotoxicity: Jaundice, biliary stasis					3		2
LT00452	thioguanine	C1=NC2=C(N1)C(=S)N=C(N2)N	C5 H5 N5 S		154-42-7	DB00352	L01BB03	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	2	Liver toxicity usually presents as the clinical syndrome of hepatic veno-occlusive disease (hyperbilirubinemia, tender hepatomegaly, weight gain due to fluid retention, and ascites) or with signs of portal hypertension (splenomegaly, thrombocytopenia, and	HH	Positive			2		1
LT00453	tolbutamide	CCCCNC(=O)NS(=O)(=O)C1=CC=C(C=C1)C	C12 H18 N2 O3 S		64-77-7	DB01124	V04CA01 A10BB03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	Cholestatic jaundice may occur rarely	HH		Moderately				1
LT00455	topiramate	CC1(O[C@@H]2CO[C@@]3([C@H]([C@@H]2O1)OC(O3)(C)C)COS(=O)(=O)N)C	C12 H21 N O8 S		97240-79-4	DB00273	N03AX11	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Liver and Biliary System Disorders: Infrequent: SGPT increased, SGOT increased.				1			2
LT00457	trifluoperazine	CN1CCN(CC1)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)C(F)(F)F	C21 H24 F3 N3 S		117-89-5	DB00831	N05AB06	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	2	Jaundice of the cholestatic type of hepatitis or liver damage has been reported.	HH	Positive	Moderately				1
LT00460	triptorelin pamoate	CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NCC(=O)N)NC(=O)C(CC2=CNC3=CC=CC=C32)NC(=O)C(CC4=CC=C(C=C4)O)NC(=O)C(CO)NC(=O)C(CC5=CNC6=CC=CC=C65)NC(=O)C(CC7=CN=CN7)NC(=O)C8CCC(=O)N8	C64 H82 N18 O13		57773-63-4		L02AE04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Abnormal hepatic function							2
LT00461	alatrofloxacin	C[C@@H](C(=O)N[C@@H](C)C(=O)NC1[C@H]2[C@@H]1CN(C2)C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F)N			157182-32-6			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						3			1
LT00462	vorinostat	C1=CC=C(C=C1)NC(=O)CCCCCCC(=O)NO	C14 H20 N2 O3		149647-78-9	DB02546	L01XX38	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00463	sacrosidase	CC1OC2=C(O1)C=C(C=C2)C(C)(C)C	C12 H16 O2		EC 3.2.1.26		A16AB06	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3								2
LT00464	doxercalciferol	C[C@H](/C=C/[C@H](C)C(C)C)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C/3\C[C@H](C[C@@H](C3=C)O)O)C	C28 H44 O2		54573-75-0		H05BX03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	hypercholesterolemia, elevated serum aspartate transaminase (AST) and alanine transaminase (ALT),							2
LT00465	nesiritide	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N1)CCCNC(=N)N)CC(=O)O)CCSC)CCCCN)CCCNC(=N)N)CC2=CC=CC=C2)	C143 H244 N50 O42 S4		124584-08-3	DB04899	C01DX19	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00475	ganirelix acetate	CCNC(=NCCCC[C@H](C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN=C(NCC)NCC)C(=O)N1CCC[C@H]1C(=O)N[C@H](C)C(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C)NCC	C80 H113 Cl N18 O13		123246-29-7		H01CC01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00477	gemtuzumab				220578-59-6	DB00056	L01XC05												1
LT00478	methylprednisolone	C[C@H]1C[C@H]2[C@@H]3CC[C@@]([C@]3(C[C@@H]([C@@H]2[C@@]4(C1=CC(=O)C=C4)C)O)C)(C(=O)CO)O	C22 H30 O5		83-43-2	DB00959	D10AA02 H02AB04 D07AA01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Increases in alanine transaminase (ALT, SGPT), aspartate transaminase (AST, SGOT), and alkaline phosphatase have been observed following corticosteroid treatment. These changes are usually small, not associated with any clinical syndrome and are reversibl							2
LT00480	gamma hydroxybutyric acid	C(CC(=O)[O-])CO.[Na+]	C4 H7 O3 . Na		502-85-2			vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00482	l-glutamine	C(CC(=O)N)[C@@H](C(=O)O)N	C5 H10 N2 O3		56-85-9		A16AA03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Hepatic Function Abnormal							2
LT00484	cetrorelix	C[C@H](C(=O)N)NC(=O)[C@@H]1CCCN1C(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CCCNC(=O)N)NC(=O)[C@H](CC2=CC=C(C=C2)O)NC(=O)[C@H](CO)NC(=O)[C@@H](CC3=CN=CC=C3)NC(=O)[C@@H](CC4=CC=C(C=C4)Cl)NC(=O)[C@@H](CC5=CC6=CC=CC=C6C=C5)NC(=O)C	C70 H92 Cl N17 O14		120287-85-6	DB00050	H01CC02	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	enzyme elevations (ALT, AST, GGT, alkaline phosphatase) were found in 1-2% of patients receiving CetrotideÂ® during controlled ovarian stimulation.							2
LT00485	tegaserod	CCCCCN=C(N)NN/C=C/1\C=NC2=C1C=C(C=C2)CO	C16 H23 N5 O		189188-57-6	DB01079	A03AE02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	cholecystitis with elevated transaminases							2
LT00488	penicillamine	CC(C)([C@H](C(=O)O)N)S	C5 H11 N O2 S		52-67-5	DB00859	M01CC01	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	2	Because of rare reports of intrahepatic cholestasis and toxic hepatitis, liver function tests are recommended every six months for the duration of therapy.					2		1
LT00492	pramlintide	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)N1CCC[C@H]1C(=O)N2CCC[C@H]2C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CC3=CC=C(C=C3)O)C(=O)N)NC(=O)[C@@H]4CCCN4	C171 H269 N51 O53 S2		151126-32-8	DB01278	A10BX05	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00493	lanthanum carbonate	C(=O)([O-])[O-].C(=O)([O-])[O-].C(=O)([O-])[O-].O.[La+3].[La+3]	3 C O3 . 2 La . H2 O				V03AE03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00494	fomepizole	CC1=CNN=C1	C4 H6 N2		7554-65-6	DB01213	V03AB34	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	hepatic enzymes and white blood cell counts should be monitored during treatment, as transient increases in serum transaminase concentrations and eosinophilia have been noted with repeated fomepizole dosing.							2
LT00498	acetazolamide	CC(=O)NC1=NN=C(S1)S(=O)(=O)N	C4 H6 N4 O3 S2		59-66-5	DB00819	S01EC01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Fatalities have occurred, although rarely, due to severe reactions to sulfonamides including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis,	HH	Positive					2
LT00499	albendazole	CCCSC1=CC2=C(C=C1)N=C(N2)NC(=O)OC	C12 H15 N3 O2 S		54965-21-8	DB00518	P02CA03	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	In clinical trials, treatment with albendazole has been associated with mild to moderate elevations of hepatic enzymes in approximately 16% of patients. These elevations have generally returned to normal upon discontinuation of therapy. There have also be	HH	Positive		1			2
LT00501	alprazolam	CC1=NN=C2N1C3=C(C=C(C=C3)Cl)C(=NC2)C4=CC=CC=C4	C17 H13 Cl N4		28981-97-7	DB00404	N05BA12	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	7	postmarketing: liver enzyme elevations, hepatitis, hepatic failure							2
LT00502	altretamine	CN(C)C1=NC(=NC(=N1)N(C)C)N(C)C	C9 H18 N6		645-05-6	DB00488	L01XX03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	Hepatic toxicity, in 							1
LT00503	amantadine	C1C2CC3CC1CC(C2)(C3)N	C10 H17 N		768-94-5	DB00915	N04BB01	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Rare instances of reversible elevation of liver enzymes have been reported	NE	Negative					1
LT00505	aminosalicylic acid	C1=CC(=C(C=C1N)O)C(=O)O	C7 H7 N O3		65-49-6		J04AA01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	5	Liver Function: In one retrospective study of 7492 patients on rapidly absorbed aminosalicylic acid preparations, drug-induced hepatitis occurred in 38 patients (0.5%); Premonitory symptoms in 90% of these 38 patients preceded jaundice by a few days to se	HH	Positive	Severely	2		Hepatotoxic	1
LT00507	amoxicillin	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)C(=O)O)C	C16 H19 N3 O5 S		26787-78-0	DB01060	J01CA04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Liver: A moderate rise in AST and/or ALT has been noted, but the significance of this finding is unknown. Hepatic dysfunction including cholestatic jaundice, hepatic cholestasis and acute cytolytic hepatitis have been reported.	WE			1		non-hepatotixic	1
LT00511	atropine	CN1[C@@H]2CC[C@H]1CC(C2)OC(=O)C(CO)C3=CC=CC=C3	C17 H23 N O3		51-55-8	DB00572	A03BA01 S01FA01	vNo-DILI-Concern	No-DILI-Concern	No match	0		HH					non-hepatotixic	1
LT00512	balsalazide	C1=CC(=CC=C1C(=O)NCCC(=O)O)N/N=C\2/C=CC(=O)C(=C2)C(=O)O	C17 H15 N3 O6		80573-04-2	DB01014	A07EC04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	8	Postmarketing adverse reactions of hepatotoxicity have been reported for products which contain (or are metabolized to) mesalamine, including elevated liver function tests (SGOT/AST, SGPT/ALT, GGT, LDH, alkaline phosphatase, bilirubin), jaundice, cholesta							2
LT00513	benoxaprofen	CC(C1=CC2=C(C=C1)OC(=N2)C3=CC=C(C=C3)Cl)C(=O)O	C16 H12 Cl N O3		67434-14-4	DB04812	M01AE06	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH			3			1
LT00515	emtricitabine	C1[C@H](O[C@H](S1)CO)N2C=C(C(=NC2=O)N)F	C8 H10 F N3 O3 S		143491-57-0	DB00879	J05AF09	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	2								2
LT00516	trospium	C1CC[N+]2(C1)[C@H]3CCC2CC(C3)OC(=O)C(C4=CC=CC=C4)(C5=CC=CC=C5)O.[Cl-]	C25 H30 N O3 . Cl		10405-02-4	DB00209	G04BD09	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00519	bromfenac	C1=CC(=C(C(=C1)CC(=O)O)N)C(=O)C2=CC=C(C=C2)Br	C15 H12 Br N O3		91714-94-2	DB00963	S01BC11	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH			3	3	Hepatotoxic	1
LT00528	gadofosveset trisodium	C1CC(CCC1OP(=O)([O-])OC[C@@H](CN(CCN(CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])N(CC(=O)[O-])CC(=O)[O-])(C2=CC=CC=C2)C3=CC=CC=C3.O.[Na+].[Na+].[Na+].[Gd+3]	C33 H38 N3 O14 P . Gd . 3 Na . H2 O		193901-90-5	DB06705	V08CA11	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00532	clonazepam	C1C(=O)NC2=C(C=C(C=C2)[N+](=O)[O-])C(=N1)C3=CC=CC=C3Cl	C15 H10 Cl N3 O3		1622-61-3	DB01068	N03AE01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Hepatic: Hepatomegaly, transient elevations of serum transaminases and alkaline phosphatase							2
LT00537	exenatide	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)NCC(=O)NCC(=O)N3CCC[C@H]3C(=O)N[C@@H](CO)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](C)C(=O)N4CCC[C@H]4C(=O)N5CCC[C@H]5C(=O)N6C	C184 H282 N50 O60 S		141732-76-5	DB01276	A10BX04	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00538	entecavir	C=C1[C@H](C[C@@H]([C@H]1CO)O)N2C=NC3=C2NC(=NC3=O)N	C12 H15 N5 O3		142217-69-4		J05AF10	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	7	Lactic acidosis with BARACLUDE use has been reported, often in association with hepatic decompensation, other serious medical conditions, or drug exposures. 							2
LT00539	danazol	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C#C)O)CCC4=CC5=C(C[C@]34C)C=NO5	C22 H27 N O2		17230-88-5	DB01406	G03XA01	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Experience with long-term therapy with danazol is limited. Peliosis hepatis and benign hepatic adenoma have been observed with long-term use. Peliosis hepatis and hepatic adenoma may be silent until complicated by acute, potentially life-threatening intra	HH	Positive	Severely	1		Hepatotoxic	1
LT00540	daunorubicin	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=C(C4=O)C=CC=C5OC)O)(C(=O)C)O)N)O	C27 H29 N O10		20830-81-3	DB00694	L01DB02	vNo-DILI-Concern	No-DILI-Concern	No match	0						1		2
LT00545	dimenhydrinate	CN1C(=C2C(=NC(=N2)Cl)N(C1=O)C)[O-].C[NH+](C)CCOC(C1=CC=CC=C1)C2=CC=CC=C2	C17 H22 N O . C7 H6 Cl N4 O2		523-87-5	DB00985	R06AA52	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00547	doxapram	CCN1CC(C(C1=O)(C2=CC=CC=C2)C3=CC=CC=C3)CCN4CCOCC4	C24 H30 N2 O2		309-29-5	DB00561	R07AB01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00554	febuxostat	CC1=C(SC(=N1)C2=CC(=C(C=C2)OCC(C)C)C#N)C(=O)O	C16 H16 N2 O3 S		144060-53-7		M04AA03	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hepatic Effects: Postmarketing reports of hepatic failure, sometimes fatal. Causality cannot be excluded.							2
LT00557	granisetron	CN1C2CCCC1CC(C2)NC(=O)C3=NN(C4=CC=CC=C43)C	C18 H24 N4 O		109889-09-0	DB00889	A04AA02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	In clinical trial: Hepatic: In comparative trials, elevation of AST and ALT (>2 times the upper limit of normal) following the administration of granisetron hydrochloride tablets occurred in 5% and 6% of patients, respectively. These frequencies were not							2
LT00558	griseofulvin	C[C@@H]1CC(=O)C=C([C@]12C(=O)C3=C(O2)C(=C(C=C3OC)OC)Cl)OC	C17 H17 Cl O6		126-07-8	DB00400	D01AA08 D01BA01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Elevations in AST, ALT, bilirubin, and jaundice have been reported with griseofulvin use. These reactions may be serious and may result in hospitalization or death.	HH	Positive			2		1
LT00559	hydralazine	C1=CC=C2C(=C1)C=NN=C2NN	C8 H8 N4		86-54-4	DB01275	C02DB02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	rarely,hepatitis.			Moderately	2		Hepatotoxic	2
LT00560	ibufenac	CC(C)CC1=CC=C(C=C1)CC(=O)O	C12 H16 O2		1553-60-2			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH			3			1
LT00562	ifosfamide	C1CN(P(=O)(OC1)NCCCl)CCCl	C7 H15 Cl2 N2 O2 P		3778-73-2	DB01181	L01AA06	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	Increases in liver enzymes and/or bilirubin were noted in 3% of the patients	HH		Moderately		2		1
LT00563	deferasirox	C1=C/C(=C/2\N/C(=C\3/C=CC=CC3=O)/N(N2)C4=CC=C(C=C4)C(=O)O)/C(=O)C=C1	C21 H15 N3 O4		201530-41-8	DB01609	V03AC03	vMost-DILI-Concern	Most-DILI-Concern	Box warning	7	hepatic toxicity, including failure							1
LT00564	rufinamide	C1=CC(=C(C(=C1)F)CN2C=C(N=N2)C(=O)N)F	C10 H8 F2 N4 O		106308-44-5		N03AF03	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	One patient experienced rash, urticaria, facial edema, fever, elevated eosinophils, stuperous state, and severe hepatitis, beginning on dayÂ 29 of Banzel therapy and extending over a course of 30Â days of continued Banzel therapy with resolution 11Â days							2
LT00565	sunitinib	CCN(CC)CCNC(=O)C1=C(NC(=C1C)/C=C\2/C3=C(C=CC(=C3)F)NC2=O)C	C22 H27 F N4 O2		341031-54-7	DB01268	L01XE04	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Hepatotoxicity has been observed in clinical trials and post-marketing experience. This hepatotoxicity may be severe, and deaths have been reported.							1
LT00568	ivermectin	CCC(C)[C@@H]1[C@H](CC[C@@]2(O1)C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@H](/C=C/C=C/4\CO[C@H]5[C@@]4([C@@H](C=C([C@H]5O)C)C(=O)O3)O)C)O[C@H]6C[C@@H]([C@H]([C@@H](O6)C)O[C@H]7C[C@@H]([C@H]([C@@H](O7)C)O)OC)OC)\C)C.C[C@H]1CC[C@]2(C[C@@H]3C[C@H](O2)C/C=C(/[C@H]([C@	C48 H74 O14 . C47 H72 O14		70288-86-7		P02CF01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	elevation in ALT and/or AST (2%),							2
LT00569	lamivudine	C1[C@H](O[C@H](S1)CO)N2C=CC(=NC2=O)N	C8 H11 N3 O3 S		134678-17-4	DB00709	J05AF05	vLess-DILI-Concern	Less-DILI-Concern	Warning and precaution	3	LACTIC ACIDOSIS AND SEVERE HEPATOMEGALY WITH STEATOSIS, INCLUDING FATAL CASES, HAVE BEEN REPORTED WITH THE USE OF NUCLEOSIDE ANALOGUES ALONE OR IN COMBINATION, INCLUDING LAMIVUDINE AND OTHER ANTIRETROVIRALS	WE	Negative	Severely	2			1
LT00570	methylnaltrexone bromide	C[N+]1(CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O)CC6CC6.[Br-]	C21 H26 N O4 . Br		83387-25-1		A06AH01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00571	lisdexamfetamine	C[C@@H](CC1=CC=CC=C1)NC(=O)[C@H](CCCCN)N	C15 H25 N3 O		608137-32-2	DB01255	N06BA12	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	hepatitis,							2
LT00572	letrozole	C1=CC(=CC=C1C#N)C(C2=CC=C(C=C2)C#N)N3C=NC=N3	C17 H11 N5		112809-51-5	DB01006	L02BG04	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	2	Subjects with cirrhosis and severe hepatic impairment who were dosed with 2.5 mg of Femara experienced approximately twice the exposure to Femara as healthy volunteers with normal liver function					2		2
LT00573	desvenlafaxine succinate	CN(C)CC(C1=CC=C(C=C1)O)C2(CCCCC2)O	C16 H25 N O2		93413-62-8	DB06700	N06AX23	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	liver function test abnormal,							2
LT00574	lomefloxacin	CCN1C=C(C(=O)C2=CC(=C(C(=C21)F)N3CCNC(C3)C)F)C(=O)O	C17 H19 F2 N3 O3		98079-51-7	DB00978	S01AX17 J01MA07	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	Hepatic: abnormal liver function.Hepatic: elevations of ALT (SGPT) (0.4%), AST (SGOT) (0.3%), bilirubin (0.1%), alkaline phosphatase (0.1%).	HH	Positive					2
LT00575	lomustine	C1CCC(CC1)NC(=O)N(CCCl)N=O	C9 H16 Cl N3 O2		13010-47-4	DB01206	L01AD02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Liver and renal function tests should be monitored periodically					1		2
LT00576	lovastatin	CC[C@H](C)C(=O)O[C@H]1C[C@H](C=C2[C@H]1[C@H]([C@H](C=C2)C)CC[C@@H]3C[C@H](CC(=O)O3)O)C	C24 H36 O5		75330-75-5	DB00227	C10AA02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3			Negative	Moderately	1		non-hepatotixic	1
LT00577	telbivudine	CC1=CN(C(=O)NC1=O)[C@@H]2C[C@H]([C@@H](O2)CO)O	C10 H14 N2 O5		3424-98-4	DB01265	J05AF11	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	2								2
LT00580	methimazole	CN1C=CNC1=S	C4 H6 N2 S		60-56-0	DB00763	H03BB02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Due to the similar hepatic toxicity profiles of methimazole and propylthiouracil, attention is drawn to the severe hepatic reactions which have occurred with both drugs. There have been rare reports of fulminant hepatitis, hepatic necrosis, encephalopathy	HH	Positive		1			1
LT00581	methocarbamol	COC1=CC=CC=C1OCC(COC(=O)N)O	C11 H15 N O5		532-03-6	DB00423	M03BA03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	5	aundice (including cholestatic jaundice)						non-hepatotixic	2
LT00584	metronidazole	CC1=NC=C(N1CCO)[N+](=O)[O-]	C6 H9 N3 O3		443-48-1	DB00916	J01XD01 D06BX01 A01AB17 P01AB01 G01AF01	vLess-DILI-Concern	No-DILI-Concern	No match	0		HH	Positive		1			1
LT00587	minoxidil	C1CCN(CC1)C2=NC(=N)N(C(=C2)N)O	C9 H15 N5 O		38304-91-5	DB00350	C02DC01 D11AX01	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	1
LT00588	mitomycin	CC1=C(C(=O)C2=C(C1=O)N3C[C@H]4[C@@H]([C@@]3([C@@H]2COC(=O)N)OC)N4)N	C15 H18 N4 O5		50-07-7	DB00305	L01DC03	vLess-DILI-Concern	No-DILI-Concern	No match	0						0	Hepatotoxic	1
LT00589	modafinil	C1=CC=C(C=C1)C(C2=CC=CC=C2)S(=O)CC(=O)N	C15 H15 N O2 S		68693-11-8	DB00745	N06BA07	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Other associated manifestations included myocarditis, hepatitis, liver function test abnormalities, hematological abnormalities (e.g., eosinophilia, leukopenia, thrombocytopenia), pruritus, and asthenia.				1		non-hepatotixic	2
LT00590	fesoterodine fumarate	CC(C)C(=O)OC1=C(C=C(C=C1)CO)[C@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2.C(=C/C(=O)O)\C(=O)O	C26 H37 N O3 . C4 H4 O4		286930-03-8	DB06702	G04BD11	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00592	naloxone	C=CCN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O	C19 H21 N O4		465-65-6	DB01183	V03AB15	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00593	naproxen	CC(C1=CC2=C(C=C1)C=C(C=C2)OC)C(=O)O	C14 H14 O3		22204-53-1	DB00788	M01AE02 M02AA12 G02CC02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Borderline elevations of one or more liver tests may occur in up to 15% of patients taking NSAIDs including naproxen tablets and naproxen delayed-release tablets	WE		Moderately	2	3	Hepatotoxic	1
LT00594	nateglinide	CC(C)C1CCC(CC1)C(=O)N[C@@H](CC2=CC=CC=C2)C(=O)O	C19 H27 N O3		105816-04-4	DB00731	A10BX03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	, cases of jaundice, cholestatic hepatitis and elevated liver enzymes have been reported						non-hepatotixic	2
LT00595	neomycin	C1C(C(C(C(C1N)OC2C(C(C(C(O2)CN)O)O)N)OC3C(C(C(O3)CO)OC4C(C(C(C(O4)CN)O)O)N)O)O)N	C23 H46 N6 O13		1404-04-2	DB00994	D06AX04 J01GB05 A01AB08 S01AA03 R02AB01 S03AA01 B0	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00600	levocetirizine dihydrochloride	C1CN(CCN1CCOCC(=O)O)[C@H](C2=CC=CC=C2)C3=CC=C(C=C3)Cl	C21 H25 Cl N2 O3		130018-77-8		R06AE09	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	Elevations of blood bilirubin and transaminases were reported in < 1% of patients in the clinical trials. The elevations were transient and did not lead to discontinuation in any patient.							2
LT00602	nystatin	C[C@@H]1[C@H]([C@@H]([C@@H](C(O1)OC\2CC(C(C(CC(=O)CC(C(CCC(CC(CC(CC(=O)OC(C(C(C(/C=C/C=C/CC/C=C/C=C/C=C/C=C2)C)O)C)C)O)O)O)O)O)O)C(=O)O)O)O)N)O	C47 H75 N O17		1400-61-9	DB00646	D01AA01 G01AA01 A07AA02	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00605	oxytetracycline	C[C@@]1([C@H]2[C@@H]([C@H]3[C@@H](C(=O)/C(=C(\N)/O)/C(=O)[C@]3(C(=O)C2=C(C4=C1C=CC=C4O)O)O)N(C)C)O)O	C22 H24 N2 O9		79-57-2	DB00595	S01AA04 G01AA07 J01AA06 D06AA03	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	2	If renal impairment exists, even usual oral or parenteral doses may lead to excessive systemic accumulation of the drug and possible liver toxicity.							1
LT00606	pantoprazole	COC1=C(C(=NC=C1)CS(=O)C2=NC3=C(N2)C=C(C=C3)OC(F)F)OC	C16 H15 F2 N3 O4 S		102625-70-7	DB00213	A02BC02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	hepatitis				1			2
LT00607	nilotinib hydrochloride monohydrate	CC1=C(C=C(C=C1)C(=O)NC2=CC(=CC(=C2)N3C=C(N=C3)C)C(F)(F)F)NC4=NC=CC(=N4)C5=CN=CC=C5	C28 H22 F3 N7 O		641571-10-0	DB04868	L01XE08	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	4	The use of Tasigna may result in elevations in bilirubin, AST/ALT, and alkaline phosphatase. Hepatic function tests should be checked monthly or as clinically indicated							2
LT00610	pralidoxime	CN\1C=CC=C/C1=C\[NH+]=O	C7 H9 N2 O		6735-59-7	DB00733	V03AB04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Elevations in SGOT and/or SGPT enzyme levels were observed .Levels returned to normal in about 2 weeks.							2
LT00612	prednisolone	C[C@]12C[C@@H]([C@H]3[C@H]([C@@H]1CC[C@@]2(C(=O)CO)O)CCC4=CC(=O)C=C[C@]34C)O	C21 H28 O5		50-24-8	DB00860	R01AD02 S03BA02 D07AA03 S02BA03 H02AB06 S01BA04 C0	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Elevation in serum liver enzymes levels, hepatomegaly							1
LT00613	primaquine	CC(CCCN)NC1=C2C(=CC(=C1)OC)C=CC=N2	C15 H21 N3 O		90-34-6	DB01087	P01BA03	vNo-DILI-Concern	No-DILI-Concern	No match	0		WE	Negative					1
LT00614	procarbazine	CC(C)NC(=O)C1=CC=C(C=C1)CNNC	C12 H19 N3 O		671-16-9	DB01168	L01XB01	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Hepatic and renal evaluation are indicated prior to beginning therapy	HH	Positive			1		2
LT00617	lanreotide acetate	CC(C)C1C(=O)NC(CSSCC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N1)CCCCN)CC2=CNC3=CC=CC=C32)CC4=CC=C(C=C4)O)NC(=O)C(CC5=CC6=CC=CC=C6C=C5)N)C(=O)NC(C(C)O)C(=O)N	C54 H69 N11 O10 S2		108736-35-2		H01CB03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	Cholelithiasis							2
LT00618	ambrisentan	CC1=CC(=NC(=N1)OC(C(=O)O)C(C2=CC=CC=C2)(C3=CC=CC=C3)OC)C	C22 H22 N2 O4		177036-94-1		C02KX02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	7	Elevations of liver aminotransferases (ALT, AST) have been reported with LETAIRIS use; in most cases alternative causes of the liver injury could be identified (heart failure, hepatic congestion, hepatitis, alcohol use, hepatotoxic medications).							1
LT00623	doripenem	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)CNS(=O)(=O)N)C(=O)O)[C@@H](C)O	C15 H24 N4 O6 S2		148016-81-3		J01DH04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	, aspartate aminotransferase increased, hepatic enzyme increased, and transaminases increased							2
LT00624	secobarbital	CCC[C@@H](C)C1(C(=O)NC(=O)NC1=O)CC=C	C12 H18 N2 O3		76-73-3	DB00418	N05CA06	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	periodic laboratory evaluation of organic systems, including hematopoietic, renal, and hepatic systems							2
LT00625	sertraline	CN[C@H]1CC[C@H](C2=CC=CC=C12)C3=CC(=C(C=C3)Cl)Cl	C17 H17 Cl2 N		79617-96-2	DB01104	N06AB06	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Rare: abnormal hepatic function; asymptomatic elevations in serum transaminases	WE	Negative		2		non-hepatotixic	1
LT00627	sotalol	CC(C)NCC(C1=CC=C(C=C1)NS(=O)(=O)C)O	C12 H20 N2 O3 S		3930-20-9	DB00489	C07AA07	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Occasional reports of elevated serum liver enzymes have occurred with sotalol therapy but no cause and effect relationship has been established.						non-hepatotixic	2
LT00628	streptozocin	CN(C(=O)N[C@@H]1[C@H]([C@@H]([C@H](O[C@@H]1O)CO)O)O)N=O	C8 H15 N3 O7		18883-66-4	DB00428	L01AD04	Ambiguous DILI-concern	Less-DILI-concern	Warning and precautions	3	In addition, liver dysfunction, diarrhea, and hematological changes have been observed in some patients	NE				3		1
LT00632	sulfathiazole	C1=CC(=CC=C1N)S(=O)(=O)NC2=NC=CS2	C9 H9 N3 O2 S2		72-14-0	DB06147	D06BA02 J01EB07	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn									1
LT00634	terbinafine	CC(C)(C)C#CC=CCN(C)CC1=CC=CC2=CC=CC=C21	C21 H25 N		91161-71-6	DB00857	D01BA02 D01AE15	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Rare cases of liver failure, some leading to death or liver transplant have occurred			Moderately	2	3		1
LT00635	thiabendazole	C1=CC=C2C(=C1)NC(=N2)C3=CSC=N3	C10 H7 N3 S		148-79-8	DB00730	D01AC06 P02CA02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	Jaundice, cholestasis, and parenchymal liver damage have been reported in patients treated with MINTEZOL. In rare cases, liver damage has been severe and has led to irreversible hepatic failure.							2
LT00636	ticrynafen	C1=CSC(=C1)C(=O)C2=C(C(=C(C=C2)OCC(=O)O)Cl)Cl	C13 H8 Cl2 O4 S		40180-04-9		C03CC02	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH			3		Hepatotoxic	1
LT00637	tinidazole	CCS(=O)(=O)CCN1C(=NC=C1[N+](=O)[O-])C	C8 H13 N3 O4 S		19387-91-8	DB00911	P01AB02 J01XD02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	hepatic abnormalities including raised transaminase level				1			2
LT00639	torasemide	CC1=CC(=CC=C1)NC2=C(C=NC=C2)S(=O)(=O)NC(=O)NC(C)C	C16 H20 N4 O3 S		56211-40-6	DB00214	C03CA04	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	2	No significant trends have been observed in any liver enzyme tests other than alkaline phosphatase.						non-hepatotixic	2
LT00640	maraviroc	CC1=NN=C(N1C2C[C@H]3CC[C@@H](C2)N3CC[C@@H](C4=CC=CC=C4)NC(=O)C5CCC(CC5)(F)F)C(C)C	C29 H41 F2 N5 O		376348-65-1		J05AX09	vMost-DILI-Concern	Most-DILI-Concern	Box warning	3	Hepatotoxicity has been reported which may be preceded by severe rash or other features of a systemic allergic reaction (e.g., fever, eosinophilia, or elevated IgE).							1
LT00642	raltegravir potassium	CC1=NN=C(O1)C(=O)NC(C)(C)C2=N/C(=C(/NCC3=CC=C(C=C3)F)\O)/C(=O)C(=O)N2C	C20 H21 F N6 O5		871038-72-1		J05AX08	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	Severe, potentially life-threatening, and fatal skin reactions have been reported. These include cases of Stevens-Johnson syndrome and toxic epidermal necrolysis. Hypersensitivity reactions have also been reported and were characterized by rash, constitut							2
LT00644	clevidipine butyrate	CCCC(=O)OCOC(=O)C1=C(NC(=C(C1C2=C(C(=CC=C2)Cl)Cl)C(=O)OC)C)C	C21 H23 Cl2 N O6		166432-28-6		C08CA16	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00645	trovafloxacin	C1[C@@H]2[C@@H](C2N)CN1C3=C(C=C4C(=O)C(=CN(C4=N3)C5=C(C=C(C=C5)F)F)C(=O)O)F	C20 H15 F3 N4 O3		147059-72-1	DB00685	J01MA13	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn		Hyperbilirubinemia	HH	Positive		3	3		1
LT00646	regadenoson	CNC(=O)C1=CN(N=C1)C2=NC3=C(C(=N2)N)N=CN3[C@H]4[C@@H]([C@@H]([C@H](O4)CO)O)O	C15 H18 N8 O5		313348-27-5		C01EB21	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00647	warfarin	CC(=O)CC(C1=CC=CC=C1)C2=C(OC3=CC=CC=C3C2=O)O	C19 H16 O4		81-81-2	DB00682	B01AA03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Infrequently: hepatitis, cholestatic hepatic injury, jaundice, elevated liver enzymes	WE	Negative	Moderately	1		non-hepatotixic	1
LT00648	zaleplon	CCN(C1=CC=CC(=C1)C2=CC=NC3=C(C=NN23)C#N)C(=O)C	C17 H15 N5 O		151319-34-5	DB00962	N05CF03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00649	zileuton	CC(C1=CC2=CC=CC=C2S1)N(C(=O)N)O	C11 H12 N2 O2 S		111406-87-2	DB00744		vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	5	In these trials, one patient developed symptomatic hepatitis with jaundice	HH	Positive	Severely			Hepatotoxic	1
LT00650	ferumoxytol	O[Fe]=O.O[Fe]=O.[Fe]	Fe . 2 Fe H O2		1317-61-9			vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00653	etravirine	CC1=CC(=CC(=C1OC2=NC(=NC(=C2Br)N)NC3=CC=C(C=C3)C#N)C)C#N	C20 H15 Br N6 O		269055-15-4	DB07191	J05AG04	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Hypersensitivity reactions have also been reported and were characterized by rash, constitutional findings, and sometimes organ dysfunction, including hepatic failure.							2
LT00654	iloperidone	CC(=O)C1=CC(=C(C=C1)OCCCN2CCC(CC2)C3=NOC4=C3C=CC(=C4)F)OC	C24 H27 F N2 O4		133454-47-4		N05AX14	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	Hepatobiliary Disorders: Infrequent – cholelithiasis							2
LT00655	degarelix acetate	C[C@H](C(=O)N)NC(=O)C1CCCN1C(=O)[C@H](CCCCNC(C)C)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](CC2=CC=C(C=C2)NC(=O)N)NC(=O)[C@H](CC3=CC=C(C=C3)NC(=O)[C@H]4CC(=O)NC(=O)N4)NC(=O)[C@H](CO)NC(=O)[C@@H](CC5=CN=CC=C5)NC(=O)[C@@H](CC6=CC=C(C=C6)Cl)NC(=O)[C@@H](CC7=CC8=CC=CC=C	C82 H103 Cl N18 O16		214766-78-6	DB06699	L02BX02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Hepatic laboratory abnormalities were primarily Grade 1 or 2 and were generally reversible. Grade 3 hepatic laboratory abnormalities occurred in less than 1% of patients							2
LT00656	silodosin	C[C@H](CC1=CC2=C(C(=C1)C(=O)N)N(CC2)CCCO)NCCOC3=CC=CC=C3OCC(F)(F)F	C25 H32 F3 N3 O4					Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	jaundice, impaired hepatic function associated with increased transaminase values							2
LT00658	fospropofol disodium	CC(C)C1=C(C(=CC=C1)C(C)C)OCOP(=O)([O-])[O-].[Na+].[Na+]	C13 H19 O5 P . 2 Na		258516-87-9	DB06716		vLess-DILI-Concern	No-DILI-Concern	No match	0								2
LT00659	bendamustine hydrochloride	CN1C2=C(C=C(C=C2)N(CCCl)CCCl)N=C1CCCC(=O)O	C16 H21 Cl2 N3 O2		16506-27-7		L01AA09	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00660	lacosamide	CC(=O)N[C@H](COC)C(=O)NCC1=CC=CC=C1	C13 H18 N2 O3		175481-36-4		N03AX18	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	One case of symptomatic hepatitis and nephritis was observed among 4011 subjects exposed to VIMPAT during clinical development.							2
LT00661	tolvaptan	CC1=CC=CC=C1C(=O)NC2=CC(=C(C=C2)C(=O)N3CCCC(C4=C3C=CC(=C4)Cl)O)C	C26 H25 Cl N2 O3		150683-30-0		C03XA01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	AMSCA can cause serious and potentially fatal liver injury.							2
LT00663	eltrombopag	CC1=C(C=C(C=C1)N2C(=O)C(=C(N2)C)N/N=C/3\C=CC=C(C3=O)C4=CC(=CC=C4)C(=O)O)C.C(CO)N.C(CO)N			496775-61-2 496775-62-3		B02BX05	vMost-DILI-Concern	Most-DILI-Concern	Box warning	4	Measure serum alanineaminotransferase (ALT), aspartate aminotransferase (AST), and bilirubin prior to initiation of PROMACTA, every 2Â weeks during the dose adjustment phase, and monthly following establishment of a stable dose. If bilirubin is elevated,							1
LT00664	tapentadol hydrochloride	CCC(C1=CC(=CC=C1)O)C(C)CN(C)C	C14 H23 N O		175591-23-8		N02AX06	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00665	prasugrel hydrochloride	CC(=O)OC1=CC2=C(S1)CCN(C2)C(C3=CC=CC=C3F)C(=O)C4CC4	C20 H20 F N O3 S			DB06209	B01AC22	vLess-DILI-Concern	No-DILI-Concern	No match	0								2
LT00667	saxagliptin hydrochloride	C1[C@@H]2C[C@@H]2N([C@@H]1C#N)C(=O)[C@H](C34CC5CC(C3)CC(C5)(C4)O)N.Cl			361442-04-8	DB06335	A10BH03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00668	pitavastatin calcium	C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.C1C(C1)C2=NC3=CC=CC=C3C(=C2/C=C/[C@@H](O)C[C@@H](O)CC(=O)[O-])C4=CC=C(C=C4)F.[Ca+2]	2 C25 H23 F N O4 . Ca		147526-32-7		C10AA08	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3								2
LT00669	romidepsin	C/C=C\1/C(=O)N[C@H](C(=O)O[C@H]\2CC(=O)N[C@@H](C(=O)N[C@H](CSSCC/C=C2)C(=O)N1)C(C)C)C(C)C	C24 H36 N4 O6 S2				L01XX39	vNo-DILI-Concern	No-DILI-concern	No match	0								2
LT00670	fenofibric acid	CC(C(=O)O)OC1=CC=C(C=C1)OC2=CC=C(C=C2)Cl	C15 H13 Cl O4		26129-32-8			Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	2	Hepatocellular, chronic active and cholestatic hepatitis associated with fenofibrate therapy have been reported after exposures of weeks to several years.							2
LT00671	dronedarone hydrochloride	CCCCC1=C(C2=C(O1)C=CC(=C2)NS(=O)(=O)C)C(=O)C3=CC=C(C=C3)OCCCN(CCCC)CCCC	C31 H44 N2 O5 S		141626-36-0		C01BD07	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	Hepatocellular liver injury, including acute liver failure requiring transplant, has been reported in patients treated with MULTAQ in the postmarketing setting.							2
LT00672	pazopanib	CC1=C(C=C(C=C1)NC2=NC=CC(=N2)N(C)C3=CC4=NN(C(=C4C=C3)C)C)S(=O)(=O)N			444731-52-6		L01XE11	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Severe and fatal hepatotoxicity has been observed in clinical trials.							1
LT00673	pralatrexate	C#CCC(CC1=CN=C2C(=N1)C(=NC(=N2)N)N)C3=CC=C(C=C3)C(=O)N[C@@H](CCC(=O)O)C(=O)O	C23 H23 N7 O5		146464-95-1		L01BA05	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	FOLOTYN can cause hepatic toxicity and liver function test abnormalities.							2
LT00674	pancrelipase	C[Si]12OCCN(CC(O1)COCC=C)CC(O2)COCC=C	C15 H27 N O5 Si		53608-75-6	DB00085	A09AA02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00677	estropipate	C[C@]12CC[C@H]3[C@H]([C@@H]1CCC2=O)CCC4=C3C=CC(=C4)OS(=O)(=O)O.C1CNCCN1	C18 H22 O5 S . C4 H10 N2		7280-37-7			Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	Cholestatic jaundice.							2
LT00682	dexchlorpheniramine maleate	CN(C)CC[C@@H](C1=CC=C(C=C1)Cl)C2=CC=CC=N2	C16 H19 Cl N2		25523-97-1	DB01114	R06AB02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00683	ecallantide	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N4CCC[C@H]4C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[	C305 H442 N88 O91 S8		460738-38-9		B06AC03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00684	divalproex sodium	CCCC(CCC)C(=O)O.CCCC(CCC)C(=O)[O-].[Na+]			99-66-1			vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Hepatotoxicity, including fatalities, usually during first 6 months of treatment.							2
LT00686	lumiracoxib	CC1=CC(=C(C=C1)NC2=C(C=CC=C2Cl)F)CC(=O)O	C15 H13 Cl F N O2		220991-20-8	DB01283	M01AH06	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						3			1
LT00687	tasosartan	CC1=C2CCC(=O)N(C2=NC(=N1)C)CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5	C23 H21 N7 O		145733-36-4	DB01349	C09CA05	vMost-DILI-Concern	Most-DILI-Concern	Discontinued			HH						1
LT00690	oxyphenisatine	CC(=O)OC1=CC=C(C=C1)C2(C3=CC=CC=C3NC2=O)C4=CC=C(C=C4)OC(=O)C			125-13-3	DB04823	A06AB01	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						3			1
LT00691	tilbroquinol	CC1=CC(=C(C2=C1C=CC=N2)O)Br	C10 H8 Br N O		09/09/7175		P01AA05	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						3			1
LT00692	alclofenac	C=CCOC1=C(C=C(C=C1)CC(=O)O)Cl	C11 H11 Cl O3		22131-79-9		M01AB06	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn									1
LT00693	aplaviroc	CCCCN1C(=O)[C@H](NC(=O)C12CCN(CC2)CC3=CC=C(C=C3)OC4=CC=C(C=C4)C(=O)O)[C@@H](C5CCCCC5)O			461023-63-2			vMost-DILI-Concern	Most-DILI-Concern	Discontinued									1
LT00694	clomacran	CN(C)CCCC1C2=CC=CC=C2NC3=C1C=C(C=C3)Cl	C18 H21 Cl N2		5310-55-4			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn									1
LT00695	dermatan	CC(=O)N[C@@H]1[C@H]([C@H]([C@H](O[C@H]1O)CO)OS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])O)O)O	C14 H21 N O15 S		24967-94-0		B01AX04	vMost-DILI-Concern	Most-DILI-Concern	Discontinued									1
LT00696	isaxonine	CC(C)NC1=NC=CC=N1	C7 H11 N3		4214-72-6			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn									1
LT00697	pipamazine	C1CN(CCC1C(=O)N)CCCN2C3=CC=CC=C3SC4=C2C=C(C=C4)Cl	C21 H24 Cl N3 O S		84-04-8			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn									1
LT00698	pralnacasan	CCO[C@H]1[C@H](CC(=O)O1)NC(=O)[C@@H]2CCCN3N2C(=O)[C@H](CCC3=O)NC(=O)C4=NC=CC5=CC=CC=C54			192755-52-5			vMost-DILI-Concern	Most-DILI-Concern	Discontinued									1
LT00699	sulfacarbamide	C1=CC(=CC=C1N)S(=O)(=O)NC(=O)N	C7 H9 N3 O3 S		547-44-4			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn									1
LT00700	triacetyldiphenolisatin	CC(=O)N1C2=CC=CC=C2C(C1=O)(C3=CC=C(C=C3)OC(=O)C)C4=CC=C(C=C4)OC(=O)C	C26 H21 N O6		18869-73-3			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn									1
LT00701	fiduxosin	COC1=CC=CC2=C1[C@@H]3CN(C[C@@H]3CO2)CCCCN4C(=O)C5=C(C6=NC(=CN=C6S5)C7=CC=CC=C7)NC4=O			208993-54-8			vMost-DILI-Concern	Most-DILI-Concern	Discontinued									1
LT00702	pafuramidine	CO/N=C(\N)/C1=CC=C(C=C1)C2=CC=C(O2)C3=CC=C(C=C3)/C(=N/OC)/N			186953-56-0			vMost-DILI-Concern	Most-DILI-Concern	Discontinued									1
LT00703	phenoxypropazine	CC(COC1=CC=CC=C1)NN	C9 H14 N2 O		3818-37-9			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn									1
LT00706	histamine phosphate	C1=C(NC=N1)CCN.OP(=O)(O)O.OP(=O)(O)O	C5 H9 N3 . 2 H3 O4 P		51-74-1		V04CG03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00707	butabarbital	CCC(C)C1(C(=O)NC(=O)NC1=O)CC	C10 H16 N2 O3		125-40-6	DB00237		Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	liver damage							2
LT00708	guanidine	C(=N)(N)N	C H5 N3		113-00-8			Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	abnormal liver function tests							2
LT00711	aminophylline	CN1C2=C(C(=O)N(C1=O)C)NC=N2.CN1C2=C(C(=O)N(C1=O)C)NC=N2.C(CN)N	2 C7 H8 N4 O2 . C2 H8 N2		317-34-0	DB01223	R03DA05	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00713	meperidine	CCOC(=O)C1(CCN(CC1)C)C2=CC=CC=C2	C15 H21 N O2		57-42-1	DB00454	N02AB02	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	2
LT00716	methamphetamine	C[C@@H](CC1=CC=CC=C1)NC	C10 H15 N		537-46-2	DB01577	N06BA03	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	2
LT00723	methadone	CCC(=O)C(CC(C)N(C)C)(C1=CC=CC=C1)C2=CC=CC=C2	C21 H27 N O		76-99-3	DB00333	N07BC02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	reversible thrombocytopenia has been described in opioid addicts with chronic hepatitis							2
LT00725	hyaluronidase				37326-33-3		B06AA03												2
LT00727	doxylamine	CC(C1=CC=CC=C1)(C2=CC=CC=N2)OCCN(C)C	C17 H22 N2 O		469-21-6	DB00366	R06AA09	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00728	protamine sulfate																		2
LT00730	bethanechol	CC(C[N+](C)(C)C)OC(=O)N	C7 H17 N2 O2		674-38-4	DB01019	N07AB02	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00734	cortisone acetate	CC(=O)OCC(=O)[C@]1(CC[C@@H]2[C@@]1(CC(=O)[C@H]3[C@H]2CCC4=CC(=O)CC[C@]34C)C)O	C23 H30 O6		50-04-4		H02AB10 S01BA03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00737	dicyclomine	CCN(CC)CCOC(=O)C1(CCCCC1)C2CCCCC2	C19 H35 N O2		77-19-0	DB00804	A03AA07	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00738	norepinephrine	C1=CC(=C(C=C1[C@H](CN)O)O)O	C8 H11 N O3		51-41-2	DB00368	C01CA03	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00740	dyphylline	CN1C2=C(C(=O)N(C1=O)C)N(C=N2)CC(CO)O	C10 H14 N4 O4		479-18-5	DB00651	R03DA01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00742	epinephrine	CNC[C@@H](C1=CC(=C(C=C1)O)O)O	C9 H13 N O3		51-43-4	DB00668	S01EA01 R01AA14 C01CA24 R03AA01 A01AD01 B02BC09	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00749	succinylcholine	C[N+](C)(C)CCOC(=O)CCC(=O)OCC[N+](C)(C)C	C14 H30 N2 O4		306-40-1	DB00202	M03AB01	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00751	thyrotropin alfa				9002-71-5		V04CJ01 H01AB01												2
LT00752	levorphanol	CN1CC[C@]23CCCC[C@H]2[C@H]1CC4=C3C=C(C=C4)O	C17 H23 N O		77-07-6	DB00854		vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00753	propantheline	CC(C)[N+](C)(CCOC(=O)C1C2=CC=CC=C2OC3=CC=CC=C13)C(C)C	C23 H30 N O3		298-50-0	DB00782	A03AB05	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00759	carbinoxamine	CN(C)CCOC(C1=CC=C(C=C1)Cl)C2=CC=CC=N2	C16 H19 Cl N2 O		486-16-8	DB00748	R06AA08	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00760	edetic acid	C(CN(CC(=O)O)CC(=O)O)N(CC(=O)O)CC(=O)O	C10 H16 N2 O8		60-00-4	DB00974	V03AB03	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Urinalysis and urine sediment, renal and hepatic function and serum electrolyte levels should be checked before each course of therapy							2
LT00774	diatrizoate	CC(=O)NC1=C(C(=C(C(=C1I)C(=O)O)I)NC(=O)C)I	C11 H9 I3 N2 O4		737-31-5	DB00271	V08AA01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00780	phytonadione	CC1=C(C(=O)C2=CC=CC=C2C1=O)CC=C(C)CCCC(C)CCCC(C)CCCC(C)C	C31 H46 O2		84-80-0	DB01022	B02BA01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00781	mecamylamine	CC1(C2CCC(C2)C1(C)NC)C	C11 H21 N		60-40-2	DB00657	C02BB01	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	2
LT00783	liothyronine	C1=CC(=C(C=C1OC2=C(C=C(C=C2I)C[C@@H](C(=O)O)N)I)I)O	C15 H12 I3 N O4		02/03/6893	DB00279	H03AA02	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE					non-hepatotixic	1
LT00787	methsuximide	CC1(CC(=O)N(C1=O)C)C2=CC=CC=C2	C12 H13 N O2		77-41-8	DB05246	N03AD03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00790	mepenzolate	C[N+]1(CCCC(C1)OC(=O)C(C2=CC=CC=C2)(C3=CC=CC=C3)O)C	C21 H26 N O3		25990-43-6		A03AB12	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00792	meclizine	CC1=CC(=CC=C1)CN2CCN(CC2)C(C3=CC=CC=C3)C4=CC=C(C=C4)Cl	C25 H27 Cl N2		569-65-3	DB00737	R06AE05	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	1
LT00795	ethotoin	CCN1C(=O)C(NC1=O)C2=CC=CC=C2	C11 H12 N2 O2		86-35-1	DB00754	N03AB01	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Liver function tests should be performed if clinical evidence suggests the possibility of hepatic dysfunction							2
LT00798	triprolidine	CC1=CC=C(C=C1)/C(=C\CN2CCCC2)/C3=CC=CC=N3	C19 H22 N2		486-12-4	DB00427	R06AX07	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00800	benzonatate	CCCCNC1=CC=C(C=C1)C(=O)OCCOCCOCCOCCOCCOCCOCCOCCOCCOC	C30 H53 N O11		104-31-4	DB00868	R05DB01	vLess-DILI-Concern	No-DILI-Concern	No match	0								1
LT00801	polystyrene sulfonate	C=CC1=CC=CC=C1S(=O)(=O)[O-].[Ca+2]	C8 H7 O3 S . Ca		28210-41-5	DB01344	V03AE01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00802	dichlorphenamide	C1=C(C=C(C(=C1S(=O)(=O)N)Cl)Cl)S(=O)(=O)N	C6 H6 Cl2 N2 O4 S2		120-97-8	DB01144	S01EC02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00803	methohexital	CCC#CC(C)C1(C(=O)NC(=O)N(C1=O)C)CC=C	C14 H18 N2 O3		151-83-7	DB00474	N05CA15 N01AF01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	liver function tests abnormal							2
LT00805	phentermine	CC(C)(CC1=CC=CC=C1)N	C10 H15 N		122-09-8	DB00191	A08AA01	vLess-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	1
LT00806	diethylpropion	CCN(CC)C(C)C(=O)C1=CC=CC=C1	C13 H19 N O		134-80-5	DB00937	A08AA03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00808	oxymorphone	CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)O)O4)O	C17 H19 N O4		76-41-5	DB01192		vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	2
LT00810	dexbrompheniramine	CN(C)CC[C@@H](C1=CC=C(C=C1)Br)C2=CC=CC=N2	C16 H19 Br N2		132-21-8	DB00405	R06AB06	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE						2
LT00814	hydroflumethiazide	C1NC2=C(C=C(C(=C2)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N1	C8 H8 F3 N3 O4 S2		135-09-1	DB00774	C03AA02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	jaundice (intrahepatic cholestatic jaundice)							2
LT00817	biperiden	C1CCN(CC1)CCC(C2CC3CC2C=C3)(C4=CC=CC=C4)O	C21 H29 N O		514-65-8	DB00810	N04AA02	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00818	isosorbide dinitrate	C1[C@H]([C@@H]2[C@H](O1)[C@H](CO2)O[N+](=O)[O-])O[N+](=O)[O-]	C6 H8 N2 O8		87-33-2	DB00883	C05AE02 C01DA08	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE		Non-toxic				2
LT00822	mepivacaine	CC1=C(C(=CC=C1)C)NC(=O)C2CCCCN2C	C15 H22 N2 O		96-88-8	DB00961	N01BB03	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	2
LT00825	bendroflumethiazide	C1=CC=C(C=C1)CC2NC3=C(C=C(C(=C3)C(F)(F)F)S(=O)(=O)N)S(=O)(=O)N2	C15 H14 F3 N3 O4 S2		73-48-3	DB00436	C03AA01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	jaundice (intrahepatic cholestatic jaundice), hepatitis,				1			2
LT00826	phendimetrazine	CC1C(OCCN1C)C2=CC=CC=C2	C12 H17 N O		634-03-7	DB01579		vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	1
LT00827	oxytocin	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCC[C@H]3C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N)CC(=O)N)CCC(=O)N	C43 H66 N12 O12 S2		50-56-6	DB00107	H01BB02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00829	guanethidine	C1CCCN(CCC1)CCN=C(N)N	C10 H22 N4		645-43-2	DB01170	S01EX01 C02CC02	vNo-DILI-Concern	No-DILI-Concern	No match	0		HH						1
LT00831	ethosuximide	CCC1(CC(=O)NC1=O)C	C7 H11 N O2		77-67-8	DB00593	N03AD01	Ambiguous DILI-concern	Less-DILI-concern	Warnings and precautions	3	In humans, abnormal liver and renal function studies have been reported. Ethosuximide should be administered with extreme caution to patients with known liver or renal disease. Periodic urinalysis and liver function studies are advised for all patients re	HH						2
LT00832	benzphetamine	CC(CC1=CC=CC=C1)N(C)CC2=CC=CC=C2	C17 H21 N		156-08-1	DB00865		vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00833	methyclothiazide	CN1C(NC2=CC(=C(C=C2S1(=O)=O)S(=O)(=O)N)Cl)CCl	C9 H11 Cl2 N3 O4 S2		135-07-9		C03AA08	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	Jaundice (intrahepatic cholestatic)							2
LT00836	glycopyrrolate	C[N+]1(CCC(C1)OC(=O)C(C2CCCC2)(C3=CC=CC=C3)O)C	C19 H28 N O3		596-51-0	DB00986	A03AB02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00838	metyrapone	CC(C)(C1=CN=CC=C1)C(=O)C2=CN=CC=C2	C14 H14 N2 O		54-36-4	DB01011	V04CD01	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00841	metaxalone	CC1=CC(=CC(=C1)OCC2CNC(=O)O2)C	C12 H15 N O3		1665-48-1	DB00660		vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Hepatobiliary: jaundice.							2
LT00845	oxandrolone	C[C@]12CC[C@H]3[C@H]([C@@H]1CC[C@]2(C)O)CC[C@@H]4[C@@]3(COC(=O)C4)C	C19 H30 O3		53-39-4	DB00621	A14AA08	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	PELIOSIS HEPATIS, A CONDITION IN WHICH LIVER AND SOMETIMES SPLENIC TISSUE IS REPLACED WITH BLOOD-FILLED CYSTS, HAS BEEN REPORTED IN PATIENTS RECEIVING ANDROGENIC ANABOLIC STEROID THERAPY. THESE CYSTS ARE SOMETIMES PRESENT WITH MINIMAL HEPATIC DYSFUNCTION,				1			1
LT00847	oxazepam	C1=CC=C(C=C1)C2=NC(C(=O)NC3=C2C=C(C=C3)Cl)O	C15 H11 Cl N2 O2		604-75-1	DB00842	N05BA04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	5	hepatic dysfunction including jaundice have been reported during therapy							2
LT00848	protriptyline	CNCCCC1C2=CC=CC=C2C=CC3=CC=CC=C13	C19 H21 N		438-60-8	DB00344	N06AA11	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00855	cosyntropin	CC(C)[C@@H](C(=O)NCC(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCCN)C(=O)N[C@H](CCCNC(=N)N)C(=O)N[C@H](CCCNC(=N)N)C(=O)N1CCC[C@H]1C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N3CCC[C@H]3C(=O)O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](	C136 H210 N40 O31 S		16960-16-0	DB01284	H01AA02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00857	flavoxate	CC1=C(OC2=C(C1=O)C=CC=C2C(=O)OCCN3CCCCC3)C4=CC=CC=C4	C24 H25 N O4		15301-69-6	DB01148	G04BD02	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00859	ketamine	CNC1(CCCCC1=O)C2=CC=CC=C2Cl	C13 H16 Cl N O		6740-88-1	DB01221	N01AX03	vLess-DILI-Concern	No-DILI-Concern	No match	0								1
LT00865	diazoxide	CC1=NS(=O)(=O)C2=C(N1)C=CC(=C2)Cl	C8 H7 Cl N2 O2 S		364-98-7	DB01119	C02DA01 V03AH01	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	serum aspartate aminotransferase (AST) level determinations							2
LT00867	pancuronium	CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1[N+]4(CCCCC4)C)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-].[Br-]	C35 H60 N2 O4 . 2 Br		16974-53-1 15500-66-0	DB01337	M03AC01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00869	pentagastrin	CC(C)COC(=O)NCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(=O)O)C(=O)N[C@@H](CC3=CC=CC=C3)C(=O)N	C37 H49 N7 O9 S		5534-95-2	DB00183	V04CG04	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00870	dextroamphetamine	C[C@@H](CC1=CC=CC=C1)N	C9 H13 N		51-64-9	DB01576	N06BA02	vNo-DILI-Concern	No-DILI-concern	No match	0		HH						2
LT00877	terbutaline	CC(C)(C)NCC(C1=CC(=CC(=C1)O)O)O	C12 H19 N O3		23031-25-6	DB00871	R03CC03 R03AC03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	There have been rare reports of elevations in liver enzymes and of hypersensitivity vasculitis	HH						2
LT00878	calcitonin salmon																		2
LT00879	pentetate calcium trisodium yb-169				67-43-6														2
LT00880	nitroprusside	[C-]#N.[C-]#N.[C-]#N.[C-]#N.[C-]#N.[N-]=O.[Fe+4]	5 C N . Fe . N O		14402-89-2 13755-38-9	DB00325	C02DD01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00881	colestipol	C1C(O1)CCl.C(CNCCNCCNCCN)N	C8 H23 N5 . C3 H5 Cl O		50925-79-6 37296-80-3	DB00375	C10AC02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Transient and modest elevations of aspartate aminotransferase (AST, SGOT), alanine aminotransferase (ALT, SGPT) and alkaline phosphatase were observed on one or more occasions in various patients treated with colestipol hydrochloride.							2
LT00886	lactulose	C([C@@H]1[C@@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2[C@H](O[C@@]([C@H]2O)(CO)O)CO)O)O)O)O	C12 H22 O11		4618-18-2	DB00581	A06AD11	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00888	somatropin recombinant				12629-01-5		H01AC01												2
LT00894	fluorescein	C1=CC=C2C(=C1)C(=O)OC23C4=C(C=C(C=C4)O)OC5=C3C=CC(=C5)O	C20 H12 O5				S01JA01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00895	metyrosine	C[C@](CC1=CC=C(C=C1)O)(C(=O)O)N	C10 H13 N O3		672-87-7	DB00765	C02KB01	vNo-DILI-Concern	No-DILI-Concern	No match	0	liver tumor						non-hepatotixic	1
LT00896	desmopressin	C1CC(N(C1)C(=O)C2CSSCCC(=O)NC(C(=O)NC(C(=O)NC(C(=O)NC(C(=O)N2)CC(=O)N)CCC(=O)N)CC3=CC=CC=C3)CC4=CC=C(C=C4)O)C(=O)NC(CCCN=C(N)N)C(=O)NCC(=O)N	C46 H64 N14 O12 S2		16679-58-6	DB00035	H01BA02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	transient increases in AST (SGOT) no higher than 1.5 times the upper limit of normal were occasionally observed. Elevated AST (SGOT) returned to the normal range despite continued use of desmopressin acetate tablets.							2
LT00898	carboprost tromethamine	CCCCC[C@@](C)(/C=C/[C@H]1[C@@H](C[C@@H]([C@@H]1C/C=C/CCCC(=O)O)O)O)O	C21 H36 O5		58551-69-2	DB00429	G02AD04	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00899	calcitriol	C[C@H](CCCC(C)(C)O)[C@H]1CC[C@@H]2[C@@]1(CCCC2=CC=C3C[C@H](C[C@@H](C3=C)O)O)C	C27 H44 O3		32222-06-3	DB00136	A11CC04 D05AX03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00905	morphine	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3[C@H](C=C4)O	C17 H19 N O3		57-27-2 64-31-3 52-26-6	DB00295	N02AA01	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	2
LT00909	marinol	CCCCCC1=CC2=C([C@@H]3C=C(CC[C@H]3C(O2)(C)C)C)C(=C1)O	C21 H30 O2		08/03/1972	DB00470	A04AD10	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	hepatic enzyme elevation							2
LT00910	nabilone	CCCCCCC(C)(C)C1=CC2=C([C@@H]3CC(=O)CC[C@H]3C(O2)(C)C)C(=C1)O	C24 H36 O3		51022-71-0	DB00486	A04AD11	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00913	acetohydroxamic acid	CC(=O)NO	C2 H5 N O2		546-88-3	DB00551	G04BX03	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Abnormalities of liver function have not been reported to date. However, a chloro-benzene derivative of acetohydroxamic acid caused significant liver dysfunction in an unrelated study. Therefore, close monitoring of liver function is recommended.							2
LT00916	vecuronium	CC(=O)O[C@H]1C[C@@H]2CC[C@@H]3[C@@H]([C@]2(C[C@@H]1N4CCCCC4)C)CC[C@]5([C@H]3C[C@@H]([C@@H]5OC(=O)C)[N+]6(CCCCC6)C)C.[Br-]	C34 H57 N2 O4 . Br		50700-72-6		M03AC03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00917	atracurium	C[N+]1(CCC2=CC(=C(C=C2C1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N+]4(CCC5=CC(=C(C=C5C4CC6=CC(=C(C=C6)OC)OC)OC)OC)C	C53 H72 N2 O12		64228-79-1	DB00732	M03AC04	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00919	hydromorphone	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)O)O[C@H]3C(=O)CC4	C17 H19 N O3		466-99-9	DB00327	N02AA03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Investigations: weight decreased, hepatic enzyme increased						non-hepatotixic	2
LT00920	sufentanil	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC3=CC=CS3)COC	C22 H30 N2 O2 S		56030-54-7	DB00708	N01AH03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00922	misoprostol	CCCCC(C)(C/C=C/[C@H]1[C@@H](CC(=O)[C@@H]1CCCCCCC(=O)OC)O)O	C22 H38 O5		59122-46-2	DB00929	A02BB01 G02AD06	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	abnormal hepatobiliary function							2
LT00923	tranexamic acid	C1CC(CCC1CN)C(=O)O	C8 H15 N O2		1197-18-8	DB00302	B02AA02	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00925	alfentanil	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCN3C(=O)N(N=N3)CC)COC	C21 H32 N6 O3		71195-58-9	DB00802	N01AH02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00926	ethanolamine	CCCCCCCC/C=C/CCCCCCCC(=O)O.C(CO)N			11/09/2272	DB06689	C05BB01	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT00928	rubidium chloride rb-82				7440-17-7														2
LT00929	urofollitropin	CCC(C)C1C(=O)NC(C(=O)NC(C(=O)NC(CSSCC(C(=O)NC(C(=O)N1)CC2=CC=C(C=C2)O)N)C(=O)N3CCCC3C(=O)NC(CC(C)C)C(=O)NCC(=O)N)CC(=O)N)C(C)O	C42 H65 N11 O12 S2		146479-72-3	DB00094	G03GA04	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00931	milrinone	CC1=C(C=C(C(=O)N1)C#N)C2=CC=NC=C2	C12 H9 N3 O		78415-72-2	DB00235	C01CE02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	liver function test abnormalities							2
LT00932	teriparatide	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC1=CNC=N1)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC2=CNC=N2)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CO)C(=O)N	C181 H291 N55 O51 S2		52232-67-4	DB06285	H05AA02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00933	l-cysteine	C([C@@H](C(=O)O)N)S	C3 H7 N O2 S		52-90-4 52-89-1			Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	liver function tests							2
LT00935	gadopentetate dimeglumine	CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C(CN(CC(=O)O)CC(=O)[O-])N(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-].[Gd+3]	C14 H20 N3 O10 . 2 C7 H17 N O5 . Gd		86050-77-3	DB00789	V08CA01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00937	rimantadine	CC(C12CC3CC(C1)CC(C3)C2)N	C12 H21 N		13392-28-4	DB00478	J05AC02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00939	goserelin	CC(C)CC(C(=O)NC(CCCN=C(N)N)C(=O)N1CCCC1C(=O)NNC(=O)N)NC(=O)C(COC(C)(C)C)NC(=O)C(CC2=CC=C(C=C2)O)NC(=O)C(CO)NC(=O)C(CC3=CNC4=CC=CC=C43)NC(=O)C(CC5=CN=CN5)NC(=O)C6CCC(=O)N6	C59 H84 N18 O14		65807-02-5	DB00014	L02AE03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Elevation of liver enzymes (AST, ALT) have been reported in female patients exposed to ZOLADEX (representing less than 1% of all patients).							2
LT00941	pegademase bovine				EC 3.5.4.-		L03AX04												2
LT00944	fenoldopam	C1CNCC(C2=CC(=C(C(=C21)Cl)O)O)C3=CC=C(C=C3)O	C16 H16 Cl N O3		67227-57-0	DB00800	C01CA19	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00946	metoprolol succinate				51384-51-1		C07AB02												2
LT00947	calcium acetate	CC(=O)[O-].CC(=O)[O-].[Ca+2]	2 C2 H3 O2 . Ca		62-54-4		A12AA12	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00950	mivacurium	C[N+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C(=C3)OC)OC)OC)OC)OC)CCCOC(=O)CC/C=C/CCC(=O)OCCC[N+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C(=C6)OC)OC)OC)OC)OC)C	C58 H80 N2 O14		106791-40-6	DB01226	M03AC10	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00951	gadodiamide	CNC(=O)CN(CCN(CCN(CC(=O)NC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].O.[Gd+3]	C16 H26 N5 O8 . Gd . H2 O		122795-43-1	DB00225	V08CA03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Liver and Biliary System Disorders: Abnormal hepatic function.							2
LT00952	gadoteridol	CC(CN1CCN(CCN(CCN(CC1)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-])O.[Gd+3]	C17 H29 N4 O7 . Gd		120066-54-8	DB00597	V08CA04	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00954	enoxaparin	C([C@@H]1C([C@@H](C(C(O1)O)NS(=O)(=O)[O-])O)O[C@H]2C([C@H](C(C(O2)C(=O)[O-])O)O)OS(=O)(=O)[O-])OS(=O)(=O)[O-]	C12 H17 N O20 S3		9005-49-6	DB01225	B01AB05	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Asymptomatic increases in aspartate (AST [SGOT]) and alanine (ALT [SGPT]) aminotransferase levels greater than three times the upper limit of normal of the laboratory reference range have been reported in up to 6.1% and 5.9% of patients							2
LT00955	perindopril	CCC[C@@H](C(=O)OCC)N[C@@H](C)C(=O)N1[C@H]2CCCC[C@H]2C[C@H]1C(=O)O	C19 H32 N2 O5		82834-16-0	DB00790	C09AA04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Elevations in ALT (1.6% perindopril erbumine versus 0.9% placebo) and AST (0.5% perindopril erbumine versus 0.4% placebo) have been observed in placebo-controlled clinical trials							2
LT00956	pentosan polysulfate	C1[C@H]([C@@H]([C@H]([C@@H](O1)O[C@@H]2CO[C@H]([C@@H]([C@H]2OS(=O)(=O)O)OS(=O)(=O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)O	C10 H18 O21 S4		37300-21-3 116001-96-8		C05BA04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	liver function abnormalities							2
LT00957	rocuronium	CC(=O)O[C@H]1[C@H](C[C@@H]2[C@@]1(CC[C@H]3[C@H]2CC[C@@H]4[C@@]3(C[C@@H]([C@H](C4)O)N5CCOCC5)C)C)[N+]6(CCCC6)CC=C	C32 H53 N2 O4		119302-91-9	DB00728	M03AC09	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00961	dalteparin sodium				08/01/9041	DB06779	B01AB04												2
LT00962	aprotinin	CC[C@H](C)[C@H]1C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)NCC(=O)N[C@H](C(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N[C@@H](CSSC[C@@H](C(=O)N[C@H](C(=O)N[C@H](C(=O)N	C284 H432 N84 O79 S7		9087-70-1	DB06692	B02AB01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	7	jaundice, hepatic failure.							2
LT00964	anagrelide	C1C2=C(C=CC(=C2Cl)Cl)NC3=NC(=O)CN31	C10 H7 Cl2 N3 O		68475-42-3	DB00261	L01XX35	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Hepatotoxicity: Patients with underlying hepatitis B or C viral infections or marked elevations in transaminases before treatment may be at increased risk for developing further transaminase elevations or hepatic decompensation. 							2
LT00966	ferumoxsil						V08CB01												2
LT00967	ferumoxides	C1=C(NC(=O)NC1=O)C(=O)O			119683-68-0														2
LT00969	vigabatrin	C=CC(CCC(=O)O)N	C6 H11 N O2		60643-86-9	DB01080	N03AG04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	Hepatobiliary: Cholestasis							2
LT00971	epoprostenol	CCCCC[C@@H](/C=C/[C@H]1[C@@H](C[C@H]2[C@@H]1CC(=CCCCC(=O)O)O2)O)O	C20 H32 O5		35121-78-9	DB01240	B01AC09	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	7	pulmonary embolism has been reported in several patients taking epoprostenol and there have been reports of hepatic failure.							2
LT00972	porfimer	CC1=C(C2=CC3=NC(=CC4=NC(=CC5=C(C(=C(N5)C=C1N2)C(C)OC(C)C6=C(C7=CC8=C(C(=C(N8)C=C9C(=C(C(=N9)C=C1C(=C(C(=N1)C=C6N7)C)CCC(=O)O)CCC(=O)O)C)C)C(C)O)C)C)C(=C4CCC(=O)O)C)C(=C3C)CCC(=O)O)C(C)O	C68 H74 N8 O11		97067-70-4	DB00707	L01XD01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00973	tinzaparin sodium				9005-49-6		B01AB10												2
LT00974	ibutilide	CCCCCCCN(CC)CCCC(C1=CC=C(C=C1)NS(=O)(=O)C)O	C20 H36 N2 O3 S		122647-32-9	DB00308	C01BD05	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00978	cisatracurium besylate	C[N@@+]1(CCC2=CC(=C(C=C2[C@H]1CC3=CC(=C(C=C3)OC)OC)OC)OC)CCC(=O)OCCCCCOC(=O)CC[N@+]4(CCC5=CC(=C(C=C5[C@H]4CC6=CC(=C(C=C6)OC)OC)OC)OC)C.C1=CC=C(C=C1)S(=O)(=O)[O-].C1=CC=C(C=C1)S(=O)(=O)[O-]	C53 H72 N2 O12 . 2 C6 H5 O3 S		96946-42-8	DB00565	M03AC11	vNo-DILI-Concern	No-DILI-Concern	No match	0	hepatic and renal failure in pediatric use							2
LT00979	oxycodone	CN1CC[C@]23[C@@H]4C(=O)CC[C@]2([C@H]1CC5=C3C(=C(C=C5)OC)O4)O	C18 H21 N O4		76-42-6	DB00497	N02AA05	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00980	alendronate	C(CC(O)(P(=O)(O)O)P(=O)(O)O)CN	C4 H13 N O7 P2		121268-17-5	DB00630	M05BA04	vLess-DILI-Concern	No-DILI-Concern	No match	0					1			1
LT00982	tamsulosin	CCOC1=CC=CC=C1OCCN[C@H](C)CC2=CC(=C(C=C2)OC)S(=O)(=O)N	C20 H28 N2 O5 S		106133-20-4	DB00706	G04CA02	vLess-DILI-Concern	No-DILI-Concern	No match	0								1
LT00985	glatiramer acetate	C[C@@H](C(=O)O)N.CC(=O)O.C1=CC(=CC=C1C[C@@H](C(=O)O)N)O.C(CCN)C[C@@H](C(=O)O)N.C(CC(=O)O)[C@@H](C(=O)O)N	C9 H11 N O3 . C6 H14 N2 O2 . C5 H9 N O4 . C3 H7 N O2 . C2 H4 O2		147245-92-9	DB05259	L03AX13	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	liver function abnormality; liver damage; hepatitis							2
LT00986	dolasetron	C1[C@@H]2CC(CC3N2CC(=O)C1C3)OC(=O)C4=CNC5=CC=CC=C54	C19 H20 N2 O3		115956-12-2	DB00757	A04AA04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Transient increases in AST (SGOT) and/or ALT (SGPT) values have been reported. Hyperbilirubinemia, increased GGT							2
LT00987	remifentanil	CCC(=O)N(C1=CC=CC=C1)C2(CCN(CC2)CCC(=O)OC)C(=O)OC	C20 H28 N2 O5		132875-61-7	DB00899	N01AH06	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	abnormal liver function,				1			2
LT00988	sibutramine	CC(C)CC(C1(CCC1)C2=CC=C(C=C2)Cl)N(C)C	C17 H26 Cl N		106650-56-0	DB01105	A08AA10	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	Abnormal liver function tests, including increases in AST, ALT, GGT, LDH, alkaline phosphatase and bilirubin, were reported as adverse events in 1.6% of sibutramine-treated obese patients in placebo-controlled trials compared with 0.8% of placebo patients				1			2
LT00989	tiagabine	CC1=C(SC=C1)C(=CCCN2CCC[C@H](C2)C(=O)O)C3=C(C=CS3)C	C20 H25 N O2 S2		115103-54-3	DB00906	N03AG06	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	hepatomegaly, increased salivation, liver function tests abnormal							2
LT00990	ropinirole	CCCN(CCC)CCC1=C2CC(=O)NC2=CC=C1	C16 H24 N2 O		91374-21-9	DB00268	N04BC04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	Increased hepatic enzymes, bilirubinemia, cholecystitis, cholelithiasis colitis							2
LT00991	pramipexole	CCCN[C@@H]1CCC2=C(C1)SC(=N2)N	C10 H17 N3 S		104632-26-0	DB00413	N04BC05	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	Hepatobiliary disorders: Biliary colic, cholecystitis, cholecystitis chronic, cholelithiasis							2
LT00992	miglitol	C1[C@@H]([C@H]([C@@H]([C@H](N1CCO)CO)O)O)O	C8 H17 N O5		72432-03-2	DB00491	A10BF02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00995	polyethylene glycol 3350																		2
LT00996	delavirdine	CC(C)NC1=C(N=CC=C1)N2CCN(CC2)C(=O)C3=CC4=C(N3)C=CC(=C4)NS(=O)(=O)C	C22 H28 N6 O3 S		136817-59-9	DB00705	J05AG02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	5	hepatomegaly, increased appetite, increased saliva, increased thirst, jaundice							2
LT00998	tiludronate	C1=CC(=CC=C1SC(P(=O)(O)O)P(=O)(O)O)Cl	C7 H9 Cl O6 P2 S		89987-06-4	DB01133	M05BA05	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT00999	eptifibatide	C1CC2C(=O)NC(CSSCCC(=O)NC(C(=O)NCC(=O)NC(C(=O)NC(C(=O)N2C1)CC3=CNC4=CC=CC=C43)CC(=O)O)CCCCN=C(N)N)C(=O)N	C35 H49 N11 O9 S2		188627-80-7	DB00063	B01AC16	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01001	eprosartan	CCCCC1=NC=C(N1CC2=CC=C(C=C2)C(=O)O)C=C(CC3=CC=CS3)C(=O)O	C23 H24 N2 O4 S		133040-01-4	DB00876	C09CA02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Liver and Biliary: increased SGOT, increased SGPT	WE						2
LT01002	repaglinide	CCOC1=C(C=CC(=C1)CC(=O)N[C@@H](CC(C)C)C2=CC=CC=C2N3CCCCC3)C(=O)O	C27 H36 N2 O4		135062-02-1	DB00912	A10BX02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	severe hepatic dysfunction including jaundice and hepatitis				1			2
LT01005	irbesartan	CCCCC1=NC2(CCCC2)C(=O)N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5	C25 H28 N6 O		138402-11-6	DB01029	C09CA04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	increased liver function tests; jaundice; and hepatitis	WE			1			2
LT01007	naratriptan	CNS(=O)(=O)CCC1=CC2=C(C=C1)NC=C2C3CCN(CC3)C	C17 H25 N3 O2 S		121679-13-8	DB00952	N02CC02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	Rare were abnormal liver function tests, abnormal bilirubin levels							2
LT01010	zolmitriptan	CN(C)CCC1=CNC2=C1C=C(C=C2)C[C@@H]3COC(=O)N3	C16 H21 N3 O2		139264-17-8	DB00315	N02CC03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	liver function abnormality				1			2
LT01011	tolterodine	CC1=CC(=C(C=C1)O)[C@@H](CCN(C(C)C)C(C)C)C2=CC=CC=C2	C22 H31 N O		124937-51-5	DB01036	G04BD07	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01012	nelfinavir	CC1=C(C=CC=C1O)C(=O)N[C@@H](CSC2=CC=CC=C2)[C@@H](CN3C[C@H]4CCCC[C@H]4C[C@H]3C(=O)NC(C)(C)C)O	C32 H45 N3 O4 S		159989-64-7	DB00220	J05AE04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	hepatitis;liver function tests abnormal				2			2
LT01013	lepirudin	CC[C@H](C)[C@@H](C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(=O)O)C(=O)NCC(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N[C@@H](CCC(	C287 H446 N80 O111 S6		120993-53-5	DB00001	B01AE02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Abnormal liver function							2
LT01015	paricalcitol	C[C@H](/C=C/[C@H](C)C(C)(C)O)[C@H]1CC[C@@H]\2[C@@]1(CCC/C2=C\C=C3C[C@H](C[C@@H](C3)O)O)C	C27 H44 O3		131918-61-1	DB00910	A11CC07	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Hepatic enzyme abnormal							2
LT01016	rivastigmine	CCN(C)C(=O)OC1=CC=CC(=C1)[C@H](C)N(C)C	C14 H22 N2 O2		123441-03-2	DB00989	N06DA03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Clinical trial: Liver and Biliary System Disorders: Infrequent: Abnormal hepatic function tests.							2
LT01017	ziprasidone	C1CN(CCN1CCC2=C(C=C3C(=C2)CC(=O)N3)Cl)C4=NSC5=CC=CC=C54	C21 H21 Cl N4 O S		146939-27-7	DB00246	N05AE04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	cholestatic jaundice, hepatitis, hepatomegaly, leukoplakia of mouth, fatty liver deposit, melena							2
LT01020	risedronate	C1=CC(=CN=C1)CC(O)(P(=O)(O)O)P(=O)(O)O	C7 H11 N O7 P2		105462-24-6	DB00884	M05BA07	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	There have been rare reports (						non-hepatotixic	2
LT01022	candesartan	CCOC1=NC2=CC=CC(=C2N1CC3=CC=C(C=C3)C4=CC=CC=C4C5=NNN=N5)C(=O)O	C24 H20 N6 O3		139481-59-7	DB00796	C09CA06	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Abnormal hepatic function and hepatitis.	WE						2
LT01023	clopidogrel	COC(=O)[C@H](C1=CC=CC=C1Cl)N2CCC3=C(C2)C=CS3	C16 H16 Cl N O2 S		113665-84-2	DB00758	B01AC04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	7	postmarket experience: Hepato-biliary disorders: Acute liver failure, hepatitis (non-infectious), abnormal liver function test				1			2
LT01025	cilostazol	C1CCC(CC1)N2C(=NN=N2)CCCCOC3=CC4=C(C=C3)NC(=O)CC4	C20 H27 N5 O2		73963-72-1	DB01166	B01AC23	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	5	Hepatic dysfunction/abnormal liver function tests, jaundice						non-hepatotixic	2
LT01026	rizatriptan	CN(C)CCC1=CNC2=C1C=C(C=C2)CN3C=NC=N3	C15 H19 N5		145202-66-0	DB00953	N02CC04	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01027	bivalirudin	CC[C@H](C)[C@@H](C(=O)N1CCC[C@H]1C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CC2=CC=C(C=C2)O)C(=O)N[C@@H](CC(C)C)C(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CCC(=O)O)NC(=O)[C@H](CC3=CC=CC=C3)NC(=O)[C@H](CC(=O)O)NC(=O)CNC(=O)[C@H](CC(=O)N)NC(=O)CN	C98 H138 N24 O33		128270-60-0	DB00006	B01AE06	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01028	azacitidine	C1=NC(=NC(=O)N1[C@H]2[C@@H]([C@@H]([C@H](O2)CO)O)O)N	C8 H12 N4 O5		320-67-2	DB00928	L01BC07	Ambiguous DILI-concern	Most-DILI-concern	Warnings and precautions	8	Patients with extensive tumor burden due to metastatic disease have been reported to experience progressive hepatic coma and death during azacitidine treatment	HH						2
LT01029	fluorouracil	C1=C(C(=O)NC(=O)N1)F	C4 H3 F N2 O2		51-21-8	DB00544	L01BC02	vLess-DILI-Concern	No-DILI-Concern	No match	0		HH			2	2		2
LT01030	argatroban	C[C@@H]1CCN([C@H](C1)C(=O)O)C(=O)[C@H](CCCN=C(N)N)NS(=O)(=O)C2=CC=CC3=C2NC[C@@H](C3)C	C23 H36 N6 O5 S		74863-84-6	DB00278	B01AE03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01033	sildenafil	CCCC1=NN(C2=C1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)C)OCC)C	C22 H30 N6 O4 S		139755-83-2	DB00203	G04BE03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	liver function tests abnormal							2
LT01034	acarbose	C[C@@H]1[C@H]([C@@H]([C@H]([C@H](O1)O[C@@H]2[C@H](O[C@@H]([C@@H]([C@H]2O)O)O[C@@H]3[C@H](O[C@H]([C@@H]([C@H]3O)O)O)CO)CO)O)O)N[C@H]4C=C([C@@H]([C@@H]([C@H]4O)O)O)CO	C25 H43 N O18		56180-94-0	DB00284	A10BF01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Elevated Serum Transaminase Level, Jaundice; Â Cases of fulminant hepatitis with fatal outcome have been reported; the relationship to acarbose is unclear.				1			1
LT01035	acebutolol	CCCC(=O)NC1=CC(=C(C=C1)OCC(CNC(C)C)O)C(=O)C	C18 H28 N2 O4		37517-30-9	DB01193	C07AB04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	small number of cases of liver abnormalities (increased SGOT, SGPT, LDH) have been reported in association with acebutolol therapy							2
LT01037	tirofiban	CCCCS(=O)(=O)N[C@@H](CC1=CC=C(C=C1)OCCCCC2CCNCC2)C(=O)O	C22 H36 N2 O5 S		144494-65-5	DB00775	B01AC17	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01039	sevelamer	C=CCN.C1C(O1)CCl	C3 H7 N . C3 H5 Cl O		52757-95-6	DB00658	V03AE02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01040	dofetilide	CN(CCC1=CC=C(C=C1)NS(=O)(=O)C)CCOC2=CC=C(C=C2)NS(=O)(=O)C	C19 H27 N3 O5 S2		115256-11-6	DB00204	C01BD04	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	2
LT01041	acetylcysteine	CC(=O)N[C@@H](CS)C(=O)O	C5 H9 N O3 S		04/04/7218	DB06151	R05CB01 S01XA08 V03AB23	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE		Non-toxic				2
LT01042	acitretin	CC1=CC(=C(C(=C1/C=C/C(=C/C=C/C(=C\C(=O)O)/C)/C)C)C)OC	C21 H26 O3		55079-83-9	DB00459	D05BB02	vMost-DILI-Concern	Most-DILI-Concern	Box warning	5	Hepatotoxicity: Of the 525 patients treated in US clinical trials, 2 had clinical jaundice with elevated serum bilirubin and transaminases considered related to Soriatane treatment. Liver function test results in these patients returned to normal after So	HH	Positive		1	3		1
LT01044	gadoversetamide	COCCNC(=O)CN(CCN(CCN(CC(=O)NCCOC)CC(=O)[O-])CC(=O)[O-])CC(=O)[O-].[Gd+3]	C20 H34 N5 O10 . Gd		131069-91-5	DB00538	V08CA06	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01047	adenosine	C1=NC2=C(C(=N1)N)N=CN2[C@H]3[C@@H]([C@@H]([C@H](O3)CO)O)O	C10 H13 N5 O4		58-61-7	DB00640	C01EB10	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative					2
LT01048	cevimeline	C[C@@H]1O[C@]2(CN3CCC2CC3)CS1	C10 H17 N O S		107233-08-9	DB00185	N07AX03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	cholelithiasis, increased gamma-glutamyl transferase, increased hepatic enzymes, abnormal hepatic function, viral hepatitis, increased serum glutamate oxaloacetic transaminase (SGOT)							2
LT01051	albuterol	CC(C)(C)NCC(C1=CC(=C(C=C1)O)CO)O			18559-94-9	DB01001	R03AC02 R03CC02	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT01053	almotriptan	CN(C)CCC1=CNC2=C1C=C(C=C2)CS(=O)(=O)N3CCCC3	C17 H25 N3 O2 S		154323-57-6	DB00918	N02CC05	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01054	frovatriptan	CN[C@@H]1CCC2=C(C1)C3=C(N2)C=CC(=C3)C(=O)N	C14 H17 N3 O		158930-17-7	DB00998	N02CC07	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01055	amprenavir	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)O)S(=O)(=O)C3=CC=C(C=C3)N	C25 H35 N3 O6 S		161814-49-9	DB00701	J05AE05	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Patients with hepatitis B or C are at increased risk of transaminase elevations. (5.4)							2
LT01056	oxcarbazepine	C1C2=CC=CC=C2N(C3=CC=CC=C3C1=O)C(=O)N	C15 H12 N2 O2		28721-07-5	DB00776	N03AF02	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Multi-organ hypersensitivity reactions have occurred hepatobiliary (e.g., hepatitis, liver function test abnormalities),				1			2
LT01057	rifapentine	C[C@H]1/C=C/C=C(\C(=O)NC\2=C(C3=C(C(=C4C(=C3C(=O)/C2=C/NN5CCN(CC5)C6CCCC6)C(=O)[C@](O4)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C)O)O)/C	C47 H64 N4 O12		61379-65-5	DB01201	J04AB05	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	4	Hyperbilirubinemia resulting from competition for excretory pathways between rifapentine and bilirubin cannot be excluded since competition between the related drug rifampin and bilirubin can occur.							2
LT01059	levetiracetam	CC[C@H](C(=O)N)N1CCCC1=O	C8 H14 N2 O2		33996-58-6		N03AX14	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	8	abnormal liver function test, erythema multiforme, hepatic failure, hepatitis,							2
LT01060	alpidem	CCCN(CCC)C(=O)CC1=C(N=C2N1C=C(C=C2)Cl)C3=CC=C(C=C3)Cl	C21 H23 Cl2 N3 O		82626-01-5			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH			3		Hepatotoxic	1
LT01063	dexmedetomidine	CC1=C(C(=CC=C1)C(C)C2=CN=CN2)C	C13 H16 N2		113775-47-6	DB00633	N05CM18	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	Increased gamma-glutamyl transpepsidase, hepatic function abnormal, hyperbilirubinemia, alanine transaminase, aspartate aminotransferase							2
LT01064	bexarotene	CC1=CC2=C(C=C1C(=C)C3=CC=C(C=C3)C(=O)O)C(CCC2(C)C)(C)C	C24 H28 O2		153559-49-0	DB00307	L01XX25	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Liver function test abnormalities. Two patients developed cholestasis, including one patient who died of liver failure.							2
LT01065	perflutren	C(C(F)(F)F)(C(F)(F)F)(F)F	C3 F8		76-19-7			vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01067	amifostine	C(CN)CNCCSP(=O)(O)O	C5 H15 N2 O3 P S		20537-88-6	DB01143	V03AF05	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT01068	amikacin	C1[C@@H]([C@H]([C@@H]([C@H]([C@@H]1NC(=O)[C@H](CCN)O)O[C@@H]2[C@@H]([C@H]([C@@H]([C@H](O2)CO)O)N)O)O)O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)CN)O)O)O)N	C22 H43 N5 O13		37517-28-5	DB00479	J01GB06 D06AX12 S01AA21	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01069	pegvisomant				218620-50-9	DB00082	H01AX01												2
LT01070	alosetron	CC1=C(N=CN1)CN2CCC3=C(C2=O)C4=CC=CC=C4N3C	C17 H18 N4 O		122852-42-0	DB00969	A03AE01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	Hepatobiliary Tract and Pancreas: Rare: Abnormal bilirubin levels and cholecystitis.							2
LT01071	aminocaproic acid	C(CCC(=O)O)CCN	C6 H13 N O2		60-32-2	DB00513	B02AA01	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE						2
LT01072	levothyroxine	C1=C(C=C(C(=C1I)OC2=CC(=C(C(=C2)I)O)I)I)C[C@@H](C(=O)O)N	C15 H11 I4 N O4		51-48-9	DB00451	H03AA01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	elevations in liver function tests;							2
LT01075	verteporfin	CC1=C(C2=CC3=NC(=CC4=C(C(=C(N4)C=C5[C@@]6([C@@H](C(=CC=C6C(=N5)C=C1N2)C(=O)OC)C(=O)OC)C)C)CCC(=O)OC)C(=C3C)CCC(=O)O)C=C	C41 H42 N4 O8		129497-78-5	DB00460	S01LA01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Elevated liver function tests							2
LT01076	amrinone	C1=CN=CC=C1C2=CNC(=O)C(=C2)N	C10 H9 N3 O		60719-84-8	DB01427	C01CE01	Ambiguous DILI-concern	Less-DILI-concern	Adverse reactions	5	There have also been rare reports of enzyme and bilirubin elevation and jaundice.	HH	Positive					2
LT01077	linezolid	CC(=O)NC[C@H]1CN(C(=O)O1)C2=CC(=C(C=C2)N3CCOCC3)F	C16 H20 F N3 O4		165800-03-3	DB00601	J01XX08	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Abnormal liver function tests							2
LT01080	colesevelam	CCCCCCCCCCNCC=C.C[N+](C)(C)CCCCCCNCC=C.C=CCN.C1C(O1)CCl.Cl.[Cl-]	C13 H27 N . C12 H27 N2 . C3 H7 N . C3 H5 Cl O . Cl . Cl H		182815-44-7	DB00930	C10AC04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Reduced International Normalized Ratio (INR) in patients receiving warfarin therapy							2
LT01082	choriogonadotropin alfa						G03GA08												2
LT01084	gemifloxacin	CO/N=C\1/CN(CC1CN)C2=C(C=C3C(=O)C(=CN(C3=N2)C4CC4)C(=O)O)F	C18 H20 F N5 O4		175463-14-6	DB01155	J01MA15	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Liver enzyme elevations (increased ALT and/or AST) occurred at similar rates in patients receiving FACTIVE 320 mg daily relative to comparator antimicrobial agents							2
LT01085	desloratadine	C1CC2=C(C=CC(=C2)Cl)C(=C3CCNCC3)C4=C1C=CC=N4	C19 H19 Cl N2		100643-71-8	DB00967	R06AX27	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	very rarely, hepatitis				1			2
LT01086	galantamine	CN1CC[C@@]23C=C[C@@H](C[C@@H]2OC4=C(C=CC(=C34)C1)OC)O	C17 H21 N O3		357-70-0	DB00674	N06DA04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	elevated liver enzymes, hepatitis							2
LT01087	cefditoren	CC1=C(SC=N1)/C=C\C2=C(N3[C@@H](C(C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)O	C19 H18 N6 O5 S3		104145-95-1	DB01066	J01DD16	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	hepatic dysfunction including cholestasis, aplastic							2
LT01088	zoledronate	C1=CN(C=N1)CC(O)(P(=O)(O)O)P(=O)(O)O	C5 H10 N2 O7 P2		118072-93-8	DB00399	M05BA08	vLess-DILI-Concern	No-DILI-Concern	No match	0								2
LT01089	caspofungin	CCC(C)CC(C)CCCCCCCCC(=O)N[C@H]1C[C@H]([C@@H](NC(=O)[C@@H]2[C@H](CCN2C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]3C[C@H](CN3C(=O)[C@@H](NC1=O)[C@@H](C)O)O)[C@@H]([C@H](C4=CC=C(C=C4)O)O)O)[C@@H](CCN)O)O)NCCN)O	C52 H88 N10 O15		179463-17-3	DB00520	J02AX04	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	7	isolated cases of clinically significant hepatic dysfunction, hepatitis, and hepatic failure have been reported							2
LT01092	nitisinone	C1CC(=O)C(C(=O)C1)C(=O)C2=C(C=C(C=C2)C(F)(F)F)[N+](=O)[O-]	C14 H10 F3 N O5		104206-65-7	DB00348	A16AX04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	7	hepatic neoplasms, and liver failure requiring liver transplantation							2
LT01093	arsenic trioxide	O1[As]2O[As]1O2	As2 O3		1327-53-3	DB01169	L01XX27	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	ALT increased	HH						2
LT01096	atovaquone	C1CC(CCC1C2=CC=C(C=C2)Cl)C3=C(C4=CC=CC=C4C(=O)C3=O)O	C22 H19 Cl O3		94015-53-9	DB01117	P01AX06	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	8	Rare cases of hepatitis, elevated liver function tests and one case of fatal liver failure have been reported in patients treated with atovaquone							2
LT01097	voriconazole	C[C@@H](C1=NC=NC=C1F)[C@](CN2C=NC=N2)(C3=C(C=C(C=C3)F)F)O	C16 H14 F3 N5 O		137234-62-9	DB00582	J02AC03	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	In clinical trials, there have been uncommon cases of serious hepatic reactions during treatment with VFEND (including clinical hepatitis, cholestasis and fulminant hepatic failure, including fatalities).							2
LT01100	guaifenesin	COC1=CC=CC=C1OCC(CO)O	C10 H14 O4		93-14-1	DB00874	R05CA03	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	2
LT01102	olmesartan	CCCC1=NC(=C(N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NNN=N4)C(=O)OCC5=C(OC(=O)O5)C)C(C)(C)O	C29 H30 N6 O6		144689-63-4	DB00275	C09CA08	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	Elevations of liver enzymes and/or serum bilirubin were observed infrequently						non-hepatotixic	2
LT01107	alfuzosin	CN(CCCNC(=O)C1CCCO1)C2=NC3=CC(=C(C=C3C(=N2)N)OC)OC	C19 H27 N5 O4		81403-80-7	DB00346	G04CA01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	hepatocellular and cholestatic liver injury (including cases with jaundice leading to drug discontinuation)							2
LT01109	valganciclovir	CC(C)[C@@H](C(=O)OCC(CO)OCN1C=NC2=C1NC(=NC2=O)N)N	C14 H22 N6 O5		175865-59-5	DB01610	J05AB14	Ambiguous DILI-concern	Less-DILI-concern	Adverse reactions	3	Hepatobiliary disorders: abnormal hepatic function							2
LT01110	aztreonam	C[C@H]1[C@@H](C(=O)N1S(=O)(=O)[O-])NC(=O)/C(=N/OC(C)(C)C(=O)O)/C2=CSC(=N2)[NH3+]	C13 H17 N5 O8 S2		78110-38-0	DB00355	J01DF01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	5	Hepatobiliaryâ€”hepatitis, jaundice	NE	Negative				non-hepatotixic	2
LT01112	dutasteride	C[C@]12CCC3[C@H]([C@@H]1CC[C@@H]2C(=O)NC4=C(C=CC(=C4)C(F)(F)F)C(F)(F)F)CC[C@@H]5[C@@]3(C=CC(=O)N5)C	C27 H30 F6 N2 O2		164656-23-9	DB01126	G04CB02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01113	baclofen	C1=CC(=CC=C1C(CC(=O)O)CN)Cl	C10 H12 Cl N O2		1134-47-0	DB00181	M03BX01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	increased SGOT, elevated alkaline phosphatase							2
LT01116	benazepril	CCOC(=O)[C@H](CCC1=CC=CC=C1)N[C@H]2CCC3=CC=CC=C3N(C2=O)CC(=O)O	C24 H28 N2 O5		86541-75-5	DB00542	C09AA07	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3		WE	Negative			3		2
LT01117	bendazac	C1=CC=C(C=C1)CN2C3=CC=CC=C3C(=N2)OCC(=O)O	C16 H14 N2 O3		20187-55-7		M02AA11 S01BC07	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						3			1
LT01120	benzarone	CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC=C(C=C3)O	C17 H14 O3		1477-19-6			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						3			1
LT01121	benziodarone	CCC1=C(C2=CC=CC=C2O1)C(=O)C3=CC(=C(C(=C3)I)O)I	C17 H12 I2 O3		68-90-6		C01DX04	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						3			1
LT01122	ertapenem	C[C@@H]1[C@@H]2[C@H](C(=O)N2C(=C1S[C@H]3C[C@H](NC3)C(=O)NC4=CC=CC(=C4)C(=O)O)C(=O)O)[C@@H](C)O	C22 H25 N3 O7 S		153832-46-3	DB00303	J01DH03	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	periodic assessment of organ system function, including renal, hepatic, and hematopoietic, is advisable during prolonged therapy.							2
LT01123	benztropine	CN1[C@@H]2CC[C@@H]1CC(C2)OC(C3=CC=CC=C3)C4=CC=CC=C4	C21 H25 N O		86-13-5	DB00245	N04AC01	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT01125	fondaparinux sodium	CO[C@@H]1[C@@H]([C@H]([C@@H]([C@H](O1)COS(=O)(=O)[O-])O[C@H]2[C@@H]([C@H]([C@@H]([C@@H](O2)C(=O)[O-])O[C@@H]3[C@@H]([C@H]([C@@H]([C@H](O3)COS(=O)(=O)[O-])O[C@H]4[C@@H]([C@H]([C@@H]([C@H](O4)C(=O)[O-])O[C@@H]5[C@@H]([C@H]([C@@H]([C@H](O5)COS(=O)(=O)[O-])O)	C31 H43 N3 O49 S8 . 10 Na		114870-03-0	DB00569	B01AX05	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	elevations of Serum Aminotransferases							2
LT01126	miglustat	CCCCN1C[C@@H]([C@H]([C@@H]([C@H]1CO)O)O)O	C10 H21 N O4		72599-27-0	DB00419	A16AX06	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01127	gadobenate dimeglumine	CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.CNC[C@@H]([C@H]([C@@H]([C@@H](CO)O)O)O)O.C1=CC=C(C=C1)COCC(C(=O)[O-])N(CCN(CCN(CC(=O)O)CC(=O)[O-])CC(=O)[O-])CC(=O)O.[Gd+3]	C22 H28 N3 O11 . 2 C7 H17 N O5 . Gd		113662-23-0	DB00996	V08CA08	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01128	rifaximin	C[C@H]1/C=C/C=C(\C(=O)NC2=C(C3=C(C4=C(C(=C3O)C)O[C@@](C4=O)(O/C=C/[C@@H]([C@H]([C@H]([C@@H]([C@@H]([C@@H]([C@H]1O)C)O)C)OC(=O)C)C)OC)C)C5=C2N6C=CC(=CC6=N5)C)O)/C	C43 H51 N3 O11		80621-81-4	DB01220	A07AA11 D06AX11	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	7	Hepatic Encephalopathy							2
LT01129	tadalafil	CN1CC(=O)N2[C@@H](C1=O)CC3=C([C@H]2C4=CC5=C(C=C4)OCO5)NC6=CC=CC=C36	C22 H19 N3 O4		171596-29-5	DB00820	G04BE08	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	abnormal liver function tests							2
LT01130	palonosetron	C1C[C@H]2CN(C(=O)C3=C2C(=CC=C3)C1)[C@@H]4CN5CCC4CC5	C19 H24 N2 O		135729-61-2	DB00377	A04AA05	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	transient, asymptomatic increases in AST and/or ALT and bilirubin.							2
LT01132	betaxolol	CC(C)NCC(COC1=CC=C(C=C1)CCOCC2CC2)O	C18 H29 N O3		63659-18-7	DB00195	S01ED02 C07AB05	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	increased AST, increased ALT							2
LT01135	vardenafil	CCCC1=NC(=C2N1NC(=NC2=O)C3=C(C=CC(=C3)S(=O)(=O)N4CCN(CC4)CC)OCC)C	C23 H32 N6 O4 S		224785-90-4	DB00862	G04BE09	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	increase in transaminases							2
LT01136	bisoprolol	CC(C)NCC(COC1=CC=C(C=C1)COCCOC(C)C)O	C18 H31 N O4		66722-44-9	DB00612	C07AB07	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Sporadic liver test abnormalities, elevations in SGOT and SGPT							1
LT01138	bleomycin	CC1=C(N=C(N=C1N)[C@H](CC(=O)N)NC[C@@H](C(=O)N)N)C(=O)N[C@@H]([C@H](C2=CN=CN2)OC3C(C(C(C(O3)CO)O)O)OC4C(C(C(C(O4)CO)O)OC(=O)N)O)C(=O)N[C@H](C)[C@H]([C@H](C)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCCC5=NC(=CS5)C6=NC(=CS6)C(=O)NCCC[S+](C)C)O	C55 H84 N17 O21 S3		11056-06-7	DB00290	L01DC01	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Renal or hepatic toxicity, beginning as a deterioration in renal or liver function tests, have been reported, infrequently. These toxicities may occur, however, at any time after initiation of therapy				2	1		2
LT01139	atomoxetine	CC1=CC=CC=C1O[C@H](CCNC)C2=CC=CC=C2	C17 H21 N O		83015-26-3	DB00289	N06BA09	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Postmarketing reports indicate that STRATTERA can cause severe liver injury. Although no evidence of liver injury was detected in clinical trials of about 6000 patients. Rare cases of liver failure have also been reported, including a case that resulted i	HH			1			2
LT01140	bosentan	CC(C)(C)C1=CC=C(C=C1)S(=O)(=O)NC2=C(C(=NC(=N2)C3=NC=CC=N3)OCCO)OC4=CC=CC=C4OC	C27 H29 N5 O6 S		147536-97-8	DB00559	C02KX01	vMost-DILI-Concern	Most-DILI-Concern	Box warning	7	Elevations of liver aminotransferases (ALT, AST) and liver failure have been reported with Tracleer	HH			1			1
LT01141	acamprosate	CC(=O)NCCCS(=O)(=O)O	C5 H11 N O4 S		77337-76-9	DB00659	N07BB03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	hepatitis,liver function tests abnormal				1			2
LT01143	aripiprazole	C1CC(=O)NC2=C1C=CC(=C2)OCCCCN3CCN(CC3)C4=C(C(=CC=C4)Cl)Cl	C23 H27 Cl2 N3 O2		129722-12-9	DB01238	N05AX12	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	5								2
LT01144	budesonide	CCC[C@H]1O[C@@H]2C[C@H]3[C@@H]4CCC5=CC(=O)C=C[C@@]5([C@H]4[C@H](C[C@@]3([C@@]2(O1)C(=O)CO)C)O)C	C25 H34 O6		51333-22-3	DB01222	R03BA02 D07AC09 R01AD05 A07EA06	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	2
LT01145	bumetanide	CCCCNC1=C(C(=CC(=C1)C(=O)O)S(=O)(=O)N)OC2=CC=CC=C2	C17 H20 N2 O5 S		28395-03-1	DB00887	C03CA02	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Patients under treatment should be observed regularly for possible occurrence of blood dyscrasias, liver damage or idiosyncratic reactions, which have been reported occasionally in foreign marketing experience	HH	Positive					2
LT01148	buspirone	C1CCC2(C1)CC(=O)N(C(=O)C2)CCCCN3CCN(CC3)C4=NC=CC=N4	C21 H31 N5 O2		36505-84-7	DB00490	N05BE01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	During premarketing: Infrequent increases in hepatic aminotransferases	NE	Negative	Non-toxic			non-hepatotixic	1
LT01149	eplerenone	C[C@]12CCC(=O)C=C1C[C@H](C3[C@]24C(O4)C[C@]5([C@H]3CC[C@@]56CCC(=O)O6)C)C(=O)OC	C24 H30 O6		107724-20-9	DB00700	C03DA04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	Increases of ALT greater than 120 U/L and bilirubin greater than 1.2 mg/dL were reported 1/2,259 patients administered eplerenone and 0/351 placebo-treated patients. Hepatic failure was not reported in patients receiving eplerenone							2
LT01151	butorphanol	C1CC[C@]2([C@H]3CC4=C([C@]2(C1)CCN3CC5CCC5)C=C(C=C4)O)O	C21 H29 N O2		42408-82-2	DB00611	N02AF01	vNo-DILI-Concern	No-DILI-Concern	No match	0					2		non-hepatotixic	2
LT01152	cabergoline	CCNC(=O)N(CCCN(C)C)C(=O)[C@@H]1C[C@H]2[C@@H](CC3=CNC4=CC=CC2=C34)N(C1)CC=C	C26 H37 N5 O2		81409-90-7	DB00248	N04BC06 G02CB03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01153	ezetimibe	C1=CC(=CC=C1[C@@H]2[C@H](C(=O)N2C3=CC=C(C=C3)F)CC[C@@H](C4=CC=C(C=C4)F)O)O	C24 H21 F2 N O3		163222-33-1	DB00973	C10AX09	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	In controlled clinical monotherapy studies, the incidence of consecutive elevations (?3 × the upper limit of normal [ULN]) in hepatic transaminase levels was similar between ZETIA (0.5%) and placebo (0.3%).				2			2
LT01154	pregabalin	CC(C)C[C@@H](CC(=O)O)CN	C8 H17 N O2		148553-50-8	DB00230	N03AX16	vLess-DILI-Concern	No-DILI-Concern	No match	0					1			2
LT01155	adefovir dipivoxil	CC(C)(C)C(=O)OCOP(=O)(COCCN1C=NC2=C1N=CN=C2N)OCOC(=O)C(C)(C)C	C20 H32 N5 O8 P		106941-25-7	DB00718	J05AF08	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	2	Lactic Acidosis/Severe Hepatomegaly with Steatosis							2
LT01156	ibandronate	CCCCCN(C)CCC(O)(P(=O)(O)O)P(=O)(O)O	C9 H23 N O7 P2		114084-78-5	DB00710	M05BA06	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01157	pemetrexed	C1=CC(=CC=C1CCC2=CNC3=C2C(=O)N=C(N3)N)C(=O)N[C@H](CCC(=O)O)C(=O)O	C20 H21 N5 O6		137281-23-3	DB00642	L01BA04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	increased AST, increased ALT							2
LT01159	carbenicillin	CC1([C@@H](N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)C(=O)O)C(=O)O)C	C17 H18 N2 O6 S		4697-36-3	DB00578	J01CA03	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	periodic assessment of organ system function including renal, hepatic, and hematopoietic systems is recommended during prolonged therapy							2
LT01160	carbidopa	C[C@](CC1=CC(=C(C=C1)O)O)(C(=O)O)NN	C10 H14 N2 O4		28860-95-9	DB00190		Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	As with levodopa alone, periodic evaluations of hepatic, hematopoietic, cardiovascular, and renal function are recommended during extended concomitant therapy with Carbidopa and levodopa, or with Carbidopa and carbidopa-levodopa or any combination of thes	NE	Negative	Non-toxic				2
LT01161	eszopiclone	CN1CCN(CC1)C(=O)O[C@H]2C3=NC=CN=C3C(=O)N2C4=NC=C(C=C4)Cl	C17 H17 Cl N6 O3		138729-47-2	DB00402	N05CF04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	hepatitis, hepatomegaly, liver damage							2
LT01166	cefaclor	C1C(=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)C(C3=CC=CC=C3)N)C(=O)O)Cl	C15 H14 Cl N3 O4 S		53994-73-3	DB00833	J01DC04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	transient hepatitis and cholestatic jaundice have been reported rarely.				1			2
LT01167	cefadroxil	CC1=C(N2C(C(C2=O)NC(=O)C(C3=CC=C(C=C3)O)N)SC1)C(=O)O	C16 H17 N3 O5 S		66592-87-8	DB01140	J01DB05	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	7	idiosyncratic hepatic failure; elevated aspartate aminotransferase (AST), elevated alanine aminotransferase (ALT), elevated bilirubin, elevated LDH	HH			2			2
LT01169	enfuvirtide	CC[C@H](C)[C@@H](C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CCC(=O)O)C(=O)N[	C204 H301 N51 O64		159519-65-0	DB00109	J05AX07	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Hypersensitivity reactions: 'elevated serum liver transaminases.							2
LT01171	cefazolin	CC1=NN=C(S1)SCC2=C(N3C([C@@H](C3=O)NC(=O)CN4C=NN=N4)SC2)C(=O)O	C14 H14 N8 O4 S3		25953-19-9	DB01327	J01DB04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Hepatic: Transient rise in SGOT, SGPT, and alkaline phosphatase levels has been observed. As with other cephalosporins, reports of hepatitis have been received.				1			2
LT01172	cefepime	C[N+]1(CCCC1)CC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N\OC)/C4=CSC(=N4)N)SC2)C(=O)[O-]	C19 H24 N6 O5 S2		88040-23-7	DB01413	J01DE01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	increased ALT/SGPT (2.8%), AST/SGOT (2.4%),				2			2
LT01173	cefixime	C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOCC(=O)O)C3=CSC(=N3)N)SC1)C(=O)O	C16 H15 N5 O7 S2		79350-37-1	DB00671	J01DD08	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	Abnormal Laboratory Tests: Hyperbilirubinemia.							2
LT01176	cefoperazone	CCN1CCN(C(=O)C1=O)C(=O)NC(C2=CC=C(C=C2)O)C(=O)N[C@H]3[C@@H]4N(C3=O)C(=C(CS4)CSC5=NN=NN5C)C(=O)O	C25 H27 N9 O8 S2		62893-19-0	DB01329	J01DD12	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	As with other antibiotics that achieve high bile levels, mild transient elevations of liver function enzymes have been observed in 5–10% of the patients receiving CEFOBID therapy. The relevance of these findings, which were not accompanied by overt signs	NE	Negative				non-hepatotixic	2
LT01177	cefotaxime	CC(=O)OCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)C(=NOC)C3=CSC(=N3)N)SC1)C(=O)O	C16 H17 N5 O7 S2		63527-52-6	DB00493	J01DD01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	epatitis, jaundice, cholestasis, elevations of gamma GT and bilirubin.							2
LT01178	cefotetan	CN1C(=NN=N1)SCC2=C(N3C([C@@](C3=O)(NC(=O)C4SC(=C(C(=O)N)C(=O)O)S4)OC)SC2)C(=O)O	C17 H17 N7 O8 S4		69712-56-7	DB01330	J01DC05	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Hepatic: enzyme elevations occurred in 1.2% of patients and included a rise in ALT (SGPT) (1 in 150), AST (SGOT) (1 in 300), alkaline phosphatase (1 in 700), and LDH (1 in 700).	NE						2
LT01179	cefoxitin	CO[C@@]1([C@@H]2N(C1=O)C(=C(CS2)COC(=O)N)C(=O)O)NC(=O)CC3=CC=CS3	C16 H17 N3 O7 S2		35607-66-0	DB01331	J01DC01	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	periodic assessment of organ system functions, including renal, hepatic, and hematopoietic, is advisable during prolonged therapy.	HH						2
LT01180	cefpodoxime	COCC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\OC)/C3=CSC(=N3)N)SC1)C(=O)O	C15 H17 N5 O6 S2		82619-04-3	DB01416	J01DD13	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Transient increases in AST (SGOT), ALT (SGPT), GGT, alkaline phosphatase, bilirubin, and LDH.Â							2
LT01181	oxaliplatin	C1CC[C@H]([C@@H](C1)N)N.C(=O)(C(=O)[O-])[O-].[Pt+2]	C6 H14 N2 . C2 O4 . Pt		63121-00-6	DB00526	L01XA03	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	4	Hepatotoxicity as evidenced in the adjuvant study, by increase in transaminases (57% vs. 34%) and alkaline phosphatase (42% vs. 20%) was observed more commonly in the ELOXATIN combination arm than in the control arm. The incidence of increased bilirubin w							2
LT01182	cefprozil	C/C=C/C1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=C(C=C3)O)N)SC1)C(=O)O	C18 H19 N3 O5 S		92665-29-7	DB01150	J01DC10	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	Hepatobiliary: Elevations of AST (SGOT) (2%), ALT (SGPT) (2%), alkaline phosphatase (0.2%), and bilirubin values (<0.1%).							2
LT01183	ceftibuten	C1C=C(N2[C@H](S1)[C@@H](C2=O)NC(=O)/C(=C\CC(=O)O)/C3=CSC(=N3)N)C(=O)O.O.O	C15 H14 N4 O6 S2 . 2 H2 O		97519-39-6	DB01415	J01DD14	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	AST (SGOT)							2
LT01184	nitazoxanide	CC(=O)OC1=CC=CC=C1C(=O)NC2=NC=C(S2)[N+](=O)[O-]	C12 H9 N3 O5 S		55981-09-4	DB00507	P01AX11	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01185	ceftriaxone	CN1C(=NC(=O)C(=O)N1)SCC2=C(N3[C@@H]([C@@H](C3=O)NC(=O)/C(=N/OC)/C4=CSC(=N4)N)SC2)C(=O)O	C18 H18 N8 O7 S3		73384-59-5	DB01212	J01DD04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	HEPATIC - elevations of SGOT (3.1%) or SGPT (3.3%). Less frequently reported (	HH			1	2	non-hepatotixic	2
LT01186	cefuroxime	CO/N=C(\C1=CC=CO1)/C(=O)N[C@H]2[C@@H]3N(C2=O)C(=C(CS3)COC(=O)N)C(=O)O	C16 H16 N4 O8 S		55268-75-2	DB01112	J01DC02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Hepatic impairment including hepatitis and cholestasis, jaundice.				1			2
LT01187	micafungin	CCCCCOC1=CC=C(C=C1)C2=CC(=NO2)C3=CC=C(C=C3)C(=O)NC4CC(C(NC(=O)C5C(C(CN5C(=O)C(NC(=O)C(NC(=O)C6CC(CN6C(=O)C(NC4=O)C(C)O)O)C(C(C7=CC(=C(C=C7)O)OS(=O)(=O)O)O)O)C(CC(=O)N)O)C)O)O)O	C56 H71 N9 O23 S				J02AX05	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	Abnormalities in liver function tests; isolated cases of hepatic impairment, hepatitis, and hepatic failure have been observed							2
LT01188	darifenacin	C1CN(C[C@@H]1C(C2=CC=CC=C2)(C3=CC=CC=C3)C(=O)N)CCC4=CC5=C(C=C4)OCC5	C28 H30 N2 O2		133099-04-4	DB00496	G04BD10	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01189	cephalexin	CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CC=CC=C3)N)SC1)C(=O)O	C16 H17 N3 O4 S		15686-71-2	DB00567	J01DB01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	elevated alkaline phosphatase, elevated bilirubin,							2
LT01190	cetirizine	C1CN(CCN1CCOCC(=O)O)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl	C21 H25 Cl N2 O3		83881-51-0	DB00341	R06AE07	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Post-marketing experience: hepatitis				1			2
LT01191	solifenacin	C1CN2CCC1[C@H](C2)OC(=O)N3CCC4=CC=CC=C4[C@@H]3C5=CC=CC=C5.C(CC(=O)O)C(=O)O	C23 H26 N2 O2 . C4 H6 O4		242478-37-1	DB01591	G04BD08	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	liver disorders mostly characterized by abnormal liver function tests, AST (aspartate aminotransferase) , ALT (alanine aminotransferase), GGT (gamma-glutamyl transferase);							2
LT01192	ranolazine	CC1=C(C(=CC=C1)C)NC(=O)CN2CCN(CC2)CC(COC3=CC=CC=C3OC)O	C24 H33 N3 O4		142387-99-3	DB00243	C01EB18	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01193	etonogestrel	CCC12CC(=C)C3C(C1CC[C@]2(C#C)O)CCC4=CC(=O)CCC34	C22 H28 O2		54048-10-1	DB00294	G03AC08	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	5	Disturbances of liver function may necessitate the discontinuation of hormonal contraceptive use until markers of liver function return to normal. Remove NEXPLANON if jaundice develops.							2
LT01194	fosamprenavir	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CCOC2)OP(=O)(O)O)S(=O)(=O)C3=CC=C(C=C3)N	C25 H36 N3 O9 P S		226700-81-8	DB01319	J05AE07	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Use of LEXIVA with ritonavir at higher-than-recommended dosages may result in transaminase elevations and should not be used [							2
LT01195	aprepitant	C[C@H](C1=CC(=CC(=C1)C(F)(F)F)C(F)(F)F)O[C@H]2[C@H](N(CCO2)CC3=NC(=O)NN3)C4=CC=C(C=C4)F	C23 H21 F7 N4 O3		170729-80-3	DB00673	A04AD12	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	ALT Increased							2
LT01196	chloramphenicol	C1=CC(=CC=C1C(C(CO)NC(=O)C(Cl)Cl)O)[N+](=O)[O-]	C11 H12 Cl2 N2 O5		56-75-7	DB00446	S02AA01 D10AF03 J01BA01 D06AX02 G01AA05 S03AA08 S0	vNo-DILI-Concern	No-DILI-concern	No match	0		HH	Positive	Moderately				2
LT01198	chlordiazepoxide	CN=C1CN(C(=C2C=C(C=CC2=N1)Cl)C3=CC=CC=C3)O	C16 H14 Cl N3 O		58-25-3	DB00475	N05BA02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	jaundice and hepatic dysfunction have occasionally been reported during therapy							2
LT01199	atazanavir	CC(C)(C)[C@@H](C(=O)N[C@@H](CC1=CC=CC=C1)[C@H](CN(CC2=CC=C(C=C2)C3=CC=CC=N3)NC(=O)[C@H](C(C)(C)C)NC(=O)OC)O)NC(=O)OC	C38 H52 N6 O7		198904-31-3	DB01072	J05AE08	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Most patients taking REYATAZ experience asymptomatic elevations in indirect (unconjugated) bilirubin related to inhibition of UDP-glucuronosyl transferase (UGT). This hyperbilirubinemia is reversible upon discontinuation of REYATAZ. Hepatic transaminase e							2
LT01200	daptomycin	CCCCCCCCCC(=O)N[C@@H](CC1=CNC2=CC=CC=C21)C(=O)N[C@@H](CC(=O)N)C(=O)N[C@@H](CC(=O)O)C(=O)NC3C(OC(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@H](NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](NC(=O)[C@@H](NC(=O)[C@@H](NC(=O)CNC3=O)CCCN)CC(=O)O)C)CC(=O)O)CO)C(C)CC(=O)O)CC(=O)C4=CC=CC=	C72 H101 N17 O26		103060-53-3	DB00080	J01XX09	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	Abnormal liver function tests,jaundice,							2
LT01201	chlormezanone	CN1C(S(=O)(=O)CCC1=O)C2=CC=C(C=C2)Cl	C11 H12 Cl N O3 S		80-77-3	DB01178	M03BB02	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						2			1
LT01202	bortezomib	B([C@@H](CC(C)C)NC(=O)[C@@H](CC1=CC=CC=C1)NC(=O)C2=NC=CN=C2)(O)O	C19 H25 B N4 O4		179324-69-7	DB00188	L01XX32	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	Cases of acute liver failure have been reported in patients receiving multiple concomitant medications and with serious underlying medical conditions.				1			2
LT01203	anidulafungin	CCCCCOC1=CC=C(C=C1)C2=CC=C(C=C2)C3=CC=C(C=C3)C(=O)N[C@H]4C[C@H]([C@H](NC(=O)[C@@H]5[C@H]([C@H](CN5C(=O)[C@@H](NC(=O)[C@@H](NC(=O)[C@@H]6C[C@H](CN6C(=O)[C@@H](NC4=O)[C@@H](C)O)O)[C@@H]([C@H](C7=CC=C(C=C7)O)O)O)[C@@H](C)O)C)O)O)O	C58 H73 N7 O17			DB00362	J02AX06	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	7	clinically significant hepatic abnormalities have occurred. Isolated cases of significant hepatic dysfunction, hepatitis, or hepatic failure have been reported in patients; a causal relationship to ERAXIS has not been established.							2
LT01204	rasagiline	C#CCN[C@@H]1CCC2=CC=CC=C12	C12 H13 N		1875-50-9	DB01367	N04BD02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	liver function tests abnormal,							2
LT01206	clofarabine	C1=NC2=C(N1[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)F)N=C(N=C2N)Cl	C10 H11 Cl F N5 O3		123318-82-1	DB00631	L01BB06	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	8	Hepatotoxicity: Severe and fatal hepatotoxicity has occurred with Clola							2
LT01207	chloroquine	CCN(CC)CCCC(C)NC1=C2C=CC(=CC2=NC=C1)Cl	C18 H26 Cl N3		54-05-7	DB00608	P01BA01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Hepatitis, increased liver enzyme	WE			1	1	non-hepatotixic	1
LT01208	chlorothiazide	C1=C2C(=CC(=C1Cl)S(=O)(=O)N)S(=O)(=O)N=CN2	C7 H6 Cl N3 O4 S2		58-94-6	DB00880	C03AA04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	aundice (intrahepatic cholestatic jaundice)							2
LT01209	cinacalcet	C[C@H](C1=CC=CC2=CC=CC=C21)NCCCC3=CC(=CC=C3)C(F)(F)F	C22 H22 F3 N		226256-56-0	DB01012	H05BX01	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01210	conivaptan	CC1=NC2=C(N1)CCN(C3=CC=CC=C32)C(=O)C4=CC=C(C=C4)NC(=O)C5=CC=CC=C5C6=CC=CC=C6	C32 H26 N4 O2		210101-16-9	DB00872	C03XA02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01212	nebivolol	C1CC2=C(C=CC(=C2)F)OC1C(CNCC(C3CCC4=C(O3)C=CC(=C4)F)O)O	C22 H25 F2 N O4		99200-09-6	DB04861	C07AB12	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	abnormal hepatic function (including increased AST, ALT and bilirubin),							2
LT01213	chlorthalidone	C1=CC=C2C(=C1)C(=O)NC2(C3=CC(=C(C=C3)Cl)S(=O)(=O)N)O	C14 H11 Cl N2 O4 S		77-36-1	DB00310	C03BA04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	2	jaundice (intrahepatic cholestatic jaundice),							2
LT01214	erlotinib	COCCOC1=C(C=C2C(=C1)C(=NC=N2)NC3=CC=CC(=C3)C#C)OCCOC	C22 H23 N3 O4		183321-74-6	DB00530	L01XE03	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Cases of hepatic failure and hepatorenal syndrome (including fatalities) have been reported during use of TARCEVA, particularly in patients with baseline hepatic impairment							2
LT01215	alvimopan	C[C@H]1CN(CC[C@@]1(C)C2=CC(=CC=C2)O)C[C@H](CC3=CC=CC=C3)C(=O)NCC(=O)O	C25 H32 N2 O4		156053-89-3	DB06274	A06AH02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01216	cidofovir	C1=CN(C(=O)N=C1N)C[C@@H](CO)OCP(=O)(O)O	C8 H14 N3 O6 P		113852-37-2	DB00369	J05AB12	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	5	hepatitis, hepatomegaly, hepatosplenomegaly, jaundice, abnormal liver function, liver damage, liver necrosis, melena, pancreatiti							2
LT01217	ramelteon	CCC(=O)NCC[C@@H]1CCC2=C1C3=C(C=C2)OCC3	C16 H21 N O2		196597-26-9	DB00980	N05CH02	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01218	cimetidine	CC1=C(N=CN1)CSCCNC(=NC)NC#N	C10 H16 N6 S		51481-61-9	DB00501	A02BA01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	Dose-related increases in serum transaminase and rare reports of cholestatic or mixed cholestatic hepatocellular effects	WE	Negative		1	3	Hepatotoxic	1
LT01219	cinchophen	C1=CC=C(C=C1)C2=NC3=CC=CC=C3C(=C2)C(=O)O	C16 H11 N O2		132-60-5		M04AC02	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH			3			1
LT01220	tipranavir	CCC[C@]1(CC(=O)C(=C(O1)O)[C@H](CC)C2=CC(=CC=C2)NS(=O)(=O)C3=NC=C(C=C3)C(F)(F)F)CCC4=CC=CC=C4	C31 H33 F3 N2 O5 S		174484-41-4		J05AE09	vMost-DILI-Concern	Most-DILI-Concern	Box warning	8	Clinical hepatitis and hepatic decompensation including some fatalities. Extra vigilance is warranted in patients with chronic hepatitis B or hepatitis C co-infection.							1
LT01222	tigecycline	CC(C)(C)NCC(=O)NC1=C(C2=C(C[C@H]3C[C@H]4[C@@H](C(=O)C(=C([C@]4(C(=O)C3=C2O)O)O)C(=O)N)N(C)C)C(=C1)N(C)C)O			220620-09-7	DB00560	J01AA12	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	8	Increases in total bilirubin concentration, prothrombin time and transaminases have been seen in patients treated with tigecycline. Isolated cases of significant hepatic dysfunction and hepatic failure have been reported in patients being treated with tig							2
LT01224	cladribine	C1[C@@H]([C@H](O[C@H]1N2C=NC3=C2N=C(N=C3N)Cl)CO)O	C10 H12 Cl N5 O3		4291-63-8	DB00242	L01BB04	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	s with other potent chemotherapeutic agents, monitoring of renal and hepatic function is also recommended, especially in patients with underlying kidney or liver dysfunction	NE	Negative			1		2
LT01225	clindamycin	CCC[C@@H]1C[C@H](N(C1)C)C(=O)NC([C@@H]2[C@@H]([C@@H]([C@H]([C@H](O2)SC)O)O)O)C(C)Cl	C18 H33 Cl N2 O5 S		18323-44-9	DB01190	J01FF01 D10AF01 G01AA10	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	During prolonged therapy, periodic liver and kidney function tests and blood counts should be performed.	HH			1			2
LT01227	mecasermin					DB01277	H01AC03												2
LT01228	clometacin	CC1=C(C2=C(N1CC(=O)O)C=C(C=C2)OC)C(=O)C3=CC=C(C=C3)Cl	C19 H16 Cl N O4		25803-14-9			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						3			1
LT01229	urokinase				9039-53-6	DB00013	B01AD04												2
LT01230	armodafinil				112111-43-0		N06BA07												2
LT01231	clonidine	C1CN=C(N1)NC2=C(C=CC=C2Cl)Cl	C9 H9 Cl2 N3		4205-90-7	DB00575	S01EA04 C02AC01 N02CX02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Mild transient abnormalities in liver function tests	HH	Positive					1
LT01233	nelarabine	COC1=NC(=NC2=C1N=CN2[C@H]3[C@H]([C@@H]([C@H](O3)CO)O)O)N	C11 H15 N5 O5				L01BB07	vLess-DILI-Concern	Less-DILI-concern	Adverse reactions	4	AST increased; od bilirubin increased							2
LT01235	cloxacillin	CC1=C(C(=NO1)C2=CC=CC=C2Cl)C(=O)N[C@H]3[C@@H]4N(C3=O)[C@H](C(S4)(C)C)C(=O)O	C19 H18 Cl N3 O5 S		61-72-3	DB01147	J01CF02	vLess-DILI-Concern	Less-DILI-concern	Warnings and precautions	3	SGOT and SGPT values should be obtained periodically during therapy to monitor for possible liver function abnormalities	HH			1			2
LT01238	lenalidomide	C1CC(=O)NC(=O)C1N2CC3=C(C2=O)C=CC=C3N	C13 H13 N3 O3		191732-72-6	DB00480	L04AX04	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Cases of transient liver laboratory abnormalities (predominantly transaminases) were reported in patients treated with lenalidomide.							2
LT01239	tetrabenazine	CC(C)CC1CN2CCC3=CC(=C(C=C3C2CC1=O)OC)OC	C19 H27 N O3		58-46-8	DB04844	N07XX06	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	In controlled clinical trials, XENAZINE caused a small mean increase in ALT and AST laboratory values as compared to placebo.							2
LT01240	lubiprostone	CCCCC([C@]1(CC[C@H]2[C@H](O1)CC(=O)[C@H]2CCCCCCC(=O)O)O)(F)F	C20 H32 F2 O5		136790-76-6	DB01046	A07 A06AX03	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01241	sorafenib	CNC(=O)C1=NC=CC(=C1)OC2=CC=C(C=C2)NC(=O)NC3=CC(=C(C=C3)Cl)C(F)(F)F	C21 H16 Cl F3 N4 O3		284461-73-0	DB00398	L01XE05	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Drug-induced hepatitis characterized by a hepatocellular pattern may result in hepatic failure and death							2
LT01242	varenicline	C1[C@@H]2CNC[C@H]1C3=CC4=NC=CN=C4C=C23	C13 H13 N3				N07BA03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	Hepatobiliary Disorders. Infrequent: gall bladder disorder.							2
LT01243	darunavir	CC(C)CN(C[C@H]([C@H](CC1=CC=CC=C1)NC(=O)O[C@H]2CO[C@@H]3[C@H]2CCO3)O)S(=O)(=O)C4=CC=C(C=C4)N	C27 H37 N3 O7 S		206361-99-1	DB01264	J05AE10	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Post-marketing cases of liver injury, including some fatalities, have been reported. These have generally occurred in patients with advanced HIV-1 disease taking multiple concomitant medications,				1			2
LT01244	aliskiren	CC(C)[C@@H](CC1=CC(=C(C=C1)OC)OCCCOC)C[C@@H]([C@H](C[C@@H](C(C)C)C(=O)NCC(C)(C)C(=O)N)O)N	C30 H53 N3 O6		173334-57-1	DB01258	C09XA02	vLess-DILI-Concern	No-DILI-Concern	No match	0								2
LT01248	dasatinib	CC1=C(C(=CC=C1)Cl)NC(=O)C2=CN=C(S2)NC3=NC(=NC(=C3)N4CCN(CC4)CCO)C	C22 H26 Cl N7 O2 S		302962-49-8	DB01254	L01XE06	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	Elevated SGPT (ALT); Elevated Bilirubin							2
LT01249	cyclobenzaprine	CN(C)CCC=C1C2=CC=CC=C2C=CC3=CC=CC=C31	C20 H21 N		303-53-7	DB00924	M03BX08	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	5	abnormal liver function and rare reports of hepatitis, jaundice and cholestasis				1			2
LT01250	cyclofenil	CC(=O)OC1=CC=C(C=C1)C(=C2CCCCC2)C3=CC=C(C=C3)OC(=O)C	C23 H24 O4		5189-40-2		G03GB01	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						3			1
LT01251	sitagliptin	C1CN2C(=NN=C2C(F)(F)F)CN1C(=O)C[C@@H](CC3=CC(=C(C=C3F)F)F)N	C16 H15 F6 N5 O		486460-32-6	DB01261	A10BH01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	hepatic enzyme elevations;							2
LT01252	paliperidone	CC1=C(C(=O)N2CCCC(C2=N1)O)CCN3CCC(CC3)C4=NOC5=C4C=CC(=C5)F	C23 H27 F N4 O3		144598-75-4	DB01267	N05AX13	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01253	cycloserine	C1C(C(=O)NO1)N	C3 H6 N2 O2		68-41-7	DB00260	J04AB01	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Patients should be monitored by hematologic, renal excretion, blood level, and liver function studies							2
LT01254	posaconazole	CC[C@@H]([C@H](C)O)N1C(=O)N(C=N1)C2=CC=C(C=C2)N3CCN(CC3)C4=CC=C(C=C4)OCC5C[C@](OC5)(CN6C=NC=N6)C7=C(C=C(C=C7)F)F	C37 H42 F2 N8 O4				J02AC04	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	8	Isolated cases of more severe hepatic reactions including cholestasis or hepatic failure including deaths have been reported in patients with serious underlying medical conditions (e.g., hematologic malignancy) during treatment with posaconazole.							2
LT01255	cyproheptadine	CN1CCC(=C2C3=CC=CC=C3C=CC4=CC=CC=C42)CC1	C21 H21 N		129-03-3	DB00434	R06AX02	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	7	Cholestasis, hepatic failure, hepatitis, hepatic function abnormality,	HH	Positive					2
LT01256	cysteamine	C(CS)N	C2 H7 N S		60-23-1	DB00847	A16AA04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3								2
LT01257	fosaprepitant dimeglumine				172673-20-0 265121-04-8	DB06717	A04AD12												2
LT01258	hydroxocobalamin	CC1=CC2=C(C=C1C)N(C=N2)[C@@H]3[C@@H]([C@@H]([C@H](O3)CO)OP(=O)([O-])O[C@@H](C)CNC(=O)CC[C@@]\4([C@H](C5[C@]6([C@@]([C@@H](C(=N6)/C(=C\7/[C@@]([C@@H](C(=N7)/C=C\8/C([C@@H](C(=N8)/C(=C4\[N-]5)/C)CCC(=O)N)(C)C)CCC(=O)N)(C)CC(=O)N)/C)CCC(=O)N)(C)CC(=O)N)C)CC(	C62 H88 N13 O14 P . Co . H2 O		13422-51-0	DB00200	V03AB33 B03BA03	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3								2
LT01261	temsirolimus	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OC(=O)C(C)(CO)CO)C)/C)O)OC)C)C)/C)OC	C56 H87 N O16		162635-04-3	DB06287	L01XE09	vNo-DILI-Concern	No-DILI-concern	No match	0								2
LT01262	tetrahydrobiopterin	CC(C(C1CNC2=C(N1)C(=O)N=C(N2)N)O)O	C9 H15 N5 O3		17528-72-2	DB00360	A16AX07	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01263	milnacipran	CCN(CC)C(=O)[C@@]1(C[C@@H]1CN)C2=CC=CC=C2	C15 H22 N2 O		92623-85-3	DB04896	N06AX17	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	There have been cases of increased liver enzymes and reports of severe liver injury, including fulminant hepatitis with milnacipran from foreign postmarketing experience. In the cases of severe liver injury, there were significant underlying clinical cond							2
LT01265	desipramine	CNCCCN1C2=CC=CC=C2CCC3=CC=CC=C31	C18 H22 N2		50-47-5	DB01151	N06AA01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Hepatitis, jaundice (simulating obstructive), altered liver function, elevated liver function tests.	WE	Negative					1
LT01266	dexlansoprazole				138530-94-6		A02BC06												2
LT01267	everolimus	C[C@@H]1CC[C@H]2C[C@@H](/C(=C/C=C/C=C/[C@H](C[C@H](C(=O)[C@@H]([C@@H](/C(=C/[C@H](C(=O)C[C@H](OC(=O)[C@@H]3CCCCN3C(=O)C(=O)[C@@]1(O2)O)[C@H](C)C[C@@H]4CC[C@H]([C@@H](C4)OC)OCCO)C)/C)O)OC)C)C)/C)OC	C53 H83 N O14		159351-69-6	DB01590	L01XE10 L04AA18	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	Hepatobiliary Disorders: hepatic enzyme increased, bilirubin increased							2
LT01269	codeine	CN1CC[C@]23[C@@H]4[C@H]1CC5=C2C(=C(C=C5)OC)O[C@H]3[C@H](C=C4)O	C18 H21 N O3		76-57-3	DB00318	R05DA04	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01273	dexrazoxane	C[C@@H](CN1CC(=O)NC(=O)C1)N2CC(=O)NC(=O)C2	C11 H16 N4 O4		24584-09-6	DB00380	V03AF02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	Increased ALT;Increased bilirubin							2
LT01275	colistimethate	CCC(C)CCCCC(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC(C(C)O)C(=O)NC(CCNCS(=O)(=O)[O-])C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCNCS(=O)(=O)[O-])CC(C)C)CC(C)C)CCNCS(=O)(=O)[O-])CCNCS(=O)(=O)[O-])C(C)O.[Na+].[Na+].[Na+].[Na+].[Na+]	C58 H105 N16 O28 S5 . 5 Na		8068-28-8			vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT01276	benzylpenicilloyl polylysine	CC1(C(NC(S1)C(C(=O)NCCCCCC(=O)O)NC(=O)CC2=CC=CC=C2)C(=O)O)C	C22 H31 N3 O6 S					vNo-DILI-Concern	No-DILI-concern	No match	0								2
LT01279	cefradine	CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)[C@@H](C3=CCC=CC3)N)SC1)C(=O)O	C16 H19 N3 O4 S		38821-53-3	DB01333	J01DB09	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	Liver: Transient mild rise of SGOT, SGPT, and total bilirubin have been observed with no evidence of hepatocellular damage.	NE						2
LT01281	ceftizoxime	CO/N=C(/C1=CSC(=N1)N)\C(=O)N[C@H]2[C@@H]3N(C2=O)C(=CCS3)C(=O)O	C13 H13 N5 O5 S2		68401-81-0 68401-82-1		J01DD07	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	4	Elevation of bilirubin has been reported rarely.Transient elevation in AST (SGOT), ALT (SGPT), and alkaline phosphatase							2
LT01285	didanosine	C1C[C@@H](O[C@@H]1CO)N2C=NC3=C2NC=NC3=O	C10 H12 N4 O3		69655-05-6	DB00900	J05AF02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Lactic acidosis and severe hepatomegaly with steatosis, including fatal cases. Fatal lactic acidosis has been reported in pregnant women who received the combination of didanosine and stavudine.	HH	Positive	Severely	2		Hepatotoxic	1
LT01288	mycophenolate mofetil	CC1=C(C(=C(C2=C1COC2=O)O)C/C=C(\C)/CCC(=O)OCCN3CCOCC3)OC	C23 H31 N O7		128794-94-5	DB00688		vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Liver function tests abnormal							2
LT01289	cefdinir	C=CC1=C(N2[C@@H]([C@@H](C2=O)NC(=O)/C(=N\O)/C3=CSC(=N3)N)SC1)C(=O)O	C14 H13 N5 O5 S2		91832-40-5	DB00535	J01DD15	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	7	acute hepatitis, cholestasis, fulminant hepatitis, hepatic failure, jaundice,							2
LT01291	polymyxin b sulfate	CCC(C)CCCCC(=O)NC(CCN)C(=O)NC(C(C)O)C(=O)NC(CCN)C(=O)NC1CCNC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC(=O)C(NC1=O)CCN)CC2=CC=CC=C2)CC(C)C)CCN)CCN)C(C)O.OS(=O)(=O)O	C56 H98 N16 O13 . H2 O4 S		1405-20-5	DB00781	S02AA11 S03AA03 J01XB02 S01AA18 A07AA05	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01292	diltiazem	CC(=O)O[C@@H]1[C@@H](SC2=CC=CC=C2N(C1=O)CCN(C)C)C3=CC=C(C=C3)OC	C22 H26 N2 O4 S		42399-41-7	DB00343	C08DB01	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	4	Acute Hepatic Injury. Mild elevations of transaminases with and without concomitant elevation in alkaline phosphatase and bilirubin have been observed in clinical studies.		Negative		1		non-hepatotixic	2
LT01294	sterile water																		2
LT01302	disopyramide	CC(C)N(CCC(C1=CC=CC=C1)(C2=CC=CC=N2)C(=O)N)C(C)C	C21 H29 N3 O		09/05/3737	DB00280	C01BA03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	Infrequent occurrences of reversible cholestatic jaundice	HH	Positive					2
LT01303	asparaginase				9015-68-3	DB00023	L01XX02												2
LT01305	botulinum toxin type a						M03AX01												2
LT01306	interferon alfa-2b					DB05272	L03AB05												2
LT01308	dobutamine	CC(CCC1=CC=C(C=C1)O)NCCC2=CC(=C(C=C2)O)O	C18 H23 N O3		34368-04-2	DB00841	C01CA07	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative					1
LT01309	docetaxel	CC1=C2[C@H](C(=O)[C@@]3([C@H](C[C@@H]4[C@]([C@H]3[C@@H]([C@@](C2(C)C)(C[C@@H]1OC(=O)[C@@H]([C@H](C5=CC=CC=C5)NC(=O)OC(C)(C)C)O)O)OC(=O)C6=CC=CC=C6)(CO4)OC(=O)C)O)C)O	C43 H53 N O14		114977-28-5	DB01248	L01CD02	vLess-DILI-Concern	Less-DILI-Concern	Warning and precautions	3	Should not be given if bilirubin > ULN, or if AST and/or ALT > 1.5 × ULN concomitant with alkaline phosphatase > 2.5 × ULN. LFT elevations increase risk of severe or life-threatening complications. Obtain LFTs before each treatment cycle				1	3		1
LT01311	interferon alfa-2a, recombinant				76543-88-9		L03AB04												2
LT01313	doxazosin	COC1=C(C=C2C(=C1)C(=NC(=N2)N3CCN(CC3)C(=O)C4COC5=CC=CC=C5O4)N)OC	C23 H25 N5 O5		74191-85-8	DB00590	C02CA04	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Liver/Biliary System: hepatitis, hepatitis cholestatic;							2
LT01314	doxepin	CN(C)CC/C=C/1\C2=CC=CC=C2COC3=CC=CC=C31	C19 H21 N O		1668-19-5	DB01142	N06AA12	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	Hepatobiliary Disorders: Rare: hyperbilirubinemia							2
LT01315	alteplase				EC 3.4.21.68		B01AD02 S01XA13												2
LT01316	epoetin alfa				113427-24-0	DB00016	B03XA01												2
LT01317	droperidol	C1CN(CC=C1N2C3=CC=CC=C3NC2=O)CCCC(=O)C4=CC=C(C=C4)F	C22 H22 F N3 O2		548-73-2	DB00450	N01AX01 N05AD08	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01318	droxicam	CN1C2=C(C3=CC=CC=C3S1(=O)=O)OC(=O)N(C2=O)C4=CC=CC=N4	C16 H11 N3 O5 S				M01AC04	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						3			1
LT01319	aldesleukin				110942-02-4		L03AC01												2
LT01320	filgrastim				143011-72-7	DB00099	L03AA02												2
LT01321	sargramostim				83869-56-1	DB00020	L03AA09												2
LT01322	pegaspargase				130167-69-0	DB00059	L01XX24												2
LT01323	efavirenz	C1CC1C#C[C@]2(C3=C(C=CC(=C3)Cl)NC(=O)O2)C(F)(F)F	C14 H9 Cl F3 N O2		154598-52-4	DB00625	J05AG03	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	7	A few of the postmarketing reports of hepatic failure occurred in patients with no pre-existing hepatic disease or other identifiable risk factors			Severely	1	2		2
LT01326	muromonab-cd3				140608-64-6	DB00075	L04AA02												2
LT01328	interferon beta-1b				145155-23-3	DB00068	L03AB08												2
LT01330	abciximab				143653-53-6	DB00054	B01AC13												2
LT01332	interferon beta-1a				145258-61-3	DB00060	L03AB07												2
LT01333	esmolol	CC(C)NCC(COC1=CC=C(C=C1)CCC(=O)OC)O	C16 H25 N O4		103598-03-4	DB00187	C07AB09	vNo-DILI-Concern	No-DILI-Concern	No match	0								1
LT01334	estazolam	C1C2=NN=CN2C3=C(C=C(C=C3)Cl)C(=N1)C4=CC=CC=C4	C16 H11 Cl N4		29975-16-4	DB01215	N05CD04	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01336	interferon alfacon-1				118390-30-0	DB00069	L03AB09												2
LT01339	oprelvekin				145941-26-0	DB00038	L03AC02												2
LT01342	estramustine	CC12CCC3C(C1CCC2O)CCC4=C3C=CC(=C4)OC(=O)N(CCCl)CCCl	C23 H31 Cl2 N O3		2998-57-4	DB01196	L01XX11	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	4	Abnormalities of hepatic enzymes and of bilirubin have occurred in patients receiving EMCYT				1	2		2
LT01344	ethacrynic acid	CCC(=C)C(=O)C1=C(C(=C(C=C1)OCC(=O)O)Cl)Cl	C13 H12 Cl2 O4		58-54-8	DB00903	C03CC01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	5	Rarely, jaundice and abnormal liver function tests have been reported							1
LT01345	ethambutol	CCC(CO)NCCNC(CC)CO	C10 H24 N2 O2		74-55-5	DB00330	J04AK02	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Liver toxicities have been reported				2			1
LT01346	basiliximab				152923-56-3	DB00074	L04AC02												2
LT01347	denileukin diftitox				173146-27-5	DB00004	L01XX29												2
LT01348	ethionamide	CCC1=NC=CC(=C1)C(=S)N	C8 H10 N2 S		536-33-4	DB00609	J04AD03	vLess-DILI-Concern	Less-DILI-Concern	Warnings and precautions	3	Determination of serum transaminases (SGOT, SGPT) should be made prior to initiation of therapy and should be monitored monthly. If serum transaminases become elevated during therapy, ethionamide and the companion antituberculosis drug or drugs may be dis							2
LT01349	palivizumab				188039-54-5	DB00110	J06BB16												2
LT01350	infliximab				170277-31-3	DB00065	L04AB02												2
LT01351	reteplase				133652-38-7	DB00015	B01AD07												2
LT01352	trastuzumab				180288-69-1	DB00072	L01XC03												2
LT01353	etanercept				185243-69-0	DB00005	L04AB01												2
LT01354	interferon gamma-1b																		2
LT01355	etidronic acid	CC(O)(P(=O)(O)O)P(=O)(O)O	C2 H8 O7 P2		2809-21-4	DB01077	M05BA01	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	1
LT01356	botulinum toxin type b				93384-43-1	DB00042	M03AX01												2
LT01357	etomidate	CCOC(=O)C1=CN=CN1C(C)C2=CC=CC=C2	C14 H16 N2 O2		33125-97-2	DB00292	N01AX07	vNo-DILI-Concern	No-DILI-Concern	No match	0								2
LT01359	exifone	C1=CC(=C(C(=C1C(=O)C2=CC(=C(C(=C2)O)O)O)O)O)O	C13 H10 O7		52479-85-3			vMost-DILI-Concern	Most-DILI-Concern	Withdrawn						3			1
LT01360	tenecteplase				105857-23-6	DB00031	B01AD11												2
LT01363	rasburicase				134774-45-1	DB00049	V03AF07												2
LT01364	alemtuzumab				216503-57-0	DB00087	L01XC04												2
LT01367	peginterferon alfa-2b				99210-65-8	DB00022	L03AB10												2
LT01370	fexofenadine	CC(C)(C1=CC=C(C=C1)C(CCCN2CCC(CC2)C(C3=CC=CC=C3)(C4=CC=CC=C4)O)O)C(=O)O	C32 H39 N O4		83799-24-0	DB00950	R06AX26	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE		Non-toxic				2
LT01371	fialuridine	C1=C(C(=O)NC(=O)N1[C@H]2[C@H]([C@@H]([C@H](O2)CO)O)F)I	C9 H10 F I N2 O5					vMost-DILI-Concern	Most-DILI-Concern	Discontinued			HH		Severely	2			1
LT01372	fipexide	C1CN(CCN1CC2=CC3=C(C=C2)OCO3)C(=O)COC4=CC=C(C=C4)Cl	C20 H21 Cl N2 O4		34161-24-5		N06BX05	vMost-DILI-Concern	Most-DILI-Concern	Withdrawn			HH			3			1
LT01373	anakinra				143090-92-0	DB00026	L04AC03												2
LT01374	darbepoetin alfa				11096-26-7	DB00012	B03XA02												2
LT01375	flecainide	C1CCNC(C1)CNC(=O)C2=C(C=CC(=C2)OCC(F)(F)F)OCC(F)(F)F	C17 H20 F6 N2 O3		54143-55-4	DB01195	C01BC04	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	7	there have been rare reports of hepatic dysfunction including reports of cholestasis and hepatic failure	HH	Positive					2
LT01376	peginterferon alfa-2a				215647-85-1	DB00008	L03AB11												2
LT01377	omalizumab				242138-07-4	DB00043	R03DX05												2
LT01378	ibritumomab tiuxetan				174722-31-7	DB00078	V10XX02												2
LT01380	pegfilgrastim				208265-92-3	DB00019	L03AA13												2
LT01381	flucytosine	C1=NC(=O)NC(=C1F)N	C4 H4 F N3 O		2022-85-7	DB01099	D01AE21 J02AX01	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Frequent monitoring of hepatic function and of the hematopoietic system is indicated during therapy.	HH	Positive					2
LT01382	fludarabine	C1=NC2=C(N1[C@H]3[C@H]([C@@H]([C@H](O3)COP(=O)(O)O)O)O)N=C(N=C2N)F	C10 H13 F N5 O7 P		75607-67-9	DB01073	L01BB05	vNo-DILI-Concern	No-DILI-Concern	No match	0						2		2
LT01384	flumazenil	CCOC(=O)C1=C2CN(C(=O)C3=C(N2C=N1)C=CC(=C3)F)C	C15 H14 F N3 O3		78755-81-4	DB01205	V03AB25	vNo-DILI-Concern	No-DILI-Concern	No match	0		NE	Negative	Non-toxic				2
LT01387	adalimumab				331731-18-1	DB00051	L04AB04												2
LT01389	cetuximab				205923-56-4	DB00002	L01XC06												2
LT01390	bevacizumab				216974-75-3		L01XC07												2
LT01392	palifermin				162394-19-6	DB00039	V03AF08												2
LT01393	natalizumab				189261-10-7	DB00108	L04AA23												2
LT01394	flurazepam	CCN(CC)CCN1C(=O)CN=C(C2=C1C=CC(=C2)Cl)C3=CC=CC=C3F	C21 H23 Cl F N3 O		17617-23-1	DB00690	N05CD01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	4	hallucinations and elevated SGOT, SGPT, total and direct bilirubins, and alkaline phosphatase.							2
LT01396	fluvoxamine	COCCCCC(=NOCCN)C1=CC=C(C=C1)C(F)(F)F	C15 H21 F3 N2 O2		54739-18-3	DB00176	N06AB08	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	elevated liver transaminases	HH	Positive		1		non-hepatotixic	2
LT01397	foscarnet	C(=O)(O)P(=O)(O)O	C H3 O5 P		63585-09-1	DB00529	J05AD01	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Liver and Biliary: abnormal A-G ratio, abnormal hepatic function, increased SGPT, increased SGOT	NE						2
LT01398	fosfomycin	C[C@H]1[C@H](O1)P(=O)(O)O	C3 H7 O4 P		23155-02-4	DB00828	J01XX01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	6	cholestatic jaundice, hepatic necrosis							2
LT01399	fosinopril	CCC(=O)OC(C(C)C)OP(=O)(CCCCC1=CC=CC=C1)CC(=O)N2C[C@@H](C[C@H]2C(=O)O)C3CCCCC3	C30 H46 N O7 P		98048-97-6	DB00492	C09AA09	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	hepatitis					3		2
LT01400	fosphenytoin	C1=CC=C(C=C1)C2(C(=O)N(C(=O)N2)COP(=O)(O)O)C3=CC=CC=C3	C16 H15 N2 O6 P		93390-81-9	DB00252	N03AB05	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	The clinical course of acute phenytoin hepatotoxicity ranges from prompt recovery to fatal outcomes. In these patients with acute hepatotoxicity, fosphenytoin should be immediately discontinued and not readministered.							2
LT01401	galsulfase				EC 3.1.6.12		A16AB08												2
LT01402	abatacept				213252-14-3	DB01281	L04AA24												2
LT01404	alglucosidase alfa				420794-05-0	DB01272	A16AB07												2
LT01406	ganciclovir	C1=NC2=C(N1COC(CO)CO)NC(=NC2=O)N	C9 H13 N5 O4		82410-32-0	DB01004	J05AB06 S01AD09	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	7	Abnormal liver function test ; postmarking experience: hepatic failure, hepatitis							1
LT01407	gemcitabine	C1=CN(C(=O)N=C1N)[C@H]2C([C@@H]([C@H](O2)CO)O)(F)F	C9 H11 F2 N3 O4		95058-81-4	DB00441	L01BC05	vMost-DILI-Concern	Most-DILI-Concern	Warnings and precautions	8	Serious hepatotoxicity, including liver failure and death, have occurred. Discontinue Gemcitabine Injection for severe hepatic toxicity.					3		2
LT01408	panitumumab				339177-26-3	DB01269	L01XC08												2
LT01409	idursulfase				50936-59-9	DB01271	A16AB09												2
LT01412	certolizumab pegol				428863-50-7		L04AB05												2
LT01414	eculizumab				219685-50-4	DB01257	L04AA25												2
LT01415	Rilonacept						L04AC04												2
LT01416	ustekinumab				815610-63-0		L04AC05												2
LT01417	romiplostim				267639-76-9		B02BX04												2
LT01419	golimumab				476181-74-5		L04AB06												2
LT01421	ofatumumab				679818-59-8		L01XC10												2
LT01422	guanfacine	C1=CC(=C(C(=C1)Cl)CC(=O)N=C(N)N)Cl	C9 H9 Cl2 N3 O		29110-47-2	DB01018	C02AC02	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	3	Liver and Biliary System: abnormal liver function tests							2
LT01426	heparin	CC(=O)NC1C(C(C(OC1O)COS(=O)(=O)O)OC2C(C(C(C(O2)C(=O)O)OC3C(C(C(C(O3)CO)OC4C(C(C(C(O4)C(=O)O)O)O)OS(=O)(=O)O)OS(=O)(=O)O)NS(=O)(=O)O)O)OS(=O)(=O)O)O	C26 H42 N2 O37 S5		9005-49-6	DB01109	C05BA03 S01XA14 B01AB01	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	Significant elevations of aspartate aminotransferase (AST) and alanine aminotransferase (ALT) levels have occurred							2
LT01433	hydrochlorothiazide	C1NC2=CC(=C(C=C2S(=O)(=O)N1)S(=O)(=O)N)Cl	C7 H8 Cl N3 O4 S2		58-93-5	DB00999	C03AA03	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	2	jaundice (intrahepatic cholestatic jaundice)	HH	Positive		2			2
LT01437	hydroxyzine	C1CN(CCN1CCOCCO)C(C2=CC=CC=C2)C3=CC=C(C=C3)Cl	C21 H27 Cl N2 O2		68-88-2	DB00557	N05BB01	vNo-DILI-Concern	No-DILI-Concern	No match	0							non-hepatotixic	1
LT01440	idarubicin	C[C@H]1[C@H]([C@H](C[C@@H](O1)O[C@H]2C[C@@](CC3=C(C4=C(C(=C23)O)C(=O)C5=CC=CC=C5C4=O)O)(C(=O)C)O)N)O	C26 H27 N O9		58957-92-9	DB01177	L01DB06	Ambiguous DILI-concern	Less-DILI-Concern	Warnings and precautions	3	Frequent complete blood counts and monitoring of hepatic and renal function tests are recommended.	NE	Negative					2
LT01442	antithymocyte globulin						L04AA04												2
LT01444	indapamide	CC1CC2=CC=CC=C2N1NC(=O)C3=CC(=C(C=C3)Cl)S(=O)(=O)N	C16 H16 Cl N3 O3 S		26807-65-8	DB00808	C03BA11	Ambiguous DILI-concern	Less-DILI-Concern	Adverse reactions	5	jaundice (intrahepatic cholestatic jaundice), hepatitis, pancreatitis and abnormal liver function tests. These reactions were reversible with discontinuance of the drug.							2
LT01446	indinavir	CC(C)(C)NC(=O)[C@@H]1CN(CCN1C[C@H](C[C@@H](CC2=CC=CC=C2)C(=O)N[C@@H]3[C@@H](CC4=CC=CC=C34)O)O)CC5=CN=CC=C5	C36 H47 N5 O4		150378-17-9	DB00224	J05AE02	Ambiguous DILI-concern	Most-DILI-Concern	Warnings and precautions	8	Hepatitis: cases resulting in hepatic failure and death has been reported				1		Hepatotoxic	1
LT01454	iodipamide	C1=C(C(=C(C(=C1I)NC(=O)CCCCC(=O)NC2=C(C=C(C(=C2I)C(=O)O)I)I)I)C(=O)O)I	C20 H14 I6 N2 O6		606-17-7	DB04711	V08AC04	vNo-DILI-Concern	No-DILI-concern	No match	0								2
LT01466	irinotecan	CCC1=C2C=C(C=CC2=NC3=C1CN4C3=CC5=C(C4=O)COC(=O)[C@@]5(CC)O)OC(=O)N6CCC(CC6)N7CCCCC7	C33 H38 N4 O6		100286-90-6	DB00762	L01XX19	vLess-DILI-Concern	Less-DILI-Concern	Adverse reactions	3	NCI grade 3 or 4 liver enzyme abnormalities were observed in fewer than 10% of patients					2		2